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Abstract 
Peripheral T-cell lymphomas-not otherwise specified (PTCL/NOS) are the most common T-cell 
neoplasms. This study sought to reshape the PTCL/NOS sub-classification (including its two main 
morphological variants, Lennert lymphoma, LL, and Follicular variant, F-PTCL) based on the 
correspondence between their molecular features and those of different functional T-cell subsets, 
also assessing the clinical impact of such an approach.  
We found that PTCLs/NOS could be divided into groups corresponding to T-cell subsets differently 
reliant on transcription regulators including mTOR and FOXP3, and identified minimal gene sets 
discriminating among these groups. Notably, by grouping tumors according to their dependency 
on master regulators of T-lymphocyte fate, we identified three groups (T-cytotoxic, Treg/TFH, and 
other-T-helper) characterized by specific genetic patterns and significantly different clinical 
outcomes. Immunohistochemistry partially substituted for the molecular analysis by consistently 
recognizing only Treg and TFH cases. Finally, targeted inhibition of MTOR in T-helper cases (that 
were characterized by genetic lesions targeting the pathway) was proved to be effective ex vivo. 
We conclude that PTCL/NOS can be divided into subgroups corresponding to different cellular 
counterparts, characterized by different genetic patterns and possibly sensitivity to specific 
therapeutic approaches. 
Furthermore, we identified different gene and microRNA signatures for LL capable of 
differentiating it from other PTCL/NOS and enriched in cytotoxic function. Moreover, 
PI3K/Akt/mTOR pathway emerged as novel therapeutic targets for LL. Additionally, LL showed 
some differences with other PTCL/NOS in terms of clinical features, all supporting its recognition 
as a distinct entity. Besides, we found that F-PTCL has a distinct molecular signature more similar 
to PTCL/NOS rather than AITL, and therefore cannot be included among AITLs at least based on 
GEP, although this necessities more genetic studies. 
Overall, these results may impact on PTCL classification as well as on future studies aimed to 
define the more appropriate therapeutic strategy for each identified subgroup/entity. 
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1.1. T-lymphocytes development 
T-lymphocytes or T-cells are a group of white blood cells that are involved in the cell-
mediated immunity. They are the central element in adaptive immune system, and act 
different levels including primary response by naïve T-cells, followed by further processing 
mediated by activated T-cells, and persistence of Antigen-specific memory T-cells (1). Upon 
maturation in the thymus, T-cells express a unique T-cell receptor (TCR) on their cell surface 
that is the marker distinguishing T-cells from other lymphocytes. Two classes of mature T-
cells are recognized based on the type of protein chains of TCR: Alpha–Beta (αß) and 
Gamma–Delta (γδ). Alpha-Beta subtype account > 95 % of T-cells and comprise CD4+ 
(cluster of differentiation 4) and CD8+ (cluster of differentiation 8) T-cells, named after the 
expression of CD4 or CD8 glycoprotein at the cell surface, whereas γδ T-cells (either CD4-
CD8- or CD4-CD8+) account for < 5% of T-cells (2). T-lymphocytes leave thymus as naïve T-
cells and enter to secondary (peripheral) lymph system. When naïve T-cells encounter an 
antigen in secondary lymphoid tissue, TCR triggers a cascade of signaling events that leads 
to activation of naïve T-cells, leading to their enlargement and conversion to blast T-cells 
with high potencies in proliferation and generating large population of clones further 
differentiate into effector or memory T-cells. The former perform the effector function such 
as cytokine production, cell-mediate cytotoxicity, and assisting B-cells. Most effector T-cells 
have a short life span and disappear at the end of immune response, although some would 
switch to memory T-cells. At the end of immune response, memory T-cells would survive for 
the years in peripheral and lymphoid tissues. Memory T-cells, either CD4+ or CD8+, are 
divided into two groups, TCM (central memory T-cells) and TEM (effector memory T-cells), 
recognized based on their cell surface markers. These cells would be activated in a 
secondary immune response, when re-exposed to their cognate antigen (3, 4). Upon re-
activation, TEM and TCM cells have potency to home in the peripheral lymphoid tissues. 
However, TEM cells immediately perform effector functions, whether TCM cells would first 





1.2. T-cell subsets 
As mentioned above, T-cells, either effector or memory classes, could be divided into two 
major classes, CD4+ and CD8+. CD4+ T-cells comprises several specialized subsets, including 
T helper1, T helper2, T helper17, regulatory T, and T follicular helper cells. Each of these 
subtypes has a specific gene expression program, which in turn is regulated by specific 
cytokines, transcription factors and epigenetic mechanisms (6). 
T helper1 (Th1) cells act against intracellular pathogens, through producing cytokines 
including IFN-γ (interferon gamma). IFN-γ can activate macrophages and upregulated iNOS 
(the inducible isoform of Nitric oxide synthases) which directly leads to killing intracellular 
pathogens. The IFN-γ production is induced by expression of transcription factors such as 
STAT4 (Signal transducer and activator of transcription 4) and TBX21 (T-box protein 21 or T-
bet), and the latter is the key transcription factor in Th1 differentiation. Following the cell 
response to interlucin-2 (IL-2) and the activation of mTOR (mammalian target of 
rapamycin)/Akt signaling, T-bet is expressed which led to the differentiation of the Th1 cells 
(7). In addition, through producing factors such as IL-2, IFN-γ and TNF-β (Tumor necrosis 
factor-beta), Th1 cells activate cytotoxic T-cells (8). 
T helper2 (Th2) cells have a role in the humoral immune system and host defense against 
extracellular pathogens. These cells are also involved in asthma and other allergic diseases 
(9, 10). The differentiation of Th2 cells is induced by IL-4/IL-4R-mediated signaling, which 
leads to activation of STAT6 (Signal transducer and activator of transcription 6), and in turn 
it induces GATA3 (GATA binding protein 3) expression. GATA3 is the master regulator of Th2 
cell differentiation, which operates by inducing the expression of IL-4, IL-5 and IL-13 (11-13). 
T helper17 (Th17) cells can perform host defense against extracellular bacteria and fungi 
mainly at mucosal surface. These cells are also associated with autoimmune and 
inflammatory diseases. Th17 cells differentiation is induced by IL-6 and TGF-β (Transforming 
growth factor-beta) cytokines, followed by expression of the STAT3 transcription factor. This 
transcription factor induces expression of RORγt (Retinoic acid receptor-related orphan 
receptor gamma t), the master regulator of Th17 cell differentiation (14, 15). 
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Regulatory T (Treg) cells are in charge for regulating immune responses; maintaining 
tolerance to self-antigens, and preventing autoimmune diseases and cancer. Treg cells exist 
in many forms and the well-studied forms express markers such as CD4, CD25 and FOXP3 
(forkhead box P3). By producing immunosuppressive cytokines such as TGF-β and IL-10, Treg 
cells mediate immune responses through contact-dependent and contact-independent 
mechanisms (16-19). T follicular helper (Tfh) cells are another subset of CD4+ T-cells which 
induce the activation and differentiation of B-cells into immunoglobulin producing cells. In 
activated form, they reside within and in proximity of germinal centers (GCs) of secondary 
lymphoid organs, while memory Tfh cells circulate in the blood. Similar to the other CD4+ T-
cell lineages (Th1, Th2, Th17 and Treg cells), the development and differentiation of Tfh cells 
require signaling pathways activated by cytokines and subsequent launch of transcription 
factors (20). The master regulator of Tfh differentiation is BCL6 (B-cell lymphoma 6). The 
early differentiation process is induced by the presence of cytokines including TGF-β (21, 
22), IL-6, IL-12 (23), IL-21 and IL-23 in T-cell zone (nascent stage of a germinal center 
reaction). This leads to the formation of pre-Tfh cells that exhibit a specific secretory profile 
(expression of IL-21 and CXCL13 (CXC chemokine ligand 13) chemokines, critical for B-cell 
recruitment into GCs and activation) and a specific cell surface receptor including CXCR5 
(receptor of CXCL13, essential to localization of Tfh cells to GCs) and co-stimulatory 
molecules such as ICOS (inducible T-cell costimulator), PD1 (programmed cell death-1), 
CD28, and CD40L. These events prepare for a strong interaction of Tfh cells with B-cells, 
causing the differentiation of pre-Tfh into mature Tfh cells and entrance into GC along with 
B-cells (24-27). Tfh cells present in GC (referred to GC Tfh cells) are characterized by high 
level of markers like BCL-6, CXCR5, ICOS, PD-1 and IL-21, which assist in activation, 
differentiation into the immunoglobulin-producing cells, and B-cell survival (23, 24, 27). 
On the other hand, CD8+ cells, known as Cytotoxic T (Tc) cells or CTL, are involved in 
destroying intracellular pathogens like bacteria and viruses and also tumor cells. This is 
achieved through production of cytolytic molecules such as Perforin and the granule 
enzymes (granzymes). Furthermore, they can induce apoptosis of target cells by secretion of 
some pro-inflammatory cytokines such as IFN-γ and TNF-α (28, 29). The cytotoxic function is 
triggered via Perforin which punctures holes in the membrane of a target cell. In the next 
step, TIA-1 (T-cell-restricted intracellular antigen), a cytotoxic granule-associated protein 
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along with granzyme B, enter in the cytoplasm through the formed holes and activate some 
target proteins which in turn induce apoptosis. Of note, TIA-1 is expressed irrespective of 
the activation state of cytotoxic T-cells, whereas Perforin and granzyme B are only 
expressed upon activation of these cells (28). An overview of T-cell variants discussed is 


















Figure 1.1. T-lymphocyte subpopulations including: TH, TC, TH1, TH2, TH17, TFH, and Treg. 
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1.3. The World Health Organization classification of nodal Peripheral T-cell lymphomas 
The transition of a normal to a neoplastic T-cell is partially due to accumulation of genetic or 
epigenetic alterations (30) which leads to uncontrollable growth of neoplastic cells. 
Cancerous lymphocytes can travel to many parts of the body, including the lymph nodes, 
spleen, bone marrow, blood, or other organs, and form tumor masses. 
There are many different forms of T-cell lymphomas, but here we describe the main topic of 
this thesis, i.e. nodal Peripheral T-cell lymphomas.  
Peripheral T-cell lymphomas (PTCLs) are a rare heterogeneous group of non-Hodgkin 
lymphomas (NHL), which account for 10–15 % in Western countries and 20–25% in Asia 
(31). PTCLs are derived from mature T-lymphocytes or Natural killer cells and exhibit great 
versatility in their clinical, morphological, immunophenotypic, cytogenetic, and molecular 
features (32). 
Clinically, most PTCLs are aggressive, generally non-response to conventional 
chemotherapy, and have a poor prognosis (33). According to The (2008) World Health 
Organization (WHO) classification of Haematopoietic and Lymphoid Tissues, based on the 
morphological, immunophenotypic, genetic, and clinical features, PTCLs are classified into 
nodal, extranodal, cutaneous, and leukemic forms (34). Some entities are fairly well-defined, 
while others are more heterogeneous. The most common type of PTCLs have nodal origin 
including Anaplastic large cell lymphoma (ALCL), Angioimmunoblastic T-cell lymphoma 
(AITL), and Peripheral T-cell lymphoma-not otherwise specified (PTCL/NOS). The latter 
accounts for more than a third of the PTCLs (30–50% of the cases), but cannot be further 
classified into any more specific entity (31, 35). 
The majority of tumor cells in PTCLs are CD4+, a large proportion of which appears to be 
related to Tfh cells. There are also minor subtypes that seem to arise from the Th1, Th2, 
Th17 and Treg subsets (36). There are a number of increasing evidences suggesting that the 
cell of origin is a major determinant of the biology of PTCLs, and a substantial factor for 
further classification of PTCLs. Nevertheless, the cellular origin of many PTCLs (except for 
AITL and a follicular variant of PTCL/NOS, F-PTCL) remains controversial, probably due to the 
related heterogeneity (37). 
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Nowadays, genome-wide techniques such as microarray-based gene and microRNA (miRNA) 
expression profiling and massive parallel sequencing are becoming substantial in research 
and diagnosis, mainly because of lowered prices concomitant advances in bioinformatic 
methods (38). As concerned with PTCLs, just like any other class of tumors, these 
technologies have equipped us with novel information at genome and transcriptome level, 
and improved our comprehension regarding molecular diagnosis and prognosis, besides 
identification of novel molecular subtypes that could not be recognized by conventional 
methods (37, 39-42).  
Recently, integration of massive parallel sequencing methods and gene expression profiling 
has discovered master genetic alterations in most common subtypes of PTCL which are 
responsible for activation of oncogenic pathways. As a result, genes altered in specific 
disease subtypes can be potentially be used for more tailored therapies, even with 
treatments already approved by FDA. Some examples of such targets include IDH2, NF-κB, 
JAK/STAT, or mTOR pathways, and they have illustrated the value of genome-wide 
techniques in spotting new targets in PTCL therapy (38).  
It should be mentioned, however, that despite all the advances, there is a proportional lack 
of understanding of the biology of PTCLs, caused by their rarity and diversity and lack of 
appropriate cell lines and animal models. 
1.3.1. Anaplastic large cell lymphoma (ALCL) 
ALCL, characterized by large cells and consistent CD30 expression, is an aggressive tumor 
which responds well to therapy (43). Based on presence of a translocation involving a 
tyrosine kinase named anaplastic lymphoma kinase (ALK) gene, it is subdivided into 2 
distinct entities as including ALK-positive (ALK+) and ALK-negative (ALK-) ALCL (43-45). The 
translocation is found in different varieties and the most common form involves 
nucleophosmin gene (NPM1). The overexpression of ALK causes the activation of several 
signaling pathways, including JAK/STAT3 and PI3K/AKT/mTOR, which result in cell growth 
and resistance to apoptosis. It has been shown that ALK protein is necessary and sufficient 
for inducing ALCL development in vivo, and STAT3 also displays a substantial role in ALCL 
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tumorigenesis. As a result, several therapies targeting ALK and the STAT3 are currently in 
clinical trials for ALK+ALCL patients (46).  
Phenotypically, both ALK+ and ALK- ALCL express cytotoxic markers including TIA-1, perforin 
and/or granzyme B (47). Furthermore, they might share some signature which is 
independent of ALK that could be used for classifying them from other PTCLs (48). This 
includes, for example, the dependence of both subtypes upon IRF (Interferon regulatory 
factor) and MYC (v-myc avian myelocytomatosis viral oncogene homolog) signaling, and 
MTOR gene signature (49). In addition, a low expression of TCR signaling-related genes has 
been reported (40, 50). 
However, distinct signatures have been described and used for molecular classification of 
ALCLs subtypes (40, 48, 51, 52). A combination of gene expression profiling along with 
proteomics and disease models indicate that signaling pathways significant in ALK-positive 
ALCL include ALK/STAT3, RAS/ERK, and PI3K/AKT/mTOR pathways (48, 53-55). Furthermore, 
gene expression profiling analysis indicated enrichment of several pathways like IL-10, H-
Ras/K-Ras, and HIF1-alpha (hypoxia inducible factor 1 alpha subunit) in ALK-positive ALCL 
(40, 48, 51). 
On the other hand, overexpression of several key genes such as TNFRSF8 (tumor necrosis 
factor receptor superfamily member 8), BATF3 (basic leucine zipper ATF-like transcription 
factor 3), and TMOD1 (tropomodulin 1) is reported in ALK-negative ALCL (40). Interestingly, 
the same 3 genes could be used to distinguishing ALK-negative ALCL from CD30+ PTCL-NOS 
(56), previously achieved using gene expression profiling (52). Furthermore, another study 
found inactivation of PRDM1 (PR domain 1)/BLIMP1 in 52% of ALK-negative ALCL, and 
proposed its correlation with a more aggressive course (57). Although not carrying the 
major translocation, recent studies showed the presence of 2 specific recurrent 
rearrangements in ALK-negative ALCL. These include DUSP22-IRF4 rearrangement observed 
in 30% of cases which resulted in lowered expression of DUSP22 (at protein level), and TP63 
(tumor protein p63, homolog of TP53) in 8% of cases. Of note, these two rearrangements 




1.3.2. Angioimmunoblastic T-cell lymphoma (AITL) 
As the second most common subtype of PTCL, AITL accounts for almost 20% of PTCLs. AITL 
has some unique clinical features and morphologic characteristics such as proliferation of 
high endothelial venules (HEV) and follicular dendritic cells (FDCs), and infiltration of tumors 
by inflammatory cells, including Epstein-Barr virus-positive B-cells, which are very useful in 
distinguishing it from other PTCLs (60). This lymphoma rarely responds to the currently used 
chemotherapy and the 5-year overall survival is less than 30% (60, 61). Tfh markers such as 
BCL6, PD-1, ICOS, CXCR5 and CXCL13 are expressed in AITL malignant cells, and there are 
other documents supporting Tfh cells as the cell of origin of AITL (62-66). 
Gene expression profiling identified a dominance of microenvironmental signature (i.e., high 
expression of B cell and FDC-related genes) in AITL. Several major oncogenic signaling 
pathways were found to be highly active in AITL, including NF-κB, IL-6, TGFβ, and 
angiogenesis (represented mainly by VEGF) (38, 63-67). Of note, VEGF is produced by 
malignant cells as well, and besides promoting angiogenesis could induce tumor growth in 
an autocrine/paracrine loop (67). 
Frequent mutations of some important gens like IDH2, TET2, DNMT3A and RHOA has been 
reported in AITL. Very importantly, besides DNMT3A which has substantial role in regulating 
epigenetic status of the cell, IDH2, TET2 participate in this process as well, emphasizing how 
epigenetic regulation might participate in AITL pathogenesis (41, 42, 68-71). A recent study 
by Wang et al reported the presence of TET2 and DNMT3A mutations in other subtypes of 
PTCL. This, however, did not apply to IDH2 mutations, suggesting a unique role for these 
mutations in the pathogenesis of AITL. This idea was supported by distinct gene expression 
signature of IDH2 mutated cases (71). 
1.3.3. Peripheral T-cell lymphoma, not otherwise specified (PTCL/NOS)  
PTCL/NOS, the most common T-cell-derived malignancy accounting for 26%-40% of all 
PTCLs, represent a heterogeneous group of tumors based on morphology and phenotype 
(34, 36, 72). At clinical ground, these tumors occur more frequently in adults with a median 
age of 60 years (73). Being mainly involved in lymph node, however, its distribution to 
extranodal sites has been observed, including bone marrow, liver, spleen, skin and lung (73, 
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74). PTCL/NOS responds poorly to the conventional chemotherapy, and 5-year overall 
survival (OS) is almost 32% (75). 
The extreme heterogeneity in PTCL/NOS suggests it to include different diseases (34, 36, 
72).  At least at morphological level, it has been indicated the presence of three specific 
variants in PTCL/NOS including Lymphoepithelioid, follicular and T-zone variants (34).  
However, more molecular studies are needed in order to understand biological 
characteristics of PTCL/NOS category, aiming to achieve an accurate classification. 
According to the immunophenotype, PTCL/NOS are mostly referred as central memory T-
lymphocytes (TCM). Global gene expression profiling analysis has allowed tumors 
corresponding to T-lymphocytes related to T-helper (TH) or T-cytotoxic (TC) lineages to be 
distinguished (52, 62, 64, 76, 77). Because of frequent aberrant antigen expression by the 
neoplastic cells, gene expression profiling turned out to be more efficient at distinguishing 
these tumors than was immunophenotyping. This phenomenon, confirmed in large studies 
(64, 75, 78), was shown to be relevant for the distinction between TH and TC PTCL/NOS, 
which could not be reliably recognized on the basis of CD4/CD8 immunohistochemical 
expression  (62, 79). Remarkably, the distinction between TH and TC cases is suggested to 
have prognostic relevance (64). Furthermore a subset of PTCL/NOS with Tfh phenotype (Tfh-
PTCL/NOS) frequently shows some biological and clinicopathological features of AITL, 
questioning if the spectrum of AITL might be broader than is currently thought (41, 63, 80).  
More recently, further evidences of the relevance of cellular derivation for PTCL/NOS has 
been provided at the molecular level. In particular, it has been shown that the expression of 
specific transcription factors, TBX21 (master regulator of Th1) and GATA3 (master regulator 
of Th2), involved in the specification of T-cell fate was associated with clinical outcome. On 
note, there was a difference in the oncogenic pathways activated in the two groups, with 
constitutive activation of the NF-κB and STAT3 in the TBX21 subgroup, and constitutive 
activation of mTOR and PI3K in GATA3 subgroup (40, 81). Subsequently, using 
immunohistochemistry, an independent study identified high expression of GATA-3 in 
almost half of the cases of PTCL/NOS, which was also associated with inferior survival. On 
the other hand, the TBX21 group was found to be more heterogeneous, comprising a subset 
of cases with a cytotoxic profile (82). 
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These studies further strengthen the necessity for a deeper understanding of the potential 
cellular derivations of PTCL/NOS. Despite these advances in the understanding of PTCL 
pathobiology, systematic characterization of PTCLs/NOS neoplastic clones with respect to 
their potential recapitulation of different functional T-cell statuses is still lacking.  
1.3.3.1. Lennert Lymphoma 
Lennert lymphoma (LL) was first described by Karl Lennert in 1952, and later in 1968, by 
Lennert and Mestdagh (83). Although at first, the disease was classified as 
"lymphoepithelioid cellular lymphoma", it took some time for it to be recognized as a T-cell 
lymphoma (84). Since its discovery, the term LL has been used to describe a wide range of 
malignant lymphomas, all of which are characterized by the high level of epithelioid cells, 
although those lymphomas might actually correspond to different categories (34). In the 
fifth edition of the World Health Organization (WHO) classification, LL is classified as a 
morphological variant of PTCL/NOS characterized by the high level of epithelioid cells, clear 
cell cytology and, generally, cytotoxic immunophenotype. So far, few publications have 
dealt with the biological nature of LL, most probably because of the very low incidence level 
and lack of well-described diagnosis criteria. By means of immunohistochemistry, recent 
studies have discovered the prevalent expression of cytotoxic T-cell markers, e.g. CD8, 
Granzyme B, and T-cell Intracellular Antigen-1 (TIA-1), in LL, and have suggested the CD8+ T-
cells as the cell of origin of most cases of LL (75, 85-87). Furthermore, LL was found to 
present different morphological and phonotypical features, when compared to the other 
epithelioid-rich subtypes of PTCL (88-91). These findings suggest the necessity of further 
studies on LL. 
Nowadays Lennert Lymphoma is diagnosed by a combination of morphological and 
immunophenotyping features and some of them contained: 1) Predominantly proliferation 
of small lymphoid cells, 2) Dense clusters of epithelioid histocytes, 3) cytotoxic 
immunophenotype in the majority of cases (CD3+, CD8+, TIA-1+ and Granzyme B−), 4) low 
proliferation rate (lower Ki-67) respect to other PTCL subtypes (75, 86, 87, 92-94).  
Based on cytogenetic studies Lennert Lymphoma differs morphologically and phenotypically 
from other epithelioid-rich PTCL subtypes and it is often derived from CD8+ cytotoxic T-cells 
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and as well as has a survival superior to other CD8+ PTCLs  (75, 85, 86). These findings 
suggest that this special variant of PTCL/NOS should be further studied by precise molecular 
technologies to understand its accurate position among other PTCL subtypes and possibly 
could be separated as a distinctive entity in the future lymphoma classifications. 
1.3.3.2. Follicular variant of Peripheral T-cell lymphoma, not otherwise specified  
Follicular variant of Peripheral T-cell lymphoma, not otherwise specified (F-PTCL) is a rare 
morphological variant of PTCL/NOS (20–41%) which show a follicular growth pattern. The 
neoplastic cells are CD4+ αß T-cells that express Tfh markers (PD1, ICOS, CXCL13 and BCL6) 
(64, 80, 95-97). In the fourth version of World Health Organization (WHO) classification F-
PTCL is not considered a subtype of AITL because a) it shows no proliferating of follicular 
dendritic cell (FDCs) or high endothelial venules (HEVs) which are hallmark feature of AITL 
(34) and b) the presence of t(5;9) ITK-SYK translocation in 20% of F-PTCL cases, which was 
considered a genetic abnormality specific to F-PTCL (96). However, recent research 
identified t(5;9) in very small percentage of AITL as well, though it is still relatively specific to 
F-PTCL (98-100). SYK is a non-receptor protein tyrosine kinase which functions as regulator 
of multiple signal transduction pathways. Its overexpression has been reported in PTCL/NOS 
cases independently of ITK-SYK, suggesting that the SYK pathway is important in this 
condition (101). Since F-PTCL may present some biological and clinicopathological features 
overlapping with those of AITL (96, 102), hence, it has raised the controversy if F-PTCL might 
actually belong to the spectrum of AITL (96, 103). 
1.3.3.3. T-zone variant of Peripheral T-cell lymphoma, not otherwise specified 
T-zone variant is named for its involvement in a specific area of the lymph node that consists 
of a dense accumulation of T-cells and has been characterized by prominent high 
endothelial venules and numerous reactive cells, including plasma cells, eosinophils, and 
epithelioid histiocytes and also shows an interfollicular growth pattern with small or 
medium-sized cells without pronounced nuclear pleomorphism (34). 
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1.4. Aim of the thesis 
This thesis follows three main aims including: 
1.  Reshaping the PTCL/NOS sub-classification based on the correspondence between their 
molecular features and those of different functional T-cell subsets, as well as assessing the 
clinical impact of such an approach. 
2. Clarifying the accurate position of Lennert lymphoma among other PTCL/NOS based on its 
molecular expression signature.  






Material and Methods 
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2.1. Case selection  
We studied 186 PTCLs/NOS including 106 cases from which GEPs (Gene expression profiling) 
had been determined using fresh/frozen tissues (52, 62, 64, 65, 104) (77 previously included 
in GEO data sets GSE6338 and GSE19069) and 80 cases for which GEP was performed on 
formalin-fixed-paraffin-embedded (FFPE) specimens. All of the cases were reviewed by at 
least two expert hematopathologists and diagnosed according to the WHO Classification 
(34); furthermore, the diagnosis was refined by applying a molecular classifier recently 
developed by our group (52). The detailed clinico-pathological characteristics of these cases 
were previously reported (104). We also studied the molecular profiles of normal T-cell 
subpopulations (CD4+, CD8+, TH1, TH2, TH17, Treg, and TFH) from which the GEPs were 
previously generated (62, 105).  
2.2. Ethics statements  
The study was conducted according to the principles of the Helsinki Declaration after 
obtaining approval from the local Ethical Committee. Written informed consent was 
obtained from all patients for the tissue analysis. All cases were studied by both GEP and 
extensive IHC. 
2.3. Gene and microRNA expression profile generation 
RecoverAll™ Total Nucleic Acid Isolation Kit was used to extract total RNA from FFPE 
samples. Up to five 10 μm-thick sections were processed per reaction. The samples were 
rehydrated using a series of xylene and ethanol washes. Next, they were subjected to a 
rigorous protease digestion with an incubation time tailored for recovery of total RNA. RNA 
was purified using a rapid glass-fiber filter methodology that includes an on-filter DNAse 
treatment and were eluted into the low salt buffer provided. RNA was quantified using 
NanoDrop spectrophotometer.  
In order to generate gene expression profiles, RNA was the processed as for manufacturer’s 
instructions to produce biotinylated cDNA (106, 107). Briefly, biotinylated -cDNA was then 
annealed to the DASL Assay Pool (DAP) probe groups that contain oligonucleotides 
specifically designed to interrogate each target sequence in the transcripts. Following this, 
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the correctly annealed, assay-specific, oligos were extended and ligated to generate 
amplifiable products. These templates were labeled during PCR amplification by including 
fluorescent primers in the reaction. The resulting PCR products were hybridized on the 
Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip and scanned using the 
BeadArray Reader or iScan System to determine the presence or absence of specific genes. 
MicroRNA expression profiles were generated using the TaqMan Array Human MicroRNA 
Cards A v.2.0 (Life Technologies, Carlsbad, CA USA) according to the manufacturer’s 
instruction, as described previously (108). Of note, this qRT-PCR-based array enables 
accurate quantitation of 377 human microRNAs. 
2.4. Gene and microRNA expression analysis 
Gene and miRNA expression analysis was carried on as previously reported (62, 109, 110). 
Statistical Analysis was performed using GeneSpring version GX 12 (Agilent, MI, Italy). The 
expression value of each probe was normalized to have a zero mean value and unit standard 
deviation. Principal Component Analysis (PCA) was used to discriminate the different 
biological samples on the basis of the distances of a reduced set of new variables (Principal 
Components). Only the top 3 principal components were used for depicting the results. The 
distance between two individual samples was calculated by Pearson correlation with the 
normalized expression values. Unsupervised clustering was generated using a hierarchical 
algorithm based on the average-linkage method. Differentially expressed genes among 
sample groups were identified using ANOVA method, with adjusted p-value based on the 
case. Differentially expressed genes and miRNAs between any two groups of samples were 
identified with a two-tailed T-test with Welch approximation for different variance among 
groups and with different stringency criteria for false discovery rate (Benjamini correction, 
adjusted Bonferroni correction, or no correction). Based on the stringency criteria, the 
results of the test were further filtered based on a fold change in absolute value [fold 
change = mean (group A) – mean (group B)], which was chosen on a case-based method. 
The resulting genes/miRNAs were used to produce hierarchical clustering analysis based on 
the average-linkage method. 
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Different approaches were used for identifying the cellular counterparts of PTCLs. First, we 
generated the molecular signatures specific of CD4+, CD8+, TCM, TEM, TH1, and TH2. 
Secondly, we used a Support Vector Machine (SVM) algorithm as well as Broad Institute 
Gene Set Enrichment Analysis (GSEA) software (111, 112) to classify cell type correlating a 
given PTCL/NOS sample with either one of two possible molecular phenotypes (i.e. CD4 vs. 
CD8, TH1 vs. TH2, and TCM vs. TEM), based on the expression of genes characteristic of the 
different normal subpopulations (52, 62, 109, 110).  This analysis was carried on 77 
PTCL/NOS cases, for which frozen tissue was available. In brief, the classifier is a confidence 
measure scoring function based on the values of a set of genes (gene cluster), which are 
differentially expressed in two sets of cell types, and thus, can be used for cell type 
classification. The higher the score, the more likely it is that a cell type is related to the 
phenotype set. Samples with confidence measure score minor than 0.05 were not assigned 
to a particular cellular counterpart and flagged as unclassified. For GSEA, in case of nominal 
P values and False Discovery Rate (FDR) for enrichment scores minor than 0.01, a significant 
enrichments in single signatures was defined. 
Third, GSEA was adopted to evaluate the possible enrichment in Treg, TH17, and TFH 
signatures, which were designed according to literature data (see Supplementary Table 1), 
being not available the cellular populations isolated in vivo from humans (nor deposited raw 
GEP). 
Finally, stepwise discriminant analysis was performed using IBM SPSS Statistics 20.0 (IBM, 
Armonk, USA) to identify the minimal number of genes able to correctly classify a given 
sample in different molecular subtypes. To run this analysis, a training set was created 
selecting a random permutation of about one third of cases of PTCL/NOS (N=28), using the 
shuf function in UNIX Bash shell. The remaining cases constituted the test set (N=49). For 
every step of the analysis the gene that minimize Wilks' lambda test probability distribution 
was selected to enter in the discriminant model and included in the list of discriminant 
genes if its probability associated to F exact test was minor than 0,05. Otherwise, the genes 
with probability associated to F exact test greater than 0.10 were excluded from the list. 
Stepwise method was run until no further genes could be added or excluded to reduce 
Wilks' lambda probability distribution. A discriminant score was calculated for each sample 
and for each classification step. Each case from the validation set was then assigned to a 
18 
 
specific cellular counterpart or another according to the distance between its discriminant 
score and a cut-off value calculated for each predicted group. 
As further validation, the discriminant function was then applied to a series of lymphomas 
for which the cellular counterpart was already recognized (namely AITL, corresponding to 
TFH (N=34); adult T-cell lymphoma/leukemia, ATLL, corresponding to Treg (N=13); and 
anaplastic large cell lymphoma ALCL, sometimes matching TH17 (N=33)) (34, 63-65, 113) 
(GEO data sets: GSE6338 and GSE19069). Finally, we applied it to FFPE for which GEP were 
generated using the Illumina DASL assay (106, 107). Gene expression studies were 
conducted according to MIAMI guidelines. The data discussed in this publication have been 
deposited in NCBI's Gene Expression Omnibus (114) and are accessible through GEO Series 
accession number GSE45712 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45712). 
Broad Institute GSEA was used to identify KEGG pathways significantly enriched for genes 
mutated in every PTCL/NOS subgroup. DAVID Functional Annotation Bioinformatics 
Microarray Analysis (http://david.abcc.ncifcrf.gov/) was also used to establish whether 
specific biological processes defined according to Gene Ontology were significantly 
represented among different PTCL/NOS subgroups.   
Ingenuity Pathway Analysis, (IPA, IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) 
software was used for creating signal transduction networks in the samples. 
2.5. High throughput massive parallel sequencing  
Total DNA was extracted from 29 PTCL/NOS frozen samples with QIAamp DNA mini kit 
Qiagen according to manufacturer’s procedure (Qiagen, Italy). 1 µg of DNA were sheared 
using Covaris instrument into 100–500 bp fragments and quality control of fragmentation 
was assessed using a DNA-7500 kit (Agilent, USA). Pre-enrichment DNA libraries were 
constructed following Illumina's TruSeq DNA Sample Preparation v2 Guide. Briefly, after end 
repair, adenylate 3’ends and ligate adapters steps we performed a PCR reaction to 
selectively enrich those DNA fragments that had adapter molecules on both ends. PCR 
libraries products were purified by AmpureXP beads (BeckmanCoulter, CA, USA) and exome 
enrichment was performed according to Illumina's TruSeq Exome Enrichment Guide 
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(Illumina, San Diego, USA). Two 20-h biotinylated bait-based hybridizations were performed 
with each followed with Streptavidin Magnetic Beads binding, a washing step and an elution 
step. A 10-cycle PCR enrichment was performed after the second elution and the enriched 
libraries were subjected to quality control analysis using a DNA-1000 kit (Agilent, USA). The 
quantification was performed by Quant-it PicoGreen dsDNA Assay Kit according to 
manufacturer’s protocol (Invitrogen, Life Technologies, USA).  
The paired-end libraries (2x100 base pair) were sequenced on an Illumina HiScan SQ 
(Illumina, San Diego, USA) following the manufacturer's instructions, generating an average 
of about 51 million 100bp paired-ends raw reads, with theoretical coverage, calculated on 
hg19 RefSeq non redundant exome length, ranging from 35X to 108X. Quality control on raw 
reads was performed using FastQC V0.10.0 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Illumina reads were mapped 
to Human GRCh37 Genome Assembly using the Burrows-Wheeler Aligner version 0.6.1 
(BWA) (115). Multiple mapped reads pairs with identical external coordinates were 
collapsed to remove potential PCR duplicates using samtools command rmdup (116). 
Mapping quality score recalibration and local realignment around insertions and deletions 
(indels) was performed using Genome Analysis Toolkit (GATK) (117). Single-nucleotide 
variants (SNVs) and small insertions and deletions (INDELS) were called separateley using 
GATK Unified-Genotyper. 
All the mutations detected were filtered using tresholds based on quality, coverage and 
strand of the mapped reads (118) and according to variants already present in public 
databases (Hapmap, dbSNP and 1000genome project (119)). To reduce the presence of 
germline mutations, variants already present in 25 WES samples from unaffected individuals 
were excluded. 
Annovar tool 2013May20 update (http://www.openbioinformatics.org/annovar/) was used 
for functional annotation of variants, including exonic functions and amino acid changes and 
only non-synonymous variants, including stop-gain SNVs, splicings and frameshift indels 
were selected for further analysis. 
All the mutations found were manually checked and explorated using the Integrative 
Genomic Viewer 2.03 (120). 
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Chi-Squared test with p-value <0.05 was used for every gene to find significant relations 
between number of mutated samples and PTCL/NOS subgroups.  
2.6. Tissue microarray construction and Immunohistochemical analysis 
For tissue microarray (TMA) construction, a slide stained with hematoxylin and eosin was 
prepared from each available paraffin block, and representative tumor regions were 
morphologically identified and marked on each slide. Tissue cylinders with a diameter of 1.0 
mm were punched from the marked areas of each block and brought into a recipient 
paraffin block using a precision instrument, as previously described (121). Four µm-thick 
sections were cut from each recipient block and used for Giemsa or immunohistochemical 
stains.  Details of the antibodies used, antigen retrieval, and detection methods strategies 
were previously reported (72, 78, 122). Each section was evaluated by two experienced 
pathologists. Each observer estimated the number of positive cells according to the criteria 
used by Hans et al (123). 
Specific antibodies representative of the diverse T-lymphocyte commitments were used 
including TEM-TCM (CD45RA and CCR7), TH (CD4), TC (CD8, TIA1, PERF, and GRZB), TH1 
(TBET and IFNG), TH2 (GATA3 and IL4), TH17 (IL17A), TFH (CD10, BCL6, CXCL13, and PD1), 
and Treg (FOXP3). Based on immunohistochemistry, cases were assigned to a specific group 
if the phenotype was either completely consistent (i.e. positive for the specific lineage 
markers and negative for all the others) or positive for all but one specific lineage markers 
and negative for all the other (being accepted a defective phenotype). Conversely, cases 
were defined as “unclassifiable” if inconsistent results were observed (i.e. positivity for 
markers representative of multiple lineages). PD1 and FOXP3 were accepted as consistent 
for a cytotoxic profile if at least CD8 was positive among cytotoxic markers and all the other 
markers typical of TH were negative. 
2.7. Survival analyses  
Overall survival (OS) was calculated from the time of diagnosis to death or last follow-up. 
Statistical analyses were carried out by IBM SPSS Statistics 20.0. Survival data were analyzed 
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with the Kaplan–Meier estimator method (124). The limit of significance for all analyses was 









Molecular Profiling Of Peripheral T-Cell 
Lymphomas-NOS Identifies Clinical Subgroups 




PTCL/NOS correspond to different functional T-cell subsets 
The overall study design is depicted in Figure 3.1.1. We studied 106 PTCL/NOS cases for 
genes that were differentially expressed in purified T-lymphocyte subpopulations (TH, TC, 
TH1, TH2, TH17, TFH, and Treg). A score was obtained for each PTCL/NOS sample based on a 
support vector machine method and gene set enrichment analysis (GSEA). Each sample was 
then assigned to a specific T-cell counterpart or another one according to the distance 
between the obtained score and a cut-off value calculated for each predicted group.  
First, we classified the PTCL/NOS according to their similarity to helper or cytotoxic T-cells. 
We observed that most PTCL/NOS were more closely related to TH cells (83/106, 78.3%), a 
minority were closer to TC (21/106, 19.8%), and two cases remained unclassified (1.9%). 
Within the group of PTCL/NOS classified as TH, the expression of genes characteristic of 
different TH functional/differentiation statuses was evaluated. We found that 29/83 (34.9%) 
samples were classified as TH1 cells, 34/83 (41%) as TH2, 4/83 (4.8%) as TFH, 3/83 (3.6%) as 
TH17, and 5/83 (8.1%) as Treg and that 8/83 (9.6%) cases could not be clearly assigned to 
any TH subtype (Figures 3.1.2A-D; Figure 3.1.3; Supplementary Table 2).   
Importantly, the subdivision in the above-detailed categories was not associated with 
specific presenting features, including age, performance status, extranodal involvement, 
and international prognostic index. 
Taken together, these results indicated that the heterogeneity of PTCL/NOS finds 
correspondence in the spectrum of functional T-cell subsets. 
Minimal gene sets are sufficient to identify the different PTCL/NOS subtypes 
Within the 106 fresh/frozen cases, a training set was created selecting a random 
permutation of about 50% of cases using the shuf function in UNIX Bash shell. The 
remaining cases constituted the test set. A stepwise discriminant function was then applied 
to the test set (N=57) to identify the minimal gene set (MGS) able to efficiently discriminate 
between the different PTCL/NOS subgroups (i.e., TH vs. TC, and TH1 vs. TH2 vs. TFH vs. Treg 
vs. TH17). For each classification step, a discriminant function based on a linear combination 
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of the discriminant genes was created. To validate the efficacy of the obtained MGS, the test 
set comprising 49 PTCL/NOS was analyzed (Supplementary Tables 3-4).   
Each case previously classified with a complete molecular signature was re-classified by the 
MGS with an accuracy of 92.68% and 83.33% for the TH and TC subtypes, respectively, of 
100% for TH1 and Treg, 95.24% for TH2, and 75% for TFH and TH17 (Figure 3.1.4A-B; 
Supplementary Tables 5-10). 
The molecular classification relies on robust pathobiological features 
To assess whether the obtained classification was provided with a robust biological 
significance, we first looked for molecular pathways differentially regulated in the various 
groups. Interestingly, by GSEA we found that 3 main groups could be appreciated, 
corresponding to cytotoxic (group A), Th1/Th2/Th17 (group B), and Tfh/Treg (group C) cases 
and relying on different master pathways.  The latter included MTOR pathway (p=0.000252), 
STAT3 targets (p<0.0001), IFNA response genes (p<0.0001), and genes silenced by 
methylation (p<0.0001). Overall, this was in line with the notion that different effector or 
regulatory functions of helper T-cell phenotypes and the Th-cell differentiation hierarchy 
relies on specific signaling with TH1/TH2/TH17 subsets sharing mTORC1/mTORC2 
dependency (Figure 3.1.5 and 3.1.6A; Supplementary Table 11). 
Second, we investigated by whole exome sequencing whether different genetic lesions were 
associated with the molecular groups. The analysis was performed in a subset of 29 cases, 
for which genomic DNA was available. Indeed, we found a few lesions that were highly 
recurrent within each single group. Beside the already known FYN, IDH2 and TET2 mutations 
we identified several lesions previously not reported in PTCLs such as ABCB1, BAHCC1, 
BTN2A2, CX3CR1, NDUFV3, PLCL2, and the tumor suppressor PRDM2 in the TH1/TH2/TH17 
group, SOGA2, A2ML1, CCPG1, CDC27, LRP3, MOCS2, and MTDH in the TC group, and 
ATXN3, C3, COG3, CRYGS, FAM198B, GPAT2, IDH1,PHKA1, RBMXL1, TMEM204, TRIM61, 
TRMT44,  and VWA1 in the TFH/TREG group (Figure 3.1.6B; Supplementary Table 12).  
Remarkably, we found that the different genetic lesions targeted specific pathways in the 3 
groups that largely corresponded to the pathways highlighted by the GEP analysis as 
characteristic of the 3 groups. Specifically, cytotoxic cases presented with mutations mainly 
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occurring in T-acute lymphoblastic leukemia and targeting KRAS, JAK2, NOTCH1, LEF1, BMI1, 
RB1, TP53, EZH2, and HOXA9 (p<0.0001). This finding was quite relevant being in line with a 
higher aggressiveness of the tumor and suggests sensitivity to more aggressive 
chemotherapeutic regimens as well as to specific inhibitors. The TH1/TH2/TH17 group 
presented a preferential occurrence of lesions interfering with the MTOR/AKT pathway 
(p<0.0001) in line with the GEP. Finally, TFH/TREG cases presented mutations affecting the 
epigenetic regulation of gene expression (EZH2 and histone deacetylase targets) as well as 
the FOXP3 network (p<0.0001) (Supplementary Table 13). 
Based on the emerging evidence of specific pathways involved as drivers of PTCL/NOS 
subclassification, we tried to verify whether the selective inhibition of a master pathway 
could exert antitumor activity in PTCL cells. To this end, we first applied the molecular 
classifier to some PTCL cell lines. The two cutaneous T-cell lymphoma (HH and MAC1) lines 
and the only available PTCL/NOS cell line (Fe-Pd) were classified as belonging to the 
TH1/TH2/TH17 group. We thus treated them with MTOR and PI3K inhibitors (Everolimus 
and LY-294002) alone and in combination. Notably, though the single agents were scarcely 
effective, the combination potently and synergistically induced PTCL cell death in a dose- 
dependent manner (Figure 3.1.6C). 
Collectively, these data indicate that molecular subgroups of PTCL/NOS corresponding to 
different counterparts rely on different pathways largely affected by genetic events, and 
that selective targeted treatment may be a rationale approach in this setting. 
The molecular sub-classification of PTCL/NOS has clinical implications 
We then assessed whether the proposed PTCL/NOS sub-classifications had clinical 
significance. To this end, we evaluated the overall survival (OS) of patients belonging to the 
different subgroups. TC-related PTCL/NOS had a worse outcome than TH-related PTCL/NOS, 
which was consistent with previous observations (64). Specifically, after a median follow-up 
of 33.90 months, the former had a median OS of 8.84 months (95% CI 2.41-15.26), and the 
latter had a median OS of 20.05 months (95% CI 10.37-30.63) (p=0.04; Figure 3.1.7A).  
When the five TH subtypes were considered, no significant differences were observed, 
although the cases classified as Treg and TFH generally fared better. However, when the 3 
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functional and genetic subgroups were considered, significant differences in terms of OS 
were recorded. Specifically, the median OS for TC (N= 9; 8.84 months, 95% CI, 2.41-15.26) 
was significantly worse than that for TH1-TH2-TH17 (N=30; 20.5 months; 95% CI, 10.98-
30.02; p=0.05) and for TFH-Treg (N=6; 40.9 months; 95% CI, 0-85.79; p=0.02; Figure 3.1.7B). 
Notably, this difference was independent of the other main clinico-pathological parameters 
at presentation (IPI, PIT, and modified PIT). 
The molecular classification of PTCL/NOS can be applied to FFPE routine samples 
We next sought whether the developed classifier could be efficiently applied to FFPE tissues, 
in order to evaluate its potential impact on routine diagnostics. 
We first applied the molecular signature discriminating the TH vs. TC subtypes, which 
identified two groups (Figure 3.1.8A). Consistent with this, the MGS (5 genes) correctly 
classified 69/80 (86.25%) samples (Figure 3.1.8B). Notably, such classification of the FFPE 
samples retained a significant correlation with prognosis (Figures 3.1.8C).  
Based on this evidence, we further divided TH cases into TH1-TH2-TH17 and Treg-TFH, 
which were characterized by significantly different OS. Specifically, after a median follow-up 
of 54.18 months, the TC cases had the worst outcome (N=15; 8.838 months, 95% CI 1.391-
16.284; p=0.037 vs. TH1/TH2; p=0.003 vs. Treg/TFH), the Treg/TFH (N=12) cases displayed a 
better outcome (40.903 months, 95% CI 17.338-64.469; p=0.033 vs. TH1/TH2), and the 
remaining TH subsets (N=34) showed an intermediate outcome (15.901 months, 95% CI 
8.396-23.407) (Figure 3.1.8D).  
Altogether, these results demonstrated that PTCL/NOS sub-grouping, based on an 
integrated diagnostic approach, is clinically relevant and feasible in routine samples. 
Immunohistochemistry can only partially replicate the molecular profiling 
Given that the molecular PTCL/NOS sub-grouping had both biological and clinical relevance 
and could be reliably applied to routine samples, we sought to assess whether it could be 
efficiently substituted by IHC analyses.  
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We studied 16 markers representative of T-cell commitment, the complete panel of 
antibodies being evaluable in 63/80 cases. We found that 33/63 (52%) cases had a 
phenotype consistent with TH cells and that 11/63 (17%) had a phenotype consistent with 
TC cells but that 19/63 (30%) could not be assigned to a phenotype, either for discordant 
CD4/CD8 expression (double-negative or double-positive) or inconsistent expression of 
additional molecules. Among TH, 8/63 (13%) had a phenotype consistent with TH1, 14/63 
(22%), TH2; 7/63 (11%), TFH; and 4/63 (6%), Treg. None of the analyzed cases was 
characterized by IL-17A expression, which is characteristic of TH17 and was only observed in 
scattered reactive lymphoid and myeloid cells (Figure 3.1.9A; Supplementary Table 14). 
Accordingly, the IHC-based classification did not determine a clinically meaningful 
distinction (Figure 3.1.9B). 
These data suggest a note of caution about the applicability of immunophenotyping to fully 
recapitulate the GEP categories. Consistent with this, survival analysis based on 
immunohistochemistry-derived categories failed to offer significant prognostic information, 
reflecting an overall discrepancy between immunohistochemistry and GEP. In fact, IHC was 
quite accurate almost exclusively for the identification of Treg and TFH cases, as confirmed 
by GSEA. Particularly, immunohistochemistry performance was poor in the crucial 
distinction between TH and TC, being consistent with GSEA in 46.03% of cases only. 



















Figure 3.1.2. Molecular classification of peripheral T-cell lymphomas not otherwise 
specified according to their correspondence to different functional T-cell subsets. The pie 
charts and the scatter plots show the distribution of cases according to their molecular 
classification into the TH vs. TC (A-B), and TH1 vs. TH2 vs. TH17 vs. Treg vs. TFH (C-D) 
subgroups. The colors indicate different molecular subgroups. Cases with a confidence 
measure score less than 0.05 in absolute value fall within no classification area and are 





















Figure 3.1.3. Molecular classification of PTCL/NOS according to T-cell subtype signature. A) 
Classification of PTCLs/NOS classified as helper or cytotoxic T-cells. B) Classification of 
PTCLs/NOS classified as TH in to TH subtypes. In the heat map, each column represents a 
sample, and each row represents a probeset (gene). The color scale bar shows the relative 
gene expression changes normalized to the standard deviation (0 is the mean expression 


















Figure 3.1.4. Linear discriminant analysis in the training and test sets of cases. The scatter 
plots show the distribution of the PTCL/NOS samples in the training and test sets according 
to their discriminant scores in the minimal gene sets classification step: TH vs. TC (A) and 
TH1 vs. TH2 vs. TH17 vs. Treg vs. TFH (B). The colors indicate different molecular subgroups. 
Cases with a discriminant score less than 0.6 in absolute value fall within no classification 






















Figure 3.1.6. The PTCL/NOS molecular subgroups have distinct genetic and functional 
profiles. A) Hierarchical clustering of TC, TFH/TREG, and TH1/TH2/TH17 PTCLs/NOS based 
on the expression of differentially regulated genes (ANOVA, p<0.05; FC>2, Benjamini-
Hockeberg FDR). Two main groups were generated, one corresponding to cytotoxic tumors 
(TC) and one to helper-related ones. The latter was further divided according the specific 
functions into TFH-TREG and TH1-TH2-TH17. B) Mutational landscape of PTCL/NOS 
subgroups: number of samples carrying somatic mutations (x axis) in a given gene (y axis) 
are represented by the histograms. Genes most significantly over-represented in each group 
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and mutated in only one of them are plotted. C) PTCL cell line viability upon treatment with 
Everolimus and LY-294002 in combination (Ic50 not reached with the single drugs, data not 
shown). The IC50 values at 48 hours for the combination in the three cells lines were as 























Figure 3.1.7. Survival analyses of PTCL/NOS patients divided according to the molecular 
classification steps: TH vs. TC (A), and TC vs. Treg and TFH vs. TH1, TH2 and TH17 (B). P-





















Figure 3.1.8. Molecular classification of FFPE PTCL/NOS cases. The heatmap of samples 
according to the signatures differentially expressed in TH vs. TC is plotted in panel A. In the 
matrix, each column represents a sample, and each row represents a gene. The color scale 
bar shows the relative gene expression changes normalized to the standard deviation (0 is 
the mean expression level of a given gene). In panel B the accuracy of the linear discriminant 
function was based on the 5-gene-based MGS (B). Survival analyses of PTCL/NOS patients 
studied on FFPE samples that served as validation set. TH vs. TC subgroups (C) and for TC vs. 
Treg and TFH vs. TH1, TH2 and TH17 (D). P-values less than 0.05 for the log rank Mantel-Cox 






















Figure 3.1.9. Immunohistochemical evaluation of T-cell specific markers. A) Examples of 
CD4, CD8, IFNg, nuclear GATA3, CXCL13, and FOXP3 staining are presented. B) Survival 
analyses of PTCL/NOS patients studied on FFPE samples by immunohistochemistry TH vs. TC 





Gene and miRNA expression analysis of Lennert 
lymphoma reveals a unique profile and identifies 
novel therapeutic targets 
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Unsupervised analysis suggests some shared molecular features between Lennert 
lymphoma, and other PTCL subtypes 
In order to compare the molecular features of LL with other PTCL subtypes, we analyzed the 
global gene expression profiles of 12 LL and 90 PTCLs cases which included 10 AITL, 12 ALCL 
and 68 PTCL/NOS and also 10 T lymphocyte samples taken from normal donors. First, we 
exploited two widely used unsupervised approaches, namely principal component analysis 
(PCA) hierarchical clustering analysis (HCA). The results of PCA showed a homogeneous 
dispersion of almost all cases including LLs in the 3D space (Figure 3.2.1A), with cumulative 
variance equal to 34.4%. There were, however, two exceptions, including normal T-cells and 
AITLs, which constitute quite discrete subgroups in the analysis. The results of unsupervised 
HCA turned out to be very similar to PCA (Figure 3.2.1B).  
We then focused on the comparison of LL cases with other PTCL/NOS, using the same two 
unsupervised methods mentioned above. Similarity, we were unable to discriminate the 
two groups based on their global gene expression profiles (Figure 3.2.1C-D). 
Lennert lymphoma holds a unique gene expression signature which potentially can be 
used as a molecular diagnosis tool 
To find the differentially expressed genes, we further proceeded with direct comparison of 
LL and other PTCL/NOS. First, the two groups of LL and other PTCL/NOS samples were 
randomly divided into two groups, namely training and test sets, corresponding to 6 LL and 
31 PTCL/NOS samples for the former and 6 LL and 27 PTCL/NOS cases for the latter. 
Supervised analysis of the training set (Corrected p-value <0.05, FC<2) identified 90 genes 
differentially expressed between LL and other PTCL/NOS (Figure 3.2.2A, Supplementary 
Table 16). We then sought to assess whether the genes differentiating LL from other 
PTCLS/NOS cases might have a significant role in tumorigenesis. Interestingly, analysis of 
biological processes using GSEA MsigDB tool performed separately on the up- and 
downregulated genes in LL uncovered a significant enrichment in highly relevant processes, 
such as upregulation of cell communication, intracellular signaling cascade, and signal 
transduction for the former, and cell growth/maintenance and cell proliferation for the 
latter (Figure 3.2.2B). Furthermore, when applied in a supervised HCA, the resulted 
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signature emerged to be able to differentiate the two groups of the training set correctly, 
with a p-value equal to 0.0007, as judged by Fisher’s exact test (Figure 3.2.2C).  
Thereafter, we tried to decrease the number of the differentiating genes, with the intention 
of finding the most valuable ones which could be used as a diagnosis tool for classifying LL 
from other PTCL/NOS. In this regard, the 90 genes resulting from the training set were re-
supervised in the test set (p-value <0.05, FC<2). A total number of 17 out of the initial 90 
genes were achieved (Figure 3.2.3A, Supplementary Table 17), and used to classify all LL and 
other PTCL/NOS samples. The results showed a high accuracy of the classifier:  9 out of 12 
LLs and 57 out of 68 PTCLs/NOS were correctly classified, resulting in an overall diagnostic 
accuracy (ODA) of 83% and negative predictive value (NPV) of 95%, clearly confirming the 
validity of the molecular signature as a diagnosis tool (Figure 3.2.3B, Table 3.2.1). 
Gene signature of Lennert lymphoma demonstrates unique signature of cytotoxic function 
We tried to examine the possible cytotoxic T-cell phenotype of LL cases using different 
approaches. A GSEA based on the cytotoxic molecular signature (Supplementary Table 1) 
was applied to compare LL with other PTCLS/NOS, and a significant enrichment was 
observed between the two groups (Figure 3.2.4A). A supervised analysis (p-value <0.05, 
FC<2) was then performed to explore the genes that would differentiate LL and other 
Cytotoxic-PTCL/NOS (Cy-PTCL/NOS), which resulted in 131 and 24 genes, up- and 
downregulated in LL, respectively (Supplementary Table 18). Intriguingly, this signature 
could clearly distinguish LL from other Cy-PTCL/NOS cases, when applied in a supervised 
HCA (p=0.0007) (Figure 3.2.4B). The resulting signature, when analyzed using GSEA, 
revealed a significant enrichment in the relevant biological processes such as defense 
response, regulation of apoptosis, cell development, intracellular signaling, gene regulation, 
regulation of transcription and translation (Figure 3.2.4C).  
MicroRNA and gene expression signatures of Lennert lymphoma suggest PI3K/Akt/mTOR 
pathway as a candidate therapeutic target  
To identify deregulated miRNAs in LL, we performed miRNA profiling using a TaqMan qPCR 
based assay on LL and PTCL/NOS cases. As before, a supervised analysis (p-value <0.05, fold 
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change>2) was carried out, which resulted in identification of 9 cellular miRNAs differentially 
expressed in LL, as compared to PTCL/NOS (Figure 3.2.5A, Supplementary Table 19). A HCA 
based on the expression of the deregulated miRNAs, resulted in the two diseases being 
clearly differentiated (p-value=0.009, Figure 3.2.5B). A similar approach was followed, 
comparing LL and normal T-lymphocyte samples, which identified 229 miRNAs differentially 
expressed (corrected p-value <0.01, fold change>2), most of which were underexpressed in 
LL (Figure 3.2.5C, Supplementary Table 20), and a clear classification of the normal and 
neoplastic samples was obtained in a HCA (Figure 3.2.5D).  
We further proceeded with more detailed comparison of LL with normal T-lymphocyte. 
First, a supervised analysis was utilized in order to find the genes that distinguish the two 
set of samples. Totally 622 genes were found (corrected p-value <0.005, fold change>2) 
which were differentially expressed in the two categories, most of which were upregulated 
in LL (Figure 3.2.6A, Supplementary Table 21). Importantly, when we performed a 
supervised HCA based on the expression of those genes, normal and neoplastic samples 
were clearly differentiated (Figure 3.2.6B). Gene set enrichment analysis of the differentially 
expressed genes revealed a significant enrichment of biological processes highly relevant to 
malignant phenotype. Remarkably, most of such processes could be referred to two main 
categories or both: neoplastic clone (e.g. cell growth, angiogenesis and cell adhesion/cell-
cell signaling) and microenvironment (e.g. response to wounding, collagen catabolism and 
extracellular matrix) (Figure 3.2.6C, Supplementary Table 22). As a confirmation, we 
evaluated the expression of CD68, a marker widely used for detection of tumor-associated 
macrophages in tumor microenvironment in LL samples, which turned out to be positive 
(Figure 3.2.6D). 
Searching for the master cellular pathway(s) which could be mostly responsible for the 
malignant phenotype of LL, we analyzed its molecular signature, including both differentially 
expressed genes and predicted targets of differentially expressed miRNAs (as compared to 
normal T-cells) in Ingenuity Pathway Analysis (IPA) software. Very interestingly, 
PI3K/Akt/mTOR signaling axis, a well-described pathway in human malignancies, emerged to 
have a central role in molecular pathology of LL (Figure 3.2.7A). Very importantly, the tumor 
samples showed positivity for STAT5, as judged by IHC (Figure 3.2.7B). This is in line with the 
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above mentioned observation that PI3K/Akt/mTOR signaling axis inhibition could be a 
rationale therapeutic strategy in PTCLs.  
Clinical features add more documents supporting Lennert lymphoma as a distinct entity 
In addition, we analyzed different aspects of clinical information for LL patients and 
compared it to other PTCL/NOS, by means of Fisher's exact test or T-test for non-continuous 
and continuous variables, respectively. The data was available for 10 out of 12 LL and 68 of 
other PTCL/NOS patients. As described in Table 3.2.2, we found significant differences in 
some characteristics including male/female ratio (9 vs. 1, p-value=0.02) and B-symptoms (1 
out of 10 patients, p-value=0.036). As concerns for treatment response and survival, a 
favorable trend was observed in LL, although the differences were not statistically 





Figure 3.2.1. Unsupervised analysis hardly discriminates Lennert lymphoma from other PTCL 
subtypes with nodal origin. Principal component analysis (A) and unsupervised hierarchical 
clustering (B) performed on Lennert lymphoma, PTCL subtypes, and normal T-cells failed to 
discriminate them. There was, however, a distinct clustering of AITL and normal T-cell samples. 
Similarly, principal component analysis (C) and unsupervised hierarchical clustering (D) turned out 
to be incompetent in classifying LL from other PTCL/NOS cases. Each sphere in the three-
dimensional space represents a single sample, and each dimension represents a principal 
component. In the heat map, each column represents a sample, and each row represents a 
probeset (gene). The color scale bar shows the relative gene expression changes normalized to the 




Figure 3.2.2. Supervised analysis identified genes distinguishing Lennert lymphoma from 
PTCL/NOS. A) Supervised HCA analysis identified 90 genes differentially expressed in Lennert 
lymphoma vs. PTCL/NOS in a training set of cases. In the volcano plot, each red square represents 
a gene. B) Based on the expression of the differentially expressed genes, the two diseases were 
clearly differentiated, when applied in a hierarchical clustering. In the heat map, each column 
represents a sample, and each row represents a probeset (gene). The color scale bar shows the 
relative gene expression changes normalized to the standard deviation (0 is the mean expression 
level of a given gene). C) GSEA showed a significant enrichment in specific biological processes 




Figure 3.2.3. Validation of the molecular signature of Lennert lymphoma as a molecular 
diagnosis tool. A) A re-supervised analysis on the 90 genes differentially expressed of training set 
in a test set of cases resulted in 17 genes as the most valuable ones. In the volcano plot, each red 
square represents a gene.  B) Based on the expression of the identified 19 genes in the test set, all 
the cases were efficiently diagnosed as Lennert lymphoma or other PTCL/NOS with an Overall 
Diagnostic Accuracy (ODA) of 83% and Negative Predictive Value (NPV) 95% and the pathological 




Figure 3.2.4. Lennert lymphoma signature is significantly enriched in genes belonging to the 
cytotoxic function. A) A gene set enrichment analysis of the cytotoxic T-cell signature 
distinguished Lennert lymphoma from other PTCL/NOS. B) A supervised analysis was performed to 
distinguish the genes differentially expressed between LL and other cytotoxic PTCL/NOS. A 
hierarchical clustering was followed based on the expression of such genes, and clearly 
distinguished LL from other cytotoxic PTCL/NOS cases (p=0.0007 In the heat map, each column 
represents a sample, and each row represents a probeset (gene). The color scale bar shows the 
relative gene expression changes normalized to the standard deviation (0 is the mean expression 
level of a given gene). C) A GSEA based on the differentially expressed genes from the previous 




Figure 3.2.5. Lennert lymphoma represents a unique microRNA signature. A) Supervised analysis 
identified 9 miRNAs differentially expressed in Lennert lymphoma vs. other PTCL/NOS. B) Based on 
the expression levels of the found miRNAs, the two diseases were clearly classified in a 
hierarchical clustering analysis. C) Supervised analysis identified 229 miRNAs differentially 
expressed in LL as compared to normal T-lymphocytes. D) By a hierarchical clustering, normal and 
neoplastic samples were clearly differentiated based on the expression of such 229 miRNAs. In the 
volcano plot, each red square represents a miRNA. In the heat map, each column represents a 
sample, and each row represents a probeset (miRNA). The color scale bar shows the relative gene 





Figure 3.2.6. Genes distinguishing Lennert lymphoma from normal T-cells are involved in 
processes related to malignant phenotype. A) A supervised statistical investigation identified 622 
genes differentially expressed in LL in comparison to normal T-lymphocytes. In the volcano plot, 
each red square represents a gene. B) The identified genes were used to classify normal and 
neoplastic samples, which turned out to be clearly differentiated in a hierarchical clustering 
analysis. In the heat map, each column represents a sample, and each row represents a probeset 
(gene). The color scale bar shows the relative gene expression changes normalized to the standard 
deviation (0 is the mean expression level of a given gene). C) Gene Set Enrichment Analysis of the 
differentially expressed genes identified significant enrichment referred to either the neoplastic 
clone or to the microenvironment or to both. D) Immunohistochemical staining of CD68, a marker 





Figure 3.2.7. The MTOR/PI3K pathway is a candidate therapeutic target in LL. A) An 
analysis performed using Ingenuity Pathway Analysis (IPA) software using genes and (targets 
of) miRNAs deregulated in Lennert lymphoma identified PI3K/Akt/mTOR pathway as a 
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possible therapeutic target in Lennert lymphoma. B) Activity of PI3K/Akt/mTOR pathway in 
Lennert lymphoma was checked by Immunohistochemical staining of STAT5. The neoplastic 










LL: Lennert Lymphoma; PTCL/NOS: Peripheral T-cell Lymphoma-Not otherwise specified; ST: 
SENSITIVITY; SP: SPECIFICITY; PtP: Pre-test Probability; PPV: Positive Predictive Value; NPV: 
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Table 3.2.2. Comparison of clinical features of Lennert lymphoma vs. other PTCL/NOS. 
 
LL: Lennert Lymphoma; PTCL/NOS: Peripheral T-cell Lymphoma-Not otherwise specified; 
CR: Complete Response; PR: Partial Response; NR: Not Response; OR: Objective Response; 
OS: Overall Survival. 
 Other PTCL/NOS LL p-value 
Number of cases 68 10 NA 
Male: Female 1:1 9:1 0.02 
Mean age, years (range) 50.9 (7-80) 48.7 (22-67) NS 
Stage III-IV (%) 47/68 (69) 6/10 (60) 0.7 
B-symptoms (%) 33/68 (49) 1/10 (10) 0.036 
Bulky disease (%) 7/68 (10) 3/10 (30) 0.11 
Mediastinal mass (%) 21/68 (31) 4/10 (40) 0.7 
Bone marrow involvement (%) 21/68 (31) 1/10 (10) 0.26 
Extra-nodal involvement (%) 26/68 (38) 2/10 (20) 0.32 
Hemophagocytic syndrome (%) 3/68 (4) 0/10 1 
    
Treatment response & Survival    
CR (%) 33/68 (49) 6/10 (60) 0.7 
PR (%) 13/68 (19) 3/10 (30) 0.4 
NR (%) 22/68 (32) 1/10 (10) 0.26 
OR (%) 46/68 (67) 9/10 (90) 0.26 




Molecular Signature of Follicular Variant of 
Peripheral T-Cell Lymphoma Not Otherwise 
Specified Implies Distinction from 
Angioimmunoblastic T-cell Lymphoma 
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Unsupervised approaches barely distinguish F-PTCL from other nodal PTCL subtypes  
We analyzed the global gene expression profiles of 82 PTCL cases which included 10 AITL, 10 
F-PTCL, 50 PTCL/NOS, 10 ALK-negative and 10 ALK-positive ALCLs. The most widely used 
unsupervised methods including principal component analysis (PCA) and hierarchical 
clustering analysis (HCA) were first utilized to compare the global profile of all the groups 
included. The results of PCA showed a dispersion of all cases, and a faint grouping of all 
categories (except for the major part of PTCL/NOS) gathering around Y-axis (Figure 3.3.1A).  
We found similar results when used HCA (Figure 3.3.1B).  
We followed our analysis with comparison of Tfh-related nodal PTCLs (i.e. F-PTCL, AITL and 
Tfh-PTCL/NOS) using the same methods. Again we found a major proportional grouping 
around Y-axis, and notably, both Tfh-positive and negative cases of PTCL/NOs showed 
similarity with F-PTCL and AITL (Figure 3.3.1C). Once more, unsupervised HCA confirmed the 
results obtained from PCA (Figure 3.3.1D). 
F-PTCL exhibits a global molecular profile more similar to PTCL/NOS rather than AITL 
As concerned with the molecular correlation of F-PTCL, we aimed to analyze the closeness 
of F-PTCL to AITL or PTCL/NOS, in terms of molecular profiles. As a control, Tfh-PTCL/NOS 
cases were treated using the same approach. We used a classifier in GeneSpring software, 
and it was found that F-PTCL tumors exhibit a molecular profile much more similar to 
PTCL/NOS, rather than to AITL (Figure 3.3.2A). OF note, all the cases grouped very closely 
together, and none happened to be in the grey zone. Similarly, Tfh-PTCL/NOS cases were 
clustered close to the molecular profile of PTCL/NOS.  
A supervised HCA based on the expression of genes differentially expressed between AITL 
and PTCL/NOS was then followed, which verified the previous results (Figure 3.3.2B). Here, 
F-PTCL samples categorized with PTCL/NOS cases, rather than AITL ones. However, unlike 





The gene expression profile of F-PTCL is distinct from AITL and Tfh-PTCL/NOS 
Concerned with the possible molecular distinction among PTCLs with nodal origin, especially 
F-PTCL and other two categories, namely AITL and Tfh-PTCL/NOS, we used supervised 
approaches to find the genes that would distinguish them. First, by means of an ANOVA 
(corrected p-value<0.01 and fold change>2) analysis, we compared all the three groups. 
Collectively, we found 881 genes differentiating them, most of which seemed to be up-
regulated in F-PTCL (Supplementary Table 23). These genes were able to cluster the groups 
accurately, when used in a HCA (Figure 3.3.3A). Of note, there was one single sample 
belonging to Tfh-PTCL/NOS happened to cluster with AITL samples (Figure 3.3.3A, red 
arrow). 
A paired supervised analysis of the three sets was then performed, using student’s T-test. 
Comparison of F-PTCL with AITL (corrected p-value<0.01 and fold change>2) resulted in 
identification of 581 genes, 248 up- and 333 downregulated in F-PTCL, respectively 
(Supplementary Table 24), which resulted in a precise classification of the two diseases 
(Figure 3.3.3B). As concerned with comparison of F-PTCL and Tfh-PTCL/NOS (corrected p-
value<0.05 and fold change>2), we found 272 genes induced in F-PTCL and 22 genes 
suppressed in F-PTCL (Supplementary Table 25). Once again, a precise categorization was 
achieved using these genes (Figure 3.3.3C). The last pair of samples compared, i.e. AITL and 
Tfh-PTCL/NOS produced 43 and 75 genes over- and under-expressed in AITL (corrected p-
value<0.05 and fold change>2, Supplementary Table 26).  Although a clear distinction of the 
two sets was achieved using HCA, as in Figure 3.3.3A, the same sample of Tfh-PTCL/NOS was 
classified with AITL cases (Figure 3.3.3D).  
Different master transcription regulators might operate in F-PTCL and AITL 
We continued with examining the correlation of F-PTCL and AITL in terms of the regulatory 
molecules. Specifically, we used the gene signature distinguishing the two groups in a GSEA, 
aiming to recognize the transcription regulators that would be (at least in some extent) 
responsible for the different molecular profiles of the two cancers. Of note, the obtained 
data suggests involvement of several such molecules (Figure 3.3.4A). Among them, we 
analyzed the expression of two master regulators widely recognized in human cancers, 
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including LEF1 (Lymphoid enhancer-binding factor 1) and SP1 (specificity protein 1). Both 
genes were differentially expressed between F-PTCL and AITL (Figure 3.3.4B), being LEF1 






Figure 3.3.1. Unsupervised approaches barely distinguish F-PTCL from other nodal PTCL 
subtypes. Principal component analysis (A) and unsupervised hierarchical clustering (B) performed 
on PTCL subtypes including AITL, ALK-positive and ALK-negative ALCL, PTCL/NOS, and F-PTCL failed 
to discriminate them. Similarly, principal component analysis (C) and unsupervised hierarchical 
clustering (D) performed on Tfh-related nodal PTCLs including  F-PTCL, AITL and Tfh-PTCL/NOS 
which did not result in clear grouping of the samples. Each sphere in the three-dimensional space 
represents a single sample, and each dimension represents a principal component. In the heat 
map, each column represents a sample, and each row represents a probeset (gene). The color 
scale bar shows the relative gene expression changes normalized to the standard deviation (0 is 









Figure 3.3.2. F-PTCL exhibits a global molecular profile more similar to PTCL/NOS rather than 
AITL. A) Using a classifier based on global gene expression profiles, F-PTCL samples exhibited 
molecular profiles more similar to PTCL/NOS, as compared to AITL. Similar as well as, Tfh-
PTCL/NOS cases were clustered close to the molecular profile of PTCL/NOS. B) Similarly, a 
supervised HCA based on the genes differentially expressed between AITL and PTCL/NOS verified 
F-PTCL samples to categorize more closely with PTCL/NOS cases. In the heat map, each column 
represents a sample, and each row represents a probeset (gene). The color scale bar shows the 
relative gene expression changes normalized to the standard deviation (0 is the mean expression 















Figure 3.3.3. The gene expression profile of F-PTCL is distinct from AITL and Tfh-PTCL/NOS. A) 
Using ANNOVA analysis three groups of F-PTCL, AITL and Tfh-PTCL/NOS were clustered based on 
the genes differentially expressed among them. Paired supervised analysis followed by HCA 
performed between F-PTCL vs. AITL (B), F-PTCL vs. Tfh-PTCL/NOS (C), and AITL vs. Tfh-PTCL/NOS 
(D) resulted in precise classification of these three groups. The sample belonging to Tfh-PTCL/NOS 
which classified with AITL samples is indicated with red arrow. In the heat map, each column 
represents a sample, and each row represents a probeset (gene). The color scale bar shows the 
relative gene expression changes normalized to the standard deviation (0 is the mean expression 





















Figure 3.3.4. Different master transcription regulators might operate in F-PTCL and AITL. 
A) The gene set enrichment analysis (GSEA) identified regulatory molecules responsible for 
the different molecular profiles of the F-PTCL and AITL. B) Among the identified molecules, 
two master regulators widely including LEF1 (Lymphoid enhancer-binding factor 1) and SP1 








The sub-classification of PTCL/NOS based on their relation with different functional T-cell 
subsets provides new insights into the pathogenesis of PTCL/NOS and, at the same time, 
offers the opportunity to identify patient groups with diverse clinical behaviors to be 
evaluated in specific clinical trials.  
PTCL/NOS have previously been shown to consist of activated TC or TH clones (34, 36, 62, 
64, 78), which had different prognoses (64, 78), and GEP was the only approach able to 
clearly distinguish the two groups (62, 64). 
Importantly, the identification of a very complex scenario further stressed a crucial issue in 
PTCL/NOS biology, i.e., whether these clones actually derive from different cell types or 
instead differentiate toward diverse lineages in response to microenvironmental stimuli or 
as a consequence of their individual characteristics. Indeed, T-cell priming conditions may 
deeply influence the relative prevalence of polarizing signals through the modulation of 
master transcription factors. A notable example is the transcription factor GATA-3, whose 
expression can be modulated by environmental signals through Notch signaling and whose 
activity in T-cell clones may go beyond the stabilization of TH2 commitment by affecting 
mature T-cell chromatin remodeling and proliferation in both the CD4+ TH and CD8+ TC 
subsets (125-127). This fact is not trivial because it might indicate a maintained sensitivity 
(or even a dependency) to the reactive milieu, which could, in turn, determine the 
functional properties of the neoplastic cells and consequently influence tumor development 
and progression. In this regard, our group recently demonstrated that non-neoplastic cells 
are associated with the clinical syndrome in AITL (128). However, a different histogenesis 
may be associated with different etiologic stimuli and/or with specific genetic events (41, 
42, 80, 96, 129, 130). In this regard, we found that specific mutation patterns characterized 
the main PTCL/NOS subgroups in terms of both single lesions and pathways. Some of them, 
including those affecting JAK2 and NOTCH1 signaling in TC, epigenetic regulation of gene 
expression in TREG/TFH, and MTOR/AKT in other TH might represent suitable therapeutic 
targets. Indeed, we found that MTOR/PI3K inhibition was effective ex vivo for TH PTCL cells. 
Our results formally demonstrate that PTCL/NOS is indeed a Pandora’s box that contains 
biologically different T-cell neoplasms, which is differently reflected by genetic, 
transcriptional and phenotypic profiles. The gene signatures used proved to be successful in 
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the specification of PTCL/NOS, even when applying an MGS. Conflicting signature 
enrichment (i.e., the expression of overlapping signatures) resulted in few unclassified cases 
that likely reflect both the establishment of aberrant T-cell clones and the puzzling effect of 
the microenvironmental pressure. Conversely, we exclude, bona fide, major artifacts due to 
the reactive components as in all cases the percentage of tumor cells exceeded 60-70%. 
Therefore, the tumor component was responsible for the main signals in GEP. 
One major limitation to the extensive usage of GEP in routine diagnostic practice is the 
limited availability of fresh/frozen samples in contrast to FFPE samples. We showed that 
reliable GEP analysis could be performed on FFPE samples, as we also recently 
demonstrated for improving nodal PTCLs diagnosis (104). Herein, we applied the cellular 
classifiers to FFPE PTCL/NOS cases with a high degree of success, even when limiting the 
number of discriminatory genes, thus enabling a simple diagnostic assay. Importantly, this 
method will allow the application of a focused custom-array if the whole genome profile is 
not requested. In fact, we identified an MGS that is able to classify PTCL/NOS cases both in 
frozen and FFPE samples.  
When applied to the PTCL/NOS classification, IHC was unable to discriminate among most of 
the subtypes, including the relevant TH vs. TC dichotomy, but proved to be quite effective at 
identifying the Treg/TFH-related cases, which are characterized by a better outcome. 
Therefore, the combination of molecular techniques and conventional immunophenotyping 
may enable an integrated diagnostic algorithm limiting the costs of extensive molecular 
analyses (Supplementary Figure 1). On the other hand, the expression of single master 
transcription factors such as TBX1 and GATA3 was not sufficient to recapitulate the entire 
classification and was not confirmed to be enough to discriminate different clinical 
subgroups. This fact could be possibly related to the actual heterogeneity and complexity of 
the disease and/or to the promiscuity of certain molecules across T-cell types (i.e. GATA3 in 
both TH2 and T-cytotoxic; Supplementary Figure 2). 
We also sought to investigate the molecular profile of two morphological variants of 
PTCL/NOS, namely Lennert lymphoma and PTCL/NOS follicular variant. In general, being rare 
diseases, there is scarce amount of information on the biological nature of LL and F-PTCL 
(34). Concerning LL, it is currently diagnosed only based on morphology and 
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immunohistochemical characteristics, misdiagnosis being quite frequent (75, 86, 87, 92-94). 
Some researchers, however, have suggested that LL might actually be a distinct entity, 
although there are few evidences supporting this hypothesis (75, 86). Here, for the first 
time, we present our results obtained from studying the molecular profile of LL concerning 
both gene and microRNA expression signatures indicating that LL is distinct from other 
PTCLs/NOS and might be regarded as distinct entity. 
We started with comparison of global gene signatures of all PTCL subtypes, along with 
normal T-cells, trying to define the general position of LL. However, the unsupervised 
methods failed a clear discrimination of LL and other PTCL/NOS. Of note, however, we 
found a sharp clustering for normal T-cell, which was somehow expected. In fact, a similar 
pattern was previously observed in previous studies on PTCLs (48, 62, 64, 65).  A comparison 
of LL with other PTCL/NOS using the same approach was then carried out, but again we 
were unsuccessful in achieving significant results.  
However, a more stringent comparison of LL and other PTCL/NOS, accomplished using 
supervised methods, supported the existence of different molecular signatures at some 
level. The differentially expressed genes turned out to be engaged in malignancy-related 
processes, probably pointing at some different tumorigenesis mechanisms in the two 
groups. The gained signature could potentially classify the two categories correctly.  
In addition, in order to prove the validity of such signature, we further processed it in a 
separate set of samples (test set) and ended up with a limited number of genes which could 
strongly differentiate LL samples from other PTCL/NOS. This strengthened our hypothesis of 
LL being a distinct. 
There are some evidences which suggest that the major part of LL could be originated from 
cytotoxic T-cells. For example, Geissinger et al. (85) performed IHC on 101 PTCL/NOS cases 
which include 18 LL and represented LL is mainly derived from CD8+ cytotoxic cells. 
Furthermore, Hartmann et al. (86) studied on 97 epithelioid cell-rich lymphomas which 
include 17 LL and they showed that the most LL cases extremely express cytotoxic T cell 
markers and are different from other epithelioid cell-rich lymphomas. Therefore, cytotoxic t-
cell markers might be used as diagnostic criteria for LL (75, 87, 94, 131, 132).   
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Inspired by the results obtained so far, we decided to expand our analysis to the miRNA 
signature of LL as compared to other PTCL/NOS. We could find some miRNAs differentiating 
the two, but again the number was limited, which once more made the similar nature of the 
two diseases standing out. The resulted miRNAs, furthermore, were capable of separating 
the two set of samples in a HCA. Of note, we have previously reported the usage of miRNAs 
profiling in classifying PTCL subtypes (108). 
Next, we compared miRNA signature of LL with normal T-cells, with the intention of 
discovering the underlying pathological mechanism of LL. Compared to what observed in 
the case of LL vs. other PTCL/NOS, here we found a much higher number of differentially 
regulated miRNAs, which could be a result of comparison of tumor vs. normal cells, as 
compared to tumor vs. tumor in the previous case. Importantly, few of the miRNAs seemed 
to be overexpressed in LL, which corresponds to the previous reports regarding a global 
lowered expression of human miRNAs in the tumors (133, 134). Very interestingly, when a 
similar approach was carried out on the gene expression profiles of LL and normal T-cells, 
we found the major part of deregulated genes to have increased expression level in LL. This, 
would reflect the linkage between gene and miRNA expression, and suggest at least some of 
those genes might be direct or indirect targets of the downregulated miRNAs in LL. Again, 
the number of the differentially expressed genes was higher compared to LL vs. other 
PTCL/NOS, and the deregulated genes, as anticipated, were involved in relevant 
tumorigenesis processes, most notably microenvironment as well as neoplastic clone. 
Analysis of CD68 expression using IHC confirmed the validity of our results, and promoted 
the inflammation induced by tumor-associated macrophage as an underlying tumorigenesis 
mechanism in this cancer (135). Conversely, PDCD4 was identified for the first time as 
aberrantly expressed in LL cells (136) (Supplementary Figure 3). 
Since our results of both miRNA and gene expression profiles of LL seemed to be correlated 
with its pathogenesis, we used them to create a functional network of correlated cell 
signaling pathways using IPA, which resulted in the discovery of PI3K/Akt/mTOR axis as the 
most relevant pathway. Although using an in silico approach, Martin-Sanchez et al. 
recognized this pathway to be activated in PTCL (137), this is for the first time that this 
hypothesis is suggested for LL.  
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Since by far we found molecular evidences supporting LL as a distinct entity, we tried to 
analyze the clinical data, as a complementary approach. We observed a significant 
difference of male:female ratio and B-symptoms in LL, as compared to other PTCL/NOS. 
Furthermore, although a trend of better treatment response and survival rate was found for 
LL in comparison with other PTCL/NOS, our results were not statistically significant. This 
might be due to the limited number of the patients analyzed by us, since Wiesenberger et 
al. reported a better overall survival in LL as compared to other PTCL/NOS (75).  
As far as F-PTCL is concerned, the recent recognition of its relatedness to FTH-lymphocytes 
raised the hypothesis that it could represent an early stage of AITL; the prototype of TFH 
related lymphoma (138-140). Our data, however, seem to indicate that F-PTCL and AITL are 
quite distinct. In fact, GEP analysis showed that F-PTCL is possibly closer to other PTCLs/NOS 
rather than to AITL. The major limitation of this study, beside the limited number of F-PTCL 
cases included, is represented by the lack of genetic analysis. In fact, it should be 
acknowledged that recurrent genetic lesions have been recently recognized in AITL, 
including those affecting TET2, IDH2, and RHOA (41, 42, 68-71). Therefore, it would be 
definitely warranted to test them in F-PTCLs to assess a possible genetic similarity. Of 
interest, in this regard, the commonest lesion recorded in F-PTCL, the t(5;9) leading to 
ITK/SYK fusion gene, has been described in a unique case of AITL, this confirming their 
diversity rather than a real similarity (98). However, only a comprehensive genomic profile 
will refine this information supporting one or the other hypothesis. Indeed, as the presence 
of some of the above mentioned mutations might be associated with a preferential 
sensitivity to some novel anti-lymphoma agents including demethylating ones, the 
comprehension of the genetic profile of the tumor would have relevant consequences not 
only for PTCL classification but also for future treatment selection.  
In terms of classification, our data currently support the inclusion of F-PTCL in a broad 
category of FTH-related PTCLs, together with AITL, a fraction of PTCL/NOS and some 
cutaneous lymphomas. This concept will be probably sustained in the upcoming edition of 
the WHO classification that is expected to be released in late 2016 (38). 
In conclusion, our study showed for the fort time that 1) PTCL/NOS can be divided into 
subgroups corresponding to different cellular counterparts and characterized by different 
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genetic patterns and possibly sensitivity to specific therapeutic approaches; 2) Lennert 
lymphoma is distinct from other PTCLs/NOS based not only on morphology and clinical 
features but also on gene and miRNA expression, this finally supporting its recognition as 
distinct entity; 3) F-PTCL cannot be included among AITLs at least based on GEP, genetic 
studies being required for a more refined classification. Overall, these results may impact on 
PTCL classification as well as on future studies aimed to define the more appropriate 
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Supplementary Figure 1. The combination of molecular techniques and conventional 



























Supplementary Figure 2. The expression of single master transcription factors (TBX1 and GATA3) 
was not sufficient to reiterate the entire classification and was not confirmed to be enough to 


































Supplementary Table 1. Gene signatures representative of normal T-cell subsets 
Cell type Probe ID Gene Symbol 











































































































214567_s_at XCL1 /// XCL2 
214591_at KLHL4 
214617_at PRF1 
215806_x_at TARP /// TRGC2 
216915_s_at PTPN12 
















226694_at AKAP2 /// PALM2 /// PALM2-AKAP2 


















206785_s_at KLRC1 /// KLRC2 
206914_at CRTAM 
207001_x_at TSC22D3 



















214567_s_at XCL1 /// XCL2 
214660_at PELO 
215806_x_at TARP /// TRGC2 
215894_at PTGDR 
216191_s_at TRA@ /// TRD@ 
216676_x_at KIR3DL3 



















TH1 1405_i_at CCL5 
200748_s_at FTH1 
200887_s_at STAT1 










































































207313_x_at KIR3DL2 /// LOC727787 

























































211632_at IGHD /// IGHM /// LOC652128 /// VSIG6  
211634_x_at IGHM /// LOC100133862 
211635_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHG1 /// IGHG3 /// IGHM /// IGHV1OR15-5 /// IGHV4-31 /// IGHV7-81 
/// LOC642131 
211636_at IGH@ /// IGHA1 /// IGHA2 /// IGHG1 /// IGHM /// LOC100126583 /// LOC652128 /// VSIG6  
211637_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG3 /// IGHG4 /// IGHM /// IGHV3-23 /// IGHV4-31 
/// LOC100126583 /// LOC642131 /// LOC652128 /// VSIG6  
211638_at IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG3 /// IGHG4 /// IGHM /// IGHV4-31 /// 
LOC100126583 /// LOC652128 /// VSIG6  
211639_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG3 /// IGHG4 /// IGHM /// IGHV4-31 /// 
LOC100126583 /// LOC642131 /// LOC652128 /// VSIG6 
211640_x_at IGHA1 /// IGHG1 /// LOC100133862 
211641_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHG1 /// IGHG3 /// IGHM /// IGHV3-23 /// IGHV4-31 
211646_at IGH@ /// IGHA1 /// IGHG1 /// IGHG2 /// IGHG3 /// IGHM /// LOC100126583 /// LOC652494 
90 
 
211647_x_at IGHA1 /// IGHG1 /// LOC100133862 
211648_at IGHA1 /// IGHG1 /// LOC100133862 
211649_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHG1 /// IGHM /// LOC642131  
211650_x_at IGHA1 /// IGHD /// IGHG1 /// IGHG3 /// IGHM /// IGHV3-23 /// IGHV4-31 /// LOC100126583 
211685_s_at NCALD 
211688_x_at KIR3DL2 /// LOC727787 
211719_x_at FN1 
211751_at PDE4DIP 





212390_at LOC727893 /// PDE4DIP 






































214916_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG2 /// IGHG3 /// IGHM /// IGHV3-23 /// IGHV4-31 
/// LOC100126583 





215949_x_at IGHM /// LOC652494 
215959_at   
216442_x_at FN1 
216491_x_at IGHM 
216510_x_at IGHA1 /// IGHD /// IGHG1 /// IGHM /// IGHV3-23 /// IGHV4-31 
216541_x_at IGHA1 /// IGHG1 /// LOC100133862 
216542_x_at IGHA1 /// IGHG1 /// IGHV3-23 
216557_x_at IGH@ /// IGHA1 /// IGHG1 /// IGHG3 /// IGHM /// IGHV3-23 /// IGHV4-31 





216907_x_at KIR3DL2 /// LOC727787 
217084_at IGHA1 /// IGHG1 /// IGHM /// IGHV3-23 /// IGHV4-31 
217169_at IGHA1 
217217_at IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG3 /// IGHG4 /// IGHM /// IGHV4-31 /// 
LOC100126583 /// LOC642131 /// LOC652128 /// VSIG6  
217236_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHD /// IGHG1 /// IGHG3 /// IGHG4 /// IGHM /// IGHV4-31 /// 
LOC100126583 /// LOC642131 /// LOC652128 /// VSIG6  
217281_x_at IGH@ /// IGHA1 /// IGHA2 /// IGHG1 /// IGHG2 /// IGHG3 /// IGHM /// IGHV4-31 /// LOC100126583 /// 
LOC652494 











































































































































































211931_s_at HNRNPA3 /// HNRNPA3P1 
211932_at HNRNPA3 
211933_s_at HNRNPA3 /// HNRNPA3P1 










































227499_at   















































211620_x_at RUNX1 /// SH3D19 
214470_at KLRB1 




















































243111_at   
1553994_at NT5E 
1553995_a_at NT5E 















































Supplementary Table 2. Molecular classification of PTCLs according to their correspondence to the different counterparts 
 
Identifier T-helper vs. T-cytotoxic Tem vs. Tcm TH1 vs. TH2 vs. TH17 vs. Treg vs. TFH 
Prediction Confidence Measure Prediction Confidence Measure Prediction Confidence Measure 
GSM472034 CD4 0.05483767 TEM 0.5397353 TH1 0.22225842 
GSM472035 CD4 0.8792574 TCM 0.43320644 TH2 0.20155877 
GSM472036 CD4 0.92096376 TCM 0.39508796 TH2 0.24746904 
GSM472037 CD4 0.16107923 TEM 0.47575614 TH1 0.05058226 
GSM472041 CD4 0.18602279 NC 0.007362604 TH17 0.64963453 
GSM472042 CD4 0.22059606 NC 0.037550926 TH17 0.74263566 
GSM472044 CD4 0.32339743 NC 0.046786785 TH2 0.092894405 
GSM472045 CD8 0.24375308 TEM 0.62550867 TH1 0.1050137 
GSM472046 CD4 0.4934061 TCM 0.2388232 TFH 0.64894566 
GSM472048 CD8 0.053890225 TEM 0.64435995 TH2 0.108162545 
GSM472051 CD4 0.5314873 TCM 0.23975971 NC 0.02408194 
GSM472052 CD4 0.32253292 NC 0.01305475 TH2 0.081010215 
GSM472053 CD4 0.14957592 TEM 0.1767476 TH1 0.18692046 
GSM472055 CD4 0.32781687 TCM 0.14525402 TH2 0.12380959 
GSM472057 CD4 0.3055477 TEM 0.26023036 TH1 0.18063259 
GSM472060 CD4 0.6237464 TCM 0.09437314 TH1 0.05671855 
GSM472061 CD4 1 TCM 0.093601584 TH2 0.19806242 
GSM472067 CD8 0.31454957 TEM 0.5730862 NC 0.002197931 
GSM472068 CD4 0.8921284 NC 0.045115566 TH2 0.13576272 
GSM472069 CD8 0.42570004 TEM 0.40469006 TH1 0.1950911 
GSM472070 CD4 0.4507805 TEM 0.15644054 TH1 0.08173423 
GSM472071 CD4 0.3802928 TEM 0.22600344 TH1 0.15021868 
GSM472072 CD4 0.89513415 TCM 0.38177902 TH2 0.23805884 
GSM472073 CD4 0.38029218 TCM 0.26621363 TH2 0.098294474 
GSM472078 CD4 0.8012558 NC 0.028153956 TH2 0.17126118 
GSM472087 CD4 0.71471405 TCM 0.29026657 NC 0.038981684 
GSM472088 CD4 0.78601414 NC 0.036012568 TH2 0.27195293 
GSM472090 CD8 0.66783565 TEM 0.8560791 TH1 0.39705765 
GSM472091 CD8 0.66949964 TEM 0.8472239 TH1 0.3944276 
GSM472092 CD4 0.19665727 TEM 0.07922295 TH17 0.72848392 
GSM472093 CD4 0.25312403 TEM 0.11955827 TFH 0.22324567 
GSM472094 CD4 0.3007129 TEM 0.12920836 TH1 0.08821334 
GSM472095 CD4 0.75019044 TCM 0.38723052 TH2 0.06832034 
GSM472097 CD4 0.91148233 TCM 0.29818636 TH2 0.106093585 
GSM472098 CD4 0.9095245 TCM 0.33320656 TH2 0.17650221 
GSM472100 CD4 0.9380916 TCM 0.23010881 TH2 0.54802024 
GSM472101 CD4 0.6088621 TCM 0.16218323 TH2 0.32242948 
GSM472102 CD8 0.90215635 TEM 1 TH1 0.2035213 
GSM472106 CD4 0.81567633 TCM 0.17600505 TH2 0.37949967 
98 
 
GSM472109 CD4 0.31734893 TEM 0.1280496 TH1 0.0695476 
GSM472128 CD4 0.7677358 TCM 0.2256378 TH2 0.647312 
GSM472129 CD4 0.597095 TEM 0.14994349 NC 4.48E-04 
GSM472133 CD4 0.54355496 NC 0.002528623 TH2 0.21704476 
GSM472146 CD4 0.096931174 TCM 0.18343353 TH2 0.13977978 
GSM472148 CD8 0.69063264 TEM 0.5687444 TH2 0.10587785 
GSM472149 CD4 0.7057298 TEM 0.21633327 TH2 0.058564898 
GSM472155 CD4 0.40983316 TCM 0.22943091 TREG 0.495486584 
GSM472156 CD4 0.19678819 TEM 0.18853916 TH1 0.15605317 
GSM472157 CD4 0.36318445 TEM 0.22466786 NC 0.047692917 
PTCL_021 CD4 0.31689897 TEM 0.06063488 TH1 0.077397525 
PTCL_025 CD4 0.5982696 TCM 0.17823666 TH2 0.08225937 
PTCL_026 CD4 0.43547502 TCM 0.06707667 NC 0.019214673 
PTCL_027 CD4 0.62213516 TCM 0.43253648 TH2 0.13232735 
PTCL_028 CD4 0.60790086 TCM 0.28131053 TH2 0.07729836 
PTCL_AV_019 CD4 0.31722522 TCM 0.29094213 TH2 0.1298176 
PTCL_AV_020 CD4 0.11305948 TEM 0.33042276 TH1 0.16004606 
PTCL_AV_022 CD4 0.6636183 TCM 0.2853693 NC 0.015093046 
PTCL_AV_023 CD4 0.78092754 TCM 0.33951902 NC 0.038951445 
PTCL_AV_024 CD4 0.5475377 TCM 0.46628696 TH2 0.20561633 
PTCL_AV_029 CD4 0.7794126 TCM 0.31514302 TFH 0.48642345 
PTCL_BO_01 CD8 0.40744558 TEM 0.6591986 TH1 0.17789663 
PTCL_BO_013 NC 0.048709106 TEM 0.45440286 TH1 0.0533007 
PTCL_BO_012 CD8 0.5987399 TCM 0.1048778 TH1 0.21674937 
PTCL_BO_02 CD4 0.5083611 TEM 0.110364504 NC 0.033066668 
PTCL_BO_03 CD8 0.14107165 TEM 0.5281591 TH1 0.106095314 
PTCL_BO_04 CD4 0.35076547 TCM 0.13343695 TH2 0.09655729 
PTCL_BO_05 CD4 0.7929655 NC 0.024722062 TH2 0.10501019 
PTCL_BO_06 CD4 0.64544487 TCM 0.11693561 TH2 0.10596316 
PTCL_BO_08 CD4 0.5823569 TCM 0.07019313 TFH 0.45756786 
PTCL_BO_09 CD8 0.087207325 TEM 0.43265566 TH1 0.25613612 
PTCL_BO_10 CD8 0.67040133 TEM 0.59567535 NC 0.044250138 
PTCL_BO_11 NC 0.02855229 NC 0.019826481 NC 0.035181366 
PTCL_PG_14 CD4 0.059059896 TEM 0.27745417 TH1 0.16193448 
PTCL_PG_15 CD4 0.32255587 TEM 0.0872888 TH1 0.08911885 
PTCL_PG_16 CD4 0.60982984 TCM 0.27298284 TREG 0.69023434 
PTCL_PG_17 CD4 0.17219996 TEM 0.32021385 TH1 0.2364545 
PTCL_PG_18 CD4 0.2693943 TEM 0.5092342 TH1 0.23905414 
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Supplementary Table 3. Minimal gene sets identified by linear discriminant analysis 
 
Classification step Minimal gene set 















































Supplementary Table 4. Molecular classification of PTCLs according to their correspondence to the different counterparts (test set, according to 
the discriminant functions based on minimal gene sets)  
 
Sample ID Classification steps 
Th vs. 
Tc 
%Th %Tc Predicted 
subtype 
Tem vs. Tcm %Tem %Tcm Predicted subtype Th1 vs. Th2 vs. Th17 vs. Treg vs. Tfh %Th1 %Th2 %Tfh %Th17 %Treg Predicted subtype 
GSM472034 CD4 72.90 27.10 CD4 TEM 100 0 TEM TH1 100     TH1 
GSM472035 CD4 100 0 CD4 TCM 0 100 TCM TH2  100    TH2 
GSM472036 CD4 100 0 CD4 TCM 0 100 TCM TH2  100    TH2 
GSM472037 CD4 87.31 12.69 CD4 TEM 89.20 10.80 TEM TH1  95.32    TH2 
GSM472041 CD4 39.91 60.09 CD8 NC 47.10 52.90 NC TH17    100  TH17 
GSM472042 CD4 51.01 48.99 NC NC 44.13 55.87 NC TH17    94.59  TH17 
GSM472044 CD4 76.53 23.47 CD4 NC 33.29 66.71 TCM TH2  63.03    TH2 
GSM472045 CD8 100 0 CD4 TEM 100 0 TEM        
GSM472046 CD4 91.74 8.26 CD4 TCM 0 100 TCM TFH   100   TFH 
GSM472048 CD8 38.71 61.29 CD8 TEM 73.88 26.12 TEM        
GSM472051 CD4 96.31 3.69 CD4 TCM 30.06 69.94 TCM NC  73.94    TH2 
GSM472052 CD4 79.19 20.81 CD4 NC 0 100 TCM TH2  81.75    TH2 
GSM472053 CD4 55.57 44.43 NC TEM 54.15 45.85 NC TH1 68.15     TH1 
GSM472055 CD4 99.57 0.43 CD4 TCM 21.05 78.95 TCM TH2  79.35    TH2 
GSM472057 CD4 85.73 14.27 CD4 TEM 85.79 14.21 TEM TH1 100     TH1 
GSM472060 CD4 100 0 CD4 TCM 37.26 62.74 TCM TH1 98.04     TH1 
GSM472061 CD4 100 0 CD4 TCM 0 100 TCM TH2  100    TH2 
GSM472067 CD8 100 0 CD4 TEM 100 0 TEM        
GSM472068 CD4 100 0 CD4 NC 57.87 42.13 NC TH2  97.01    TH2 
GSM472069 CD8 31.88 68.12 CD8 TEM 100 0 TEM        
GSM472070 CD4 100 0 CD4 TEM 50.30 49.70 NC TH1 55.46     NC 
GSM472071 CD4 89.12 10.88 CD4 TEM 83.65 16.35 TEM TH1 92.12     TH1 
GSM472072 CD4 100 0 CD4 TCM 30.67 69.33 TCM TH2  100    TH2 
GSM472073 CD4 82.46 17.54 CD4 TCM 0 100 TCM TH2  100    TH2 
GSM472078 CD4 74.85 25.15 CD4 NC 65.42 34.58 TEM TH2  100    TH2 
GSM472087 CD4 98.10 1.90 CD4 TCM 18.72 81.28 TCM NC  100    TH2 
GSM472088 CD4 100 0 CD4 NC 0 100 TCM TH2  100    TH2 
GSM472090 CD8 0 100 CD8 TEM 100 0 TEM        
GSM472091 CD8 0 100 CD8 TEM 100 0 TEM        
GSM472092 CD4 98.58 1.42 CD4 TEM 0 100 TCM TH17    100  TH17 
GSM472093 CD4 88.66 11.34 CD4 TEM 7.47 92.53 TCM TFH   82.99   TFH 
GSM472094 CD4 100 0 CD4 TEM 87.39 12.61 TEM TH1 61.37     TH1 
GSM472095 CD4 90.58 9.42 CD4 TCM 2.85 97.15 TCM TH2  100    TH2 
GSM472097 CD4 100 0 CD4 TCM 6.17 93.83 TCM TH2  100    TH2 
GSM472098 CD4 100 0 CD4 TCM 54.63 45.37 NC TH2  100    TH2 
GSM472100 CD4 100 0 CD4 TCM 0 100 TCM TH2  100    TH2 
101 
 
GSM472101 CD4 85.65 14.35 CD4 TCM 0 100 TCM TH2  100    TH2 
GSM472102 CD8 12.51 9 CD8 TEM 100 0 TEM        
GSM472106 CD4 89.39 10.61 CD4 TCM 0 100 TCM TH2  100    TH2 
GSM472109 CD4 100 0 CD4 TEM 100 0 TEM TH1 63.18     TH1 
GSM472128 CD4 100 0 CD4 TCM 0 100 TCM TH2  100    TH2 
GSM472129 CD4 98.04 1.96 CD4 TEM 0 100 TCM NC  100    TH2 
GSM472133 CD4 100 0 CD4 NC 8.88 91.12 TCM TH2  100    TH2 
GSM472146 CD4 88.81 11.19 CD4 TCM 19.67 80.33 TCM TH2  100    TH2 
GSM472148 CD8 74.99 25.01 CD4 TEM 88.07 11.93 TEM        
GSM472149 CD4 100 0 CD4 TEM 17.58 82.42 TCM TH2 57.10     NC 
GSM472155 CD4 100 0 CD4 TCM 25.62 74.38 TCM TREG     68.57 TREG 
GSM472156 CD4 70.48 29.52 CD4 TEM 35.49 64.51 TCM TH1 96.11     TH1 





Supplementary Table 5. Diagnostic accuracy of the TEM vs. TCM molecular classifier (linear discriminant function) evaluated in the test set using 
the minimal gene set 
 
  T-effector memory molecular phenotype* 
  Present Absent   
      Likelihood Ratios 
Positive 14 0 24.38 (3.27 to 181.52) 
Negative 6 18 0.30 (0.15 to 0.59) 
        
Sensitivity 70%; CI: 50 to 90 
  
Specificity 100%; CI: 100 to 100 
Prevalence 53%; CI: 37 to 69 
Positive Predictive Value 100%; CI: 100 to 100 
Negative Predictive Value 75%; CI: 58 to 92 




Supplementary Table 6. Diagnostic accuracy of the TH vs. TC molecular classifier (linear discriminant function) evaluated in the test set using the 
minimal gene set 
  T-cytotoxic molecular phenotype* 
  Present Absent   
      Likelihood Ratios 
Positive 5 1 24.38 (3.27 to 181.52) 
Negative 3 38 0.38 (0.16 to 0.94) 
        
Sensitivity 63%; CI: 29 to 96 
  
Specificity 97%; CI: 92 to 100 
Prevalence 17%; CI: 6 to 28 
Positive Predictive Value 83%; CI: 54 to 100 
Negative Predictive Value 93%; CI: 85 to 100 
 
*Calculated vs. T-helper molecular phenotype 




Supplementary Table 7. Diagnostic accuracy of the TH1 molecular classifier (linear discriminant function) evaluated in the test set using the 
minimal gene set 
  TH1 molecular phenotype* 
  Present Absent   
      Likelihood Ratios 
Positive 8 1 23.20 (3.30 to 163.18) 
Negative 2 28 0.21 (0.06 to 0.72) 
        
Sensitivity 80%; CI: 55 to 100 
  
Specificity 97%; CI: 90 to 100 
Prevalence 26%; CI: 12 to 39 
Positive Predictive Value 89%; CI: 68 to 100 
Negative Predictive Value 93%; CI: 84 to 100 
* Calculated vs. Th2-Th17-Treg-Tfh molecular phenotypes 
 
Supplementary Table 8. Diagnostic accuracy of the TH2 molecular classifier (linear discriminant function) evaluated in the test set using the 
minimal gene set 
  TH2 molecular phenotype* 
  Present Absent   
      Likelihood Ratios 
Positive 20 2 8.57 (2.31 to 31.77) 
Negative 1 16 0.05 (0.01 to 0.37) 
        
Sensitivity 95%; CI: 86 to 100 
  
Specificity 89%; CI: 74 to 100 
Prevalence 54%; CI: 38 to 69 
Positive Predictive Value 91%; CI: 79 to 100 
Negative Predictive Value 94%; CI: 83 to 100 




Supplementary Table 9. Diagnostic accuracy of the TH17 molecular classifier (linear discriminant function) evaluated in the test set using the 
minimal gene set 
  TH17 molecular phenotype* 
  Present Absent   
      Likelihood Ratios 
Positive 3 0 12.00 (4.06 to 35.46) 
Negative 0 33 0.05 (0.01 to 0.37) 
        
Sensitivity 100%; CI: 100 to 100 
  
Specificity 100%; CI: 100 to 100 
Prevalence 8%; CI: -1 to 17 
Positive Predictive Value 100%; CI: 100 to 100 
Negative Predictive Value 100%; CI: 100 to 100 
* Calculated vs. Th1-Th2-Treg-Tfh molecular phenotypes 
 
Supplementary Table 10. Diagnostic accuracy of the TFH molecular classifier (linear discriminant function) evaluated in the test set using the 
minimal gene set 
  TFH molecular phenotype* 
  Present Absent   
      Likelihood Ratios 
Positive 3 0 12.00 (4.06 to 35.46) 
Negative 0 33 0.05 (0.01 to 0.37) 
        
Sensitivity 100%; CI: 100 to 100 
  
Specificity 100%; CI: 100 to 100 
Prevalence 8%; CI: -1 to 17 
Positive Predictive Value 100%; CI: 100 to 100 
Negative Predictive Value 100%; CI: 100 to 100 
* Calculated vs. Th1-Th2-Th17-Treg molecular phenotypes 
105 
 
Supplementary Table 11. Diagnostic accuracy of the Treg molecular classifier (linear discriminant function) evaluated in the test set using the 
minimal gene set 
  Treg molecular phenotype* 
  Present Absent   
      Likelihood Ratios 
Positive 2 0 12.00 (4.06 to 35.46) 
Negative 0 34 0.05 (0.01 to 0.37) 
        
Sensitivity 100%; CI: 100 to 100 
  
Specificity 100%; CI: 100 to 100 
Prevalence 6%; CI: -2 to 13 
Positive Predictive Value 100%; CI: 100 to 100 
Negative Predictive Value 100%; CI: 100 to 100 
* Calculated vs. Th1-Th2-Th17-Tfh molecular phenotypes 
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Supplementary Table 12.  Gene set enrichment analysis shows significant enrichment in selected pathways in genes differentially expressed in the 
molecular subgroups of PTCL/NOS. 
 
Gene Set Name Description FDR q-value 
HELLER_SILENCED_BY_METHYLATION_UP Genes up-regulated in at least one of three multiple myeloma (MM) cell lines 
treated with the DNA hypomethylating agent decitabine (5-aza-2'-
deoxycytidine) [PubChem=451668]. 
0.00E+00 
WALLACE_PROSTATE_CANCER_RACE_UP Genes up-regulated in prostate cancer samples from African-American 
patients compared to those from the European-American patients. 
0.00E+00 
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION Genes up-regulated in lung tissue upon LPS aspiration with mechanical 
ventilation (MV) compared to control (PBS aspiration without MV). 
0.00E+00 
BROWNE_INTERFERON_RESPONSIVE_GENES Genes up-regulated in primary fibroblast culture after treatment with 
interferon alpha for 6 h. 
0.00E+00 
NUYTTEN_EZH2_TARGETS_UP Genes up-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 
[GeneID=2146] by RNAi. 
1.57E-12 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION Cytokine-cytokine receptor interaction 1.57E-12 
REACTOME_IMMUNE_SYSTEM Genes involved in Immune System 2.32E-12 
KEGG_GRAFT_VERSUS_HOST_DISEASE Graft-versus-host disease 4.78E-12 
BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE Genes representing interferon-induced antiviral module in sputum during 
asthma exacerbations. 
1.01E-11 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression 
of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days 
after transduction. 
1.44E-11 
DAUER_STAT3_TARGETS_DN Top 50 genes down-regulated in A549 cells (lung cancer) expressing STAT3 
[GeneID=6774] off an adenovirus vector. 
1.57E-11 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression 
of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days 
after transduction. 
2.22E-11 
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis upon 
serum starvation (5% to 0% FCS) for 22 hr. 
2.22E-11 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION Antigen processing and presentation 2.22E-11 
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_DN Genes down-regulated in monocyte-derived dendritic cells (MDDC) after 
stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that 
with bacterial lipopolysaccharide (LPS). 
3.32E-11 
MOSERLE_IFNA_RESPONSE Top 50 genes up-regulated in ovarian cancer progenitor cells (also known as 
side population, SP, cells) in response to interferon alpha (IFNA). 
3.32E-11 
WONG_ADULT_TISSUE_STEM_MODULE The 'adult tissue stem' module: genes coordinately up-regulated in a 
compendium of adult tissue stem cells. 
5.08E-11 
DER_IFN_BETA_RESPONSE_UP Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with 
interferon beta for 6 h. 
6.12E-11 
REACTOME_INTERFERON_GAMMA_SIGNALING Genes involved in Interferon gamma signaling 6.43E-11 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression 





JAATINEN_HEMATOPOIETIC_STEM_CELL_DN Genes down-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem 
cells, HSC) compared to the CD133- cells. 
7.38E-11 
DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN Genes down-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing 
the inv(14)/t(14:14) chromosomal aberration. 
1.22E-10 
HAHTOLA_SEZARY_SYNDROM_DN Genes down-regulated in monocytes isolated from peripheral blood samples 
of Sezary syndrom patients compared to those from healthy normal donors. 
2.33E-10 
FARMER_BREAST_CANCER_CLUSTER_1 Cluster 1: interferon, T and B lymphocyte genes clustered together across 
breast cancer samples. 
3.17E-10 
REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM Genes involved in Cytokine Signaling in Immune system 4.29E-10 
TAVOR_CEBPA_TARGETS_UP Genes up-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with 
BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050]. 
5.58E-10 
 
Supplementary Table 13. Somatic mutations occurring in the main PTCL/NOS subgroups. Genes affected by lesions significantly over-represented 
in each group are listed. For each group, the number of samples carrying mutations in a given gene is indicated. 







A2ML1 3 0 0 
ABCB1 1 9 0 
ANKRD18A 3 0 1 
ARHGAP33 1 0 2 
ARHGAP4 0 1 2 
ATXN3 0 0 2 
BAHCC1 0 7 0 
BTD 2 0 1 
BTN2A2 0 7 0 
C3 0 0 2 
C3orf17 0 8 1 
CCPG1 3 0 0 
CDC27 3 0 0 
CDRT4 0 1 2 
CHD2 1 0 2 
COG3 0 0 2 
CRYGS 0 0 2 
CX3CR1 0 7 0 
DBR1 0 1 2 
DCP1A 1 1 2 
FAM115C 0 1 2 
FAM198B 0 0 2 
108 
 
FAM207A 0 2 2 
GPAT2 0 0 2 
HLA_C 4 2 0 
HLA_DQB2 2 0 2 
HLA_DRB5 4 1 1 
IGFLR1 2 0 2 
IL4R 0 1 2 
IL9R 1 1 2 
KIAA0040 0 1 2 
KIAA1107 2 0 1 
KIAA2013 3 0 0 
LMF1 0 2 2 
LRP3 3 0 0 
LRRC37A3 0 1 2 
LSG1 0 2 2 
MICAL3 2 0 1 
MOCS2 3 0 0 
MORN2 3 1 1 
MTDH 3 0 0 
MTDH 3 0 0 
MTMR11 3 0 0 
MUC20 2 4 3 
MUM1 2 0 1 
NCOR1 3 0 0 
NDUFA10 0 1 2 
NDUFV3 0 7 0 
NPC1 3 0 1 
PABPC1L 0 1 2 
PARG 1 1 2 
PHKA1 0 0 2 
PKD1 3 5 3 
PKD1L3 2 0 1 
PLBD1 3 0 0 
PLCL2 0 7 0 
PRDM2 0 7 0 
PTDSS2 1 1 2 
RBMXL1 0 0 2 
SECTM1 1 1 2 
SETD1B 0 1 2 
SH3RF3 3 0 0 
SMG1 2 3 3 
SOGA2 4 2 0 
SSB 2 0 1 
TLR5 3 0 0 
TMEM204 0 0 2 
TNS3 1 1 2 
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TRIM61 0 0 2 
TRMT44 0 0 2 
TSHR 2 0 1 
TXK 0 2 2 
USP39 3 0 0 
VWA1 0 0 2 
ZBTB32 2 0 2 
ZBTB48 3 0 0 
ZNF586 0 1 2 
ZNF708 2 0 1 
ZNF831 0 1 2 
ZSWIM8 2 0 1 
 
Supplementary Table 14. Gene set enrichment analysis was performed on genes target by mutations in PTCL/NOS subgroups. Top 30 significantly 
enriched pathways in each group are listed. 
Subgroup Gene Set Name Description 
FDR q-
value 
TC RELA_DN.V1_DN Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of RELA [Gene ID=5970] gene by RNAi.  1.56E-6 
 LTE2_UP.V1_UP 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 cells (breast cancer) and long-term 
adapted for estrogen-independent growth. 
1.25E-5 
 CYCLIN_D1_UP.V1_UP Genes up-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595] gene. 2.21E-5 
 ESC_J1_UP_LATE.V1_UP Genes up-regulated during late stages of differentiation of embryoid bodies from J1 embryonic stem cells. 2.21E-5 
 RAPA_EARLY_UP.V1_DN Genes down-regulated in BJAB (lymphoma) cells by everolimus [PubChem = 6442177]. 2.21E-5 
 E2F1_UP.V1_DN Genes down-regulated in mouse fibroblasts over-expressing E2F1 [Gene ID=1869] gene. 2.21E-5 
 NFE2L2.V2 Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene ID=4780] gene. 3.85E-5 
 KRAS.LUNG_UP.V1_UP Genes up-regulated in epithelial lung cancer cell lines over-expressing an oncogenic form of KRAS [Gene ID=3845] gene. 3.85E-5 
 JAK2_DN.V1_UP Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717] gene by RNAi. 4.94E-5 
 NOTCH_DN.V1_DN Genes down-regulated in MOLT4 cells (T-ALL) by DAPT [PubChem=16219261], an inhibitor of NOTCH signaling pathway. 4.94E-5 
 VEGF_A_UP.V1_DN Genes down-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene ID=7422]. 5.85E-5 
 KRAS.600_UP.V1_DN Genes down-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of KRAS [Gene ID=3845] gene. 5.85E-5 
 RAF_UP.V1_UP 
Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 cells (breast cancer) stably over-
expressing constitutively active RAF1 [Gene ID=5894] gene. 
6.21E-5 
 IL21_UP.V1_DN 
Genes down-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 [Gene ID=3558] and then stimulated with IL21 
[Gene ID=59067]. 
1.21E-4 
 KRAS.600_UP.V1_UP Genes up-regulated in four lineages of epithelial cell lines over-expressing an oncogenic form of KRAS [Gene ID=3845] gene. 1.21E-4 
 CYCLIN_D1_KE_.V1_UP Genes up-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of CCND1 [Gene ID=595] gene. 1.21E-4 
 LEF1_UP.V1_DN Genes down-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 [Gene ID=51176]. 1.21E-4 
 KRAS.600.LUNG.BREAST_UP.V1_UP Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic form of KRAS [Gene ID=3845] gene. 1.21E-4 
 STK33_SKM_DN Genes down-regulated in SKM-1 cells (AML) after knockdown of STK33 [Gene ID=65975] by RNAi. 1.21E-4 
 ERB2_UP.V1_UP Genes up-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] and engineered to express ligand-activatable 1.21E-4 
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ERBB2 [Gene ID=2064]. 
 TBK1.DF_UP 
Genes up-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic form of KRAS [Gene ID=3845] gene and 
knockdown of TBK1 [Gene ID=29110] gene by RNAi. 
1.21E-4 
 IL21_UP.V1_UP 




Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 cells (breast cancer) stably over-
expressing constitutively active MAP2K1 [Gene ID=5604] gene. 
1.42E-4 
 RB_DN.V1_UP Genes up-regulated in primary keratinocytes from RB1 [Gene ID=5925] skin specific knockout mice. 2.45E-4 
 ESC_V6.5_UP_LATE.V1_UP Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5 embryonic stem cells.  3.74E-4 
 BMI1_DN_MEL18_DN.V1_UP Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 [Gene ID=648, 7703] genes by RNAi. 3.77E-4 
 CYCLIN_D1_KE_.V1_DN Genes down-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of CCND1 [Gene ID=595] gene. 3.77E-4 
 HOXA9_DN.V1_UP Genes up-regulated in MOLM-14 cells (AML) with knockdown of HOXA9 [Gene ID=3205] gene by RNAi vs. controls. 3.77E-4 
 P53_DN.V1_UP Genes up-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157]. 3.77E-4 
 PRC2_EZH2_UP.V1_DN Genes down-regulated in TIG3 cells (fibroblasts) upon knockdown of EZH2 [Gene ID=2146] gene. 3.77E-4 
    
TH1/TH2/TH
17 
JAK2_DN.V1_UP Genes up-regulated in HEL cells (erythroleukemia) after knockdown of JAK2 [Gene ID=3717] gene by RNAi. 1.35E-7 
 JNK_DN.V1_UP Genes up-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes. 1.35E-7 
 ATF2_S_UP.V1_UP Genes up-regulated in myometrial cells over-expressing a shortened splice form of ATF2 [Gene ID=1386] gene. 1.35E-7 
 MTOR_UP.N4.V1_UP Genes up-regulated in CEM-C1 cells (T-CLL) by everolimus [PubChem = 6442177], an mTOR pathway inhibitor. 7.05E-7 
 CYCLIN_D1_UP.V1_DN Genes down-regulated in MCF-7 cells (breast cancer) over-expressing CCND1 [Gene ID=595] gene. 1.82E-6 
 LTE2_UP.V1_DN 
Genes down-regulated in MCF-7 cells (breast cancer) positive for ESR1 [Gene ID=2099] MCF-7 cells (breast cancer) and long-term 
adapted for estrogen-independent growth. 
2.27E-6 
 KRAS.AMP.LUNG_UP.V1_UP Genes up-regulated in epithelial lung cancer cell lines over-expressing KRAS [Gene ID=3845] gene. 2.27E-6 
 NFE2L2.V2 Genes up-regulated in MEF cells (embryonic fibroblasts) with knockout of NFE2L2 [Gene ID=4780] gene. 2.39E-6 
 BMI1_DN.V1_UP Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 [Gene ID=648] gene by RNAi.  2.39E-6 
 AKT_UP_MTOR_DN.V1_UP 
Genes up-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue transgenically expressing human AKT1 gene 
[Gene ID=207] vs. untreated controls. 
2.44E-6 
 KRAS.600.LUNG.BREAST_UP.V1_UP Genes up-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic form of KRAS [Gene ID=3845] gene. 3.17E-6 
 RAPA_EARLY_UP.V1_DN Genes down-regulated in BJAB (lymphoma) cells by everolimus [PubChem = 6442177]. 3.65E-6 
 CTIP_DN.V1_DN Genes down-regulated in MCF10A cells (breast cancer) upon knockdown of RBBP8 [Gene ID=RBBP8] gene by RNAi. 4.68E-6 
 VEGF_A_UP.V1_UP Genes up-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene ID=7422]. 4.68E-6 
 TBK1.DF_DN 
Genes down-regulated in epithelial lung cancer cell lines upon over-expression of an oncogenic form of KRAS [Gene ID=3845] gene 
and knockdown of TBK1 [Gene ID=29110] gene by RNAi. 
8.25E-6 
 KRAS.600.LUNG.BREAST_UP.V1_DN 
Genes down-regulated in epithelial lung and breast cancer cell lines over-expressing an oncogenic form of KRAS [Gene ID=3845] 
gene. 
8.64E-6 
 AKT_UP.V1_DN Genes down-regulated in mouse prostate by transgenic expression of human AKT1 gene [Gene ID=207] vs. controls. 8.64E-6 
 ESC_V6.5_UP_LATE.V1_UP Genes up-regulated during late stages of differentiation of embryoid bodies from V6.5 embryonic stem cells. 1.03E-5 
 ATF2_UP.V1_UP Genes up-regulated in myometrial cells over-expressing ATF2 [Gene ID=1386] gene. 1.14E-5 
 CYCLIN_D1_KE_.V1_DN Genes down-regulated in MCF-7 cells (breast cancer) over-expressing a mutant K112E form of CCND1 [Gene ID=595] gene. 1.25E-5 
 AKT_UP_MTOR_DN.V1_DN 
Genes down-regulated by everolimus [PubChem = 6442177] in mouse prostate tissue transgenically expressing human AKT1 gene 
[Gene ID=207] vs. untreated controls. 
2.23E-5 
 BMI1_DN_MEL18_DN.V1_UP Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of BMI1 and PCGF2 [Gene ID=648, 7703] genes by RNAi.  2.23E-5 
 ATM_DN.V1_UP Genes up-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of ATM [Gene ID=472] gene by RNAi.  2.32E-5 
 ATM_DN.V1_DN Genes down-regulated in HEK293 cells (kidney fibroblasts) upon knockdown of ATM [Gene ID=472] gene by RNAi.  2.87E-5 
 PKCA_DN.V1_UP Genes up-regulated in small intenstine in PRKCA [Gene ID=5578] knockout mice. 3.18E-5 
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 JNK_DN.V1_DN Genes down-regulated in JNK inhibitor-treated (SP600125[PubChem=8515]) keratinocytes. 3.31E-5 
 P53_DN.V1_DN Genes down-regulated in NCI-60 panel of cell lines with mutated TP53 [Gene ID=7157]. 3.41E-5 
 DCA_UP.V1_DN Genes down-regulated in A549 lung carcinoma and M059K glioblastoma cells treated with dichloroacetate [PubChem=6597]. 3.41E-5 
 VEGF_A_UP.V1_DN Genes down-regulated in HUVEC cells (endothelium) by treatment with VEGFA [Gene ID=7422]. 3.41E-5 
 NRL_DN.V1_UP Genes up-regulated in retina cells from NRL [Gene ID=4901] knockout mice. 3.55E-5 
    
TFH/TREG BLALOCK_ALZHEIMERS_DISEASE_UP Genes up-regulated in brain from patients with Alzheimer's disease. 1.22E-5 
 NUYTTEN_EZH2_TARGETS_UP Genes up-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi. 1.44E-5 
 BILD_HRAS_ONCOGENIC_SIGNATURE 
Genes selected in supervised analyses to discriminate cells expressing activated HRAS [GeneID=3265] oncogene from control cel ls 
expressing GFP. 
9.2E-5 
 SMID_BREAST_CANCER_BASAL_UP Genes up-regulated in basal subtype of breast cancer samles. 1.23E-4 




Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi. 1.33E-4 




Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor 
tosedostat (CHR-2797) [PubChem=15547703] for 24 h. 
1.33E-4 
 ONKEN_UVEAL_MELANOMA_UP Genes up-regulated in uveal melanoma: class 2 vs class 1 tumors. 1.33E-4 




Genes up-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress. 1.77E-4 
 PUJANA_ATM_PCC_NETWORK 
Genes constituting the ATM-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC 





Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703]. 2.36E-4 
 ACEVEDO_LIVER_CANCER_UP Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples. 3.75E-4 




Genes with promoters occupied by SMAD2 or SMAD3 [GeneID=4087, 4088] in HaCaT cells (keratinocyte) according to a ChIP-chip 
analysis. 
7.19E-4 
 DODD_NASOPHARYNGEAL_CARCINOMA_DN Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue. 8.16E-4 
 ZHENG_BOUND_BY_FOXP3 Genes whose promoters are bound by FOXP3 [GeneID=50943] based an a ChIP-chip analysis. 1.23E-3 
 JOHNSTONE_PARVB_TARGETS_2_DN 
Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D 
collagen I and 3D Matrigel only. 
1.34E-3 
 BENPORATH_NANOG_TARGETS 
Set 'Nanog targets': genes upregulated and identified by ChIP on chip as Nanog [GeneID=79923] transcription factor targets in 

















Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue. 1.63E-3 
 MARSON_BOUND_BY_FOXP3_STIMULATED 
Genes with promoters bound by FOXP3 [GeneID=50943] in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin 
[PubChem=3733]. 
1.71E-3 
 DORN_ADENOVIRUS_INFECTION_12HR_UP Genes up-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12. 1.94E-3 
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 ZWANG_DOWN_BY_2ND_EGF_PULSE Genes down-regulated by second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium). 2.1E-3 
 BENPORATH_SOX2_TARGETS 
Set 'Sox2 targets': genes upregulated and identified by ChIP on chip as SOX2 [GeneID=6657] transcription factor targets in human 





Genes up-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi 





Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.  2.3E-3 
 
Supplementary Table 15. Classification of PTCLs/NOS according to immunohistochemistry 
 
Sample_ID T-helper T-cytotoxic T-follicular helper T-regulatory 
T-effector and 
central memory 







classification  CD4 CD8 TIA GB Perforin CXCL13 PD1 CD10 BCL6 FOXP3 CD45RA CCR7 IF gamma GATA3 IL17 Tbet 
PTCL_002 NEG NEG NEG NEG NEG NEG POS NEG ne NEG POS NEG POS POS NEG ne Th1 Ths 
PTCL_003 POS ne NEG NEG ne ne ne NEG ne ne ne ne ne ne NEG ne NC Ths 
PTCL_004 POS NEG POS POS NEG NEG NEG NEG NEG POS NEG POS NEG NEG NEG NEG Treg TFH_TREG 
PTCL_005 POS NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG POS NEG NEG Th2 Ths 
PTCL_006 ne ne NEG NEG NEG POS POS POS POS NEG NEG POS POS NEG NEG ne TFH TFH_TREG 
PTCL_007 ne NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG Th2 Ths 
PTCL_008 NEG NEG NEG NEG ne ne ne NEG ne ne ne ne ne POS NEG ne NC Ths 
PTCL_009 POS NEG NEG ne ne ne ne NEG ne ne ne ne ne ne NEG ne NC Ths 
PTCL_010 POS NEG POS NEG NEG NEG POS NEG POS NEG NEG POS NEG POS NEG NEG Th2 Ths 
PTCL_012 NEG NEG POS NEG POS NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG TC Ths 
PTCL_013 POS NEG POS NEG ne ne ne NEG ne ne ne ne ne ne NEG ne TC Ths 
PTCL_015 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS POS POS NEG NEG Th1 Ths 
PTCL_018 POS POS POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG TC Ths 
PTCL_019 ne NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NC Ths 
PTCL_020 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS POS NEG NEG NEG NC Ths 
PTCL_021 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG Th1 Ths 
PTCL_022 NEG NEG POS NEG NEG NEG POS POS NEG NEG NEG POS NEG NEG NEG NEG NC TFH_TREG 
PTCL_024 POS NEG NEG NEG NEG NEG POS NEG NEG NEG NEG POS NEG POS NEG NEG Th2 Ths 
PTCL_025 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG ne NC Ths* 
PTCL_026 POS NEG NEG NEG NEG POS POS NEG ne NEG NEG ne POS POS NEG NEG NC TC 
PTCL_027 POS NEG NEG NEG NEG NEG POS POS POS NEG NEG POS NEG POS NEG NEG TFH TFH_TREG 
PTCL_028 POS POS NEG partial POS POS NEG NEG NEG NEG NEG NEG POS NEG POS NEG NEG NC TC 
PTCL_029 POS NEG NEG NEG NEG POS POS NEG POS NEG POS POS NEG POS NEG ne TFH TFH_TREG 
PTCL_030 NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG POS NEG NEG Treg TFH_TREG 
PTCL_031 NEG NEG NEG NEG NEG NEG POS ne NEG POS NEG POS NEG POS NEG NEG Treg TFH_TREG 






NEG NEG NEG NEG NEG NEG ne NC TC* 
PTCL_034 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG POS NEG NEG Th2 Ths 
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PTCL_035 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG ne POS POS NEG NEG NEG Th1 Ths 
PTCL_036 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG ne POS POS NEG NEG ne Th1 Ths 
PTCL_037 POS NEG NEG NEG NEG NEG POS NEG NEG NEG NEG POS NEG POS NEG NEG Th2 Ths 
PTCL_038 NEG POS ne ne ne ne ne ne ne ne ne NEG NEG POS NEG NEG TC Ths 
PTCL_039 NEG POS POS POS POS NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG TC Ths 
PTCL_040 POS NEG NEG NEG NEG POS POS NEG NEG NEG NEG POS POS POS NEG ne NC TFH_TREG* 
PTCL_041 POS NEG NEG NEG NEG NEG POS NEG NEG NEG NEG POS POS NEG NEG NEG Th1 Ths 
PTCL_042 POS NEG POS POS POS ne POS NEG NEG NEG NEG NEG NEG NEG NEG NEG TC TC 
PTCL_043 POS NEG NEG NEG NEG POS NEG NEG NEG NEG NEG POS POS NEG NEG NEG Th1 TC 
PTCL_044 POS NEG NEG NEG NEG POS POS POS POS NEG NEG POS NEG POS NEG NEG TFH TFH_TREG 
PTCL_045 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG Th2 Ths 
PTCL_046 POS NEG NEG NEG NEG NEG NEG NEG POS POS NEG POS NEG POS NEG ne Treg TFH_TREG 
PTCL_047 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG POS NEG NEG Th2 Ths 





NEG NEG NEG POS NEG POS NEG NEG Th2 Ths 
PTCL_049 POS NEG NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG POS NEG NEG Th2 Ths 
PTCL_050 POS NEG NEG NEG NEG POS POS NEG POS NEG NEG NEG NEG POS NEG NEG TFH TC 
PTCL_051   NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG NEG Th1 TC 
PTCL_052 POS NEG POS NEG NEG NEG POS NEG NEG NEG NEG NEG NEG POS NEG NEG NC Ths 
PTCL_053 POS NEG NEG NEG NEG POS POS NEG POS NEG NEG POS NEG POS NEG NEG Th2 Ths 
PTCL_054 POS POS POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG TC TC* 
PTCL_055 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS POS NEG NEG NC Ths* 
PTCL_056 NEG POS NEG NEG NEG NEG POS NEG NEG NEG NEG POS NEG POS NEG ne TC Ths 
PTCL_057 POS NEG NEG NEG NEG POS POS NEG POS NEG NEG NEG ne POS NEG NEG TFH TFH_TREG 
PTCL_058 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS POS POS NEG ne NC TC 
PTCL_059 POS POS ne ne ne POS POS POS POS ne ne ne ne ne NEG ne NC TFH_TREG 
PTCL_061   NEG NEG NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NC TFH_TREG 
PTCL_062 POS NEG NEG NEG NEG NEG POS NEG NEG NEG POS POS NEG POS NEG NEG Th2 Ths 






POS NEG NEG POS NEG POS NEG NEG TFH TFH_TREG 
PTCL_064 NEG POS POS POS ne NEG NEG NEG NEG NEG NEG POS NEG NEG NEG NEG TC TC 
PTCL_065 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG NEG POS NEG NEG Th2 Ths 
PTCL_066 NEG NEG POS POS POS POS POS NEG POS NEG NEG POS NEG POS NEG ne NC TFH_TREG 
PTCL_067 NEG POS NEG NEG NEG NEG POS NEG POS NEG NEG POS NEG NEG NEG NEG TC TC* 
PTCL_068 POS NEG POS POS POS NEG POS NEG NEG NEG NEG POS NEG NEG NEG ne TC Ths 
PTCL_069 POS NEG NEG NEG ne ne NEG NEG NEG NEG ne POS POS ne NEG ne NC TC 
PTCL_070 NEG NEG NEG partial POS NEG 
partial 
POS 
NEG NEG NEG ne POS NEG NEG POS NEG NEG Th2 Ths 
PTCL_071 POS NEG NEG NEG NEG POS NEG NEG NEG NEG NEG POS NEG NEG NEG ne NC TFH_TREG 
 




Supplementary Table 16. Genes differentially expressed between LL and other PTCL/NOS 
Gene ID Corrected p-value Fold Change Absolute Regulation in Lennert lymphoma 
AARS 0.048042 8.328094 down 
ANO5 0.048042 23.54169 up 
ANP32B 0.019203 22.0195 down 
AP1M1 0.040698 15.8283 down 
ARL6IP5 0.040698 11.42905 down 
ATP5J2 0.033406 8.247275 down 
ATP6V1F 0.040698 14.39947 down 
BEST3 0.045729 109.1387 up 
BTAF1 0.04847 12.26237 down 
BTN1A1 0.018851 122.2571 up 
C16ORF58 0.015787 28.50922 down 
C16ORF82 0.045119 59.71398 up 
C1ORF116 0.042085 31.26302 up 
C1ORF21 0.045332 14.17014 up 
C1ORF212 0.04489 7.245252 down 
CBX6 0.026254 19.07741 down 
CCDC28A 0.042085 19.54007 down 
CCNA1 0.045555 37.51136 up 
CD247 0.040698 22.6524 down 
CIDECP 0.042085 19.74863 up 
CMTM8 0.048042 121.642 down 
CNDP2 0.048042 14.431 down 
CRYBA1 0.035962 29.78777 up 
CSF1R 0.020946 14.67107 down 
CST2 0.042085 113.6776 up 
DND1 0.019929 33.64642 up 
ELMO2 0.048042 6.763801 up 
ERCC2 0.042085 58.39888 down 
EXOSC8 0.042085 7.755707 down 
FAM19A5 0.045555 45.43218 up 
FBN3 0.034616 56.76897 up 
FEM1A 0.021777 13.19775 down 
FSCN1 0.04489 13.49049 down 
GADL1 0.020946 96.16802 up 
GIMAP4 0.021254 15.27739 down 
GLOD4 0.036741 49.15977 down 
GNS 0.026254 6.788456 down 
GRTP1 0.020946 63.88782 up 
GSTT2 0.037735 12.12487 up 
HDAC1 0.045119 15.8912 down 
HDDC2 0.040698 11.27747 down 
HOXC5 0.042085 22.62152 up 
HSPB7 0.045555 93.09251 up 
IFNA14 0.026254 19.9188 up 
IGSF3 0.031962 16.43183 up 
KLF16 0.040698 112.0658 up 
KLF2 0.039421 12.15451 down 
KRTAP21-2 0.045555 38.046 up 
KRTAP5-2 0.040698 67.19664 up 
METAP2 0.048042 13.55544 down 
NACAP1 0.048042 74.54222 up 
NDUFS3 0.04847 14.75795 down 
NUP62 0.021867 5.891832 down 
OR2J3 0.031306 107.6506 up 
OR51S1 0.015787 203.3402 up 
P15RS 0.045555 8.513782 down 
PCP4 0.031761 46.26405 up 
PGLYRP3 0.031962 83.86409 up 
PNLIPRP3 0.048042 26.46125 up 
PPP1R14A 0.048042 14.64327 down 
PPP1R14C 0.037638 84.77431 up 
PPP1R15A 0.045555 36.12256 down 
PRDM16 0.021777 29.96874 up 
PSMB3 0.021777 20.77113 down 
PSMC5 0.04847 10.18691 down 
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QARS 0.048042 10.3333 down 
RARS 0.045119 8.669651 down 
RFX2 0.037735 34.91593 up 
RNF123 0.041762 5.112667 down 
RPL11 0.048042 7.517418 down 
RPL5 0.037118 9.529422 down 
RPS27A 0.021777 15.52451 down 
RPUSD4 0.04489 9.614982 down 
SCGB1C1 0.04847 89.68658 up 
SEPHS2 0.045555 8.611829 down 
SFRS5 0.048042 6.598389 down 
SH3YL1 0.020946 12.46181 down 
SHANK1 0.037735 31.68711 up 
SLC13A2 0.048042 18.91503 up 
SLC25A42 0.045555 7.602004 down 
SLC38A2 0.026254 19.79868 down 
SPRY4 0.048042 9.27606 up 
SUGT1 0.040698 9.070003 down 
TAS1R2 0.045555 29.14978 up 
TIMM8B 0.04489 7.428672 down 
TMEM218 0.042085 10.55598 down 
TOMM7 0.040698 12.19069 down 
UBB 0.04489 6.179905 down 
VDAC3 0.048042 14.51976 down 
YWHAZ 0.027551 4.736977 down 
 
Supplementary Table 17. Minimum number of genes used to classify Lennert Lymphoma vs. Other 
PTCL/NOS 
Gene ID p-value Fold Change Absolute Regulation in Lennert Lymphoma 
AARS 0.034643 5.351144 up 
ANP32B 0.040764 5.276015 up 
C16ORF58 0.034774 6.782455 up 
CBX6 0.038325 3.728618 up 
FEM1A 0.03344 4.312741 up 
GRTP1 0.029674 5.317543 up 
HDDC2 0.034736 3.994825 up 
KLF2 0.007834 5.288072 up 
QARS 0.036329 6.758295 up 
RPL11 0.033991 5.052949 up 
RPUSD4 0.003753 4.535713 up 
SFRS5 0.011129 7.316927 up 
SLC38A2 0.038574 7.406537 up 
SUGT1 0.018644 7.025328 up 
TMEM218 0.031185 6.44771 up 
VDAC3 0.022675 3.537255 up 
YWHAZ 8.46E-04 4.561161 up 
 
Supplementary Table 18. Genes differentially expressed between Lennert Lymphoma and other 
Cytotoxic-PTCL/NOS. 
Gene ID Absolute fold change Regulation in Lennert lymphoma 
ACADVL 3.116902 Up 
ACRC 3.6132402 Up 
ADAMDEC1 10.209334 Up 
AP2S1 3.441176 Up 
ATP2A2 3.1684623 Up 
ATP6V0E1 12.777383 Up 
BBC3 4.3282285 Up 
BCAS2 3.981759 Up 
C10ORF46 11.763814 Up 
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C17ORF70 4.614214 Up 
C22ORF28 6.6235423 Up 
C4ORF7 17.456026 Up 
C6ORF108 7.160199 Up 
CAB39 6.009047 Up 
CALCOCO1 6.2506027 Up 
CAPS 6.525078 Up 
CARS 6.383906 Up 
CD276 4.9524817 Up 
CD68 4.7363253 Up 
CIRH1A 4.2664757 Up 
CNIH3 8.399947 Up 
COTL1 6.9181404 Up 
COX19 4.1591444 Up 
CPNE9 8.810795 Up 
CTSS 15.798656 Up 
DBT 3.7400055 Up 
DCXR 4.6417174 Up 
DGKQ 6.7778916 Up 
DOK3 14.490645 Up 
DPYD 6.0663257 Up 
EDNRA 13.539241 Up 
EIF3C 4.836497 Up 
ERAL1 3.9320552 Up 
ERH 4.4225154 Up 
FAIM3 8.564781 Up 
FAM53C 5.5226445 Up 
FAM98C 5.3446026 Up 
FKBP1A 3.443761 Up 
FKSG30 13.01743 Up 
FLJ46309 4.7801 Up 
FNDC8 14.6923685 Up 
FOXRED2 3.4148333 Up 
FTL 6.4756722 Up 
G0S2 4.957224 Up 
GATAD2B 7.516201 Up 
GNB2 5.666305 Up 
GPR153 8.613095 Up 
GPR4 8.417191 Up 
GPR50 7.3658705 Up 
GSDMB 4.5593534 Up 
GZMK 7.9394627 Up 
HDHD2 4.0754285 Up 
HERC2P2 49.46249 Up 
HERPUD1 7.6170588 Up 
HGS 7.9817104 Up 
HIST1H3F 10.317671 Up 
HLA-DRB1 16.504635 Up 
HOXB5 7.9177694 Up 
HTRA4 5.0577416 Up 
IFRD2 23.346718 Up 
IL21R 5.0096636 Up 
IL33 23.124323 Up 
KRT19 6.1300125 Up 
LDB2 7.787828 Up 
LOC440157 3.615458 Up 
LOC442582 8.34117 Up 
LTA 5.4489226 Up 
LY6E 5.0762987 Up 
MDM2 5.1392217 Up 
MED16 5.011195 Up 
MKRN1 3.026339 Up 
MLL2 6.0631843 Up 
MRPS16 4.670593 Up 
MVD 16.966854 Up 
NFKBIZ 4.431783 Up 
NR1H3 4.855749 Up 
NUPR1 8.693555 Up 
OAT 5.4859695 Up 
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OLFML3 9.461977 Up 
P2RXL1 8.162519 Up 
PHCA 4.3148108 Up 
PLA2G7 4.0816355 Up 
PLDN 15.32583 Up 
PNPLA7 5.2977753 Up 
PRDX5 5.9678206 Up 
PSMC4 4.659525 Up 
QRICH1 3.1744618 Up 
RGS12 3.7804742 Up 
RPL30 4.3365235 Up 
RPL39 10.139755 Up 
RPL41 5.6382694 Up 
RPS3 4.404897 Up 
RTN1 3.8055818 Up 
RTN4RL1 5.751417 Up 
RYR1 5.3531823 Up 
SBDSP 29.219948 Up 
SDK1 8.426482 Up 
SDK2 4.841416 Up 
SERPINA1 3.071698 Up 
SFXN3 6.677094 Up 
SKIL 5.9285398 Up 
SLC30A4 3.9101827 Up 
SLFN13 4.6696396 Up 
SNORA25 8.169617 Up 
SNRPD3 10.983438 Up 
SNX27 5.1733003 Up 
STT3A 11.5508795 Up 
SUMO2 3.3813713 Up 
TBC1D9 3.5861583 Up 
TBL1X 3.9607947 Up 
TDH 22.116198 Up 
TGM7 6.306344 Up 
TMEM141 4.822222 Up 
TMEM156 4.507389 Up 





TNFRSF4 6.17836 Up 
TRAK1 3.7911801 Up 
TSNARE1 14.135962 Up 
TSPAN33 5.745453 Up 
TSPYL4 12.93785 Up 
UBXN2A 3.5488248 Up 
UNKL 8.83826 Up 
VAMP2 9.436797 Up 
VRK2 6.4054008 Up 
ZCCHC6 5.852641 Up 
ZNF100 5.673135 Up 
ZNF148 3.759338 Up 
ZNF385A 8.265473 Up 
ZNF75D 9.818688 Up 
ZSWIM4 4.0180464 Up 
ACACA 6.219462 Down 
ANAPC1 9.536929 Down 
APBB3 4.7698927 Down 
ATG2A 10.330487 Down 
CSE1L 4.666507 Down 
CYP2J2 17.303497 Down 
DDX5 11.32598 Down 
DNAJA3 12.485661 Down 
DOPEY1 19.042269 Down 
EIF4A3 7.640334 Down 
ERP27 5.11796 Down 
GTF3C4 14.742162 Down 
KIF15 6.880068 Down 
LCMT2 22.541142 Down 
MSI2 6.35985 Down 
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PPFIA4 21.600674 Down 
QSOX2 10.239131 Down 
RABGAP1 9.783725 Down 
RFWD3 11.9629755 Down 
SFRS9 6.4106755 Down 
TACSTD2 10.699939 Down 
TUSC4 4.3865237 Down 
ZDHHC7 6.3109584 Down 
ZW10 6.3244047 Down 
 
Supplementary Table 19. MicroRNAs differentially expressed between Lennert Lymphoma and 
other PTCL/NOS. 
MicroRNA ID p-value Absolute fold change Regulation in Lennert 
lymphoma 
hsa-let-7d-4395394 0.012553142 2.7276673 down 
hsa-let-7e-4395517 0.011690697 3.0097759 down 
hsa-miR-146a-4373132 0.019856786 3.381771 up 
hsa-miR-147b-4395373 0.022377128 37.29126 up 
hsa-miR-199b-5p-4373100 0.005994446 20.567883 down 
hsa-miR-23a-4373074 0.027455721 28.169153 down 
hsa-miR-337-5p-4395267 0.017264001 16.229063 down 
hsa-miR-361-5p-4373035 0.006049584 3.3813345 down 
hsa-miR-503-4373228 0.022841154 14.025469 up 
 
Supplementary Table 20. MicroRNAs differentially expressed between Lennert Lymphoma and 
normal T-lymphocytes. 
MicroRNA ID Corrected p-value Absolute fold change Regulation in Lennert lymphoma 
hsa-let-7a-4373169 3.61E-08 80.45558 down 
hsa-let-7b-4395446 1.11E-04 58.60917 down 
hsa-let-7c-4373167 8.43E-05 54.11149 down 
hsa-let-7d-4395394 2.99E-07 60.116455 down 
hsa-let-7e-4395517 3.84E-06 58.55097 down 
hsa-let-7g-4395393 2.68E-06 35.678413 down 
hsa-miR-103-4373158 2.04E-07 18.852873 down 
hsa-miR-105-4395278 8.00E-05 66.7315 down 
hsa-miR-106a-4395280 0.007125661 9.885492 down 
hsa-miR-107-4373154 0.001655065 143.55693 down 
hsa-miR-10b-4395329 1.64E-04 88.91393 up 
hsa-miR-122-4395356 7.20E-04 28.72273 down 
hsa-miR-124-4373295 0.002220829 25.887716 down 
hsa-miR-125a-5p-4395309 1.95E-04 14.433721 down 
hsa-miR-126-4395339 6.82E-05 101.86429 up 
hsa-miR-127-5p-4395340 7.30E-05 68.620255 down 
hsa-miR-128-4395327 3.40E-05 22.22271 down 
hsa-miR-129-3p-4373297 0.00121894 104.67908 down 
hsa-miR-129-5p-4373171 6.82E-05 71.09103 down 
hsa-miR-133b-4395358 6.82E-05 84.198875 down 
hsa-miR-136-4373173 1.42E-04 56.22069 down 
hsa-miR-137-4373301 0.003990321 17.002647 down 
hsa-miR-139-5p-4395400 5.77E-04 9.9506855 down 
hsa-miR-140-3p-4395345 6.82E-05 21.325573 down 
hsa-miR-141-4373137 1.87E-04 9.826057 up 
hsa-miR-143-4395360 1.20E-06 1468.8832 up 
hsa-miR-145-4395389 0.002026504 60.935905 up 
hsa-miR-146b-3p-4395472 1.20E-06 95.16415 down 
hsa-miR-146b-5p-4373178 0.00122144 6.0564437 down 
hsa-miR-150-4373127 7.27E-05 77.75678 down 
hsa-miR-154-4373270 6.82E-05 71.09107 down 
hsa-miR-15b-4373122 5.40E-09 106.267975 down 
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hsa-miR-17-4395419 0.005749429 10.5224285 down 
hsa-miR-181a-4373117 3.40E-05 46.79759 down 
hsa-miR-181c-4373115 1.05E-04 45.563152 down 
hsa-miR-188-3p-4395217 6.22E-04 100.71986 down 
hsa-miR-191-4395410 1.72E-04 15.18671 down 
hsa-miR-192-4373108 7.67E-04 3.3630126 down 
hsa-miR-193a-5p-4395392 0.001162334 16.482971 down 
hsa-miR-193b-4395478 3.51E-04 20.11634 down 
hsa-miR-197-4373102 6.52E-05 77.87767 down 
hsa-miR-198-4395384 5.99E-04 27.235113 down 
hsa-miR-199a-3p-4395415 0.005749429 106.92413 up 
hsa-miR-19b-4373098 0.002631858 2.7876596 down 
hsa-miR-200b-4395362 9.85E-04 17.039028 down 
hsa-miR-200c-4395411 3.61E-08 40.910633 down 
hsa-miR-202-4395474 6.82E-05 62.797626 down 
hsa-miR-208-4373091 6.82E-05 88.85641 down 
hsa-miR-20a-4373286 3.09E-04 18.68084 down 
hsa-miR-210-4373089 6.82E-05 18.533596 down 
hsa-miR-21-4373090 5.06E-04 2.316405 up 
hsa-miR-215-4373084 0.00292297 10.27159 down 
hsa-miR-216a-4395331 9.60E-05 49.347176 down 
hsa-miR-216b-4395437 3.23E-04 45.986214 down 
hsa-miR-217-4395448 6.82E-05 71.09103 down 
hsa-miR-218-4373081 0.002565206 56.033585 up 
hsa-miR-219-1-3p-4395206 6.82E-05 214.05992 down 
hsa-miR-219-2-3p-4395501 6.82E-05 71.09107 down 
hsa-miR-219-5p-4373080 6.82E-05 71.09105 down 
hsa-miR-220-4373078 1.19E-04 44.10578 down 
hsa-miR-220b-4395317 6.82E-05 71.09103 down 
hsa-miR-220c-4395322 6.82E-05 71.09103 down 
hsa-miR-222-4395387 0.001010677 7.1059165 down 
hsa-miR-223-4395406 6.82E-05 74.272804 down 
hsa-miR-22-4373079 1.83E-06 745.4907 up 
hsa-miR-224-4395210 0.002565206 14.793198 up 
hsa-miR-23a-4373074 1.59E-05 102.82014 down 
hsa-miR-24-4373072 0.002967551 3.402679 down 
hsa-miR-25-4373071 3.53E-06 19.841572 down 
hsa-miR-26a-4395166 6.82E-05 37.50873 down 
hsa-miR-26b-4395167 6.70E-06 31.565748 down 
hsa-miR-27a-4373287 0.009016768 3.271165 down 
hsa-miR-28-3p-4395557 3.40E-05 14.475548 down 
hsa-miR-296-3p-4395212 7.60E-04 33.311626 down 
hsa-miR-296-5p-4373066 1.88E-05 91.032715 down 
hsa-miR-298-4395301 0.00387515 25.720179 down 
hsa-miR-299-3p-4373189 6.82E-05 71.09103 down 
hsa-miR-299-5p-4373188 6.82E-05 71.09107 down 
hsa-miR-29a-4395223 1.24E-04 5.3029532 down 
hsa-miR-302a-4378070 3.98E-04 116.27155 down 
hsa-miR-302b-4378071 0.004433442 17.031845 down 
hsa-miR-30b-4373290 2.38E-06 27.244072 down 
hsa-miR-30c-4373060 3.92E-06 33.961716 down 
hsa-miR-31-4395390 1.50E-05 65.14107 down 
hsa-miR-320-4395388 5.51E-05 64.36276 down 
hsa-miR-323-3p-4395338 7.11E-05 73.57172 down 
hsa-miR-324-3p-4395272 2.01E-05 15.925911 down 
hsa-miR-324-5p-4373052 0.003657605 5.4264016 down 
hsa-miR-325-4373051 6.82E-05 71.09107 down 
hsa-miR-326-4373050 3.61E-08 74.51434 down 
hsa-miR-328-4373049 8.24E-05 75.37232 down 
hsa-miR-329-4373191 1.93E-04 51.829296 down 
hsa-miR-330-3p-4373047 1.14E-04 51.447227 down 
hsa-miR-331-3p-4373046 2.47E-05 18.872269 down 
hsa-miR-339-5p-4395368 6.82E-05 88.839 down 
hsa-miR-33b-4395196 6.82E-05 71.09105 down 
hsa-miR-342-3p-4395371 1.26E-06 61.85865 down 
hsa-miR-342-5p-4395258 6.82E-05 79.59399 down 
hsa-miR-346-4373038 1.42E-04 56.123333 down 
hsa-miR-361-5p-4373035 3.70E-05 21.182549 down 
hsa-miR-363-4378090 6.28E-09 83.19141 down 
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hsa-miR-365-4373194 2.41E-04 10.666114 down 
hsa-miR-369-3p-4373032 6.82E-05 71.09103 down 
hsa-miR-369-5p-4373195 6.82E-05 71.09105 down 
hsa-miR-371-3p-4395235 6.82E-05 71.09105 down 
hsa-miR-375-4373027 1.08E-04 32.883205 down 
hsa-miR-376b-4373196 6.82E-05 71.09107 down 
hsa-miR-377-4373025 6.82E-05 71.09107 down 
hsa-miR-380-4373022 6.82E-05 71.09103 down 
hsa-miR-382-4373019 0.002342956 28.989588 down 
hsa-miR-384-4373017 6.82E-05 71.09107 down 
hsa-miR-409-5p-4395442 6.82E-05 71.09107 down 
hsa-miR-423-5p-4395451 1.09E-05 97.37894 down 
hsa-miR-424-4373201 0.001077875 5.71487 up 
hsa-miR-429-4373203 0.003591576 17.881916 down 
hsa-miR-431-4395173 6.82E-05 71.09105 down 
hsa-miR-448-4373206 6.82E-05 71.09105 down 
hsa-miR-450b-3p-4395319 8.00E-05 66.6514 down 
hsa-miR-450b-5p-4395318 5.72E-04 39.88836 down 
hsa-miR-452-4395440 6.86E-04 24.758244 up 
hsa-miR-453-4395429 6.82E-05 71.09107 down 
hsa-miR-455-5p-4378098 1.26E-06 122.35287 up 
hsa-miR-483-5p-4395449 9.69E-05 42.259033 down 
hsa-miR-484-4381032 0.001010677 14.543935 down 
hsa-miR-485-5p-4373212 6.82E-05 71.09103 down 
hsa-miR-486-3p-4395204 0.002686553 81.4469 down 
hsa-miR-486-5p-4378096 4.91E-04 369.4228 down 
hsa-miR-487a-4378097 2.91E-04 32.83046 down 
hsa-miR-487b-4378102 6.05E-04 30.510933 down 
hsa-miR-489-4395469 0.005155399 7.8477526 down 
hsa-miR-490-3p-4373215 6.82E-05 71.09103 down 
hsa-miR-491-3p-4395471 6.82E-05 71.09107 down 
hsa-miR-491-5p-4381053 9.34E-06 32.163155 down 
hsa-miR-492-4373217 6.82E-05 71.09103 down 
hsa-miR-496-4386771 6.87E-05 72.03769 down 
hsa-miR-499-3p-4395538 6.82E-05 71.09107 down 
hsa-miR-499-5p-4381047 6.82E-05 71.09105 down 
hsa-miR-501-3p-4395546 5.31E-04 93.96086 down 
hsa-miR-502-3p-4395194 6.89E-04 7.164897 down 
hsa-miR-502-5p-4373227 0.001968731 7.4537277 up 
hsa-miR-503-4373228 0.008556373 4.0969133 up 
hsa-miR-504-4395195 6.82E-05 71.09105 down 
hsa-miR-506-4373231 6.82E-05 71.09105 down 
hsa-miR-507-4373232 6.82E-05 75.08985 down 
hsa-miR-508-3p-4373233 5.28E-04 28.161697 down 
hsa-miR-508-5p-4395203 6.82E-05 71.09105 down 
hsa-miR-509-3-5p-4395266 6.82E-05 71.09107 down 
hsa-miR-510-4395352 6.82E-05 71.09107 down 
hsa-miR-512-5p-4373238 6.82E-05 71.09103 down 
hsa-miR-513-5p-4395201 6.82E-05 71.687325 down 
hsa-miR-515-3p-4395480 7.61E-04 29.642006 down 
hsa-miR-515-5p-4373242 6.82E-05 71.09107 down 
hsa-miR-516a-5p-4395527 6.82E-05 71.09107 down 
hsa-miR-516b-4395172 6.77E-04 26.417011 down 
hsa-miR-518a-5p-4395507 6.82E-05 71.09107 down 
hsa-miR-518b-4373246 0.008556373 26.09354 down 
hsa-miR-518c-4395512 1.42E-04 40.977566 down 
hsa-miR-518d-3p-4373248 6.82E-05 71.09107 down 
hsa-miR-518d-5p-4395500 6.82E-05 71.09107 down 
hsa-miR-518e-4395506 0.002126356 24.25924 down 
hsa-miR-518f-4395499 0.001182622 22.145823 down 
hsa-miR-519c-3p-4373251 6.82E-05 71.09105 down 
hsa-miR-520a-3p-4373268 6.82E-05 71.09105 down 
hsa-miR-520a-5p-4378085 6.82E-05 71.09103 down 
hsa-miR-520d-5p-4395504 6.82E-05 71.09107 down 
hsa-miR-520e-4373255 6.82E-05 71.09103 down 
hsa-miR-520g-4373257 8.07E-05 75.066 down 
hsa-miR-521-4373259 6.51E-05 83.90615 down 
hsa-miR-522-4395524 9.60E-05 66.788185 down 
hsa-miR-524-5p-4395174 6.82E-05 71.09107 down 
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hsa-miR-525-5p-4378088 6.82E-05 71.09103 down 
hsa-miR-526b-4395493 6.82E-05 71.09103 down 
hsa-miR-532-3p-4395466 4.99E-07 92.18991 down 
hsa-miR-539-4378103 0.002230879 17.837038 up 
hsa-miR-541-4395312 0.001162334 33.642113 down 
hsa-miR-544-4395376 6.82E-05 71.09103 down 
hsa-miR-548a-3p-4380948 0.001253028 34.723244 down 
hsa-miR-548a-5p-4395523 6.82E-05 71.09107 down 
hsa-miR-548b-3p-4380951 6.82E-05 71.09105 down 
hsa-miR-548c-3p-4380993 4.13E-04 131.35822 down 
hsa-miR-548c-5p-4395540 0.001253028 28.382477 down 
hsa-miR-548d-3p-4381008 4.45E-06 81.80428 down 
hsa-miR-548d-5p-4395348 0.001314656 26.69374 down 
hsa-miR-551b-4380945 9.85E-04 24.099463 down 
hsa-miR-556-3p-4395456 6.82E-05 71.09103 down 
hsa-miR-556-5p-4395455 6.82E-05 71.09107 down 
hsa-miR-561-4380938 1.44E-04 55.7872 down 
hsa-miR-576-5p-4395461 6.82E-05 69.40356 down 
hsa-miR-579-4395509 0.005155399 10.072881 up 
hsa-miR-582-3p-4395510 6.82E-05 71.09107 down 
hsa-miR-582-5p-4395175 6.82E-05 71.09105 down 
hsa-miR-597-4380960 4.06E-05 45.87345 down 
hsa-miR-615-3p-4386777 6.82E-05 71.09107 down 
hsa-miR-615-5p-4395464 6.82E-05 71.09105 down 
hsa-miR-616-4395525 0.002686553 50.96274 down 
hsa-miR-618-4380996 0.002672494 21.818733 down 
hsa-miR-624-4395541 6.82E-05 71.09107 down 
hsa-miR-625-4395542 6.82E-05 42.055714 down 
hsa-miR-629-4395547 6.82E-05 22.818056 down 
hsa-miR-636-4395199 2.76E-04 21.04169 down 
hsa-miR-642-4380995 1.15E-08 73.859146 down 
hsa-miR-651-4381007 1.35E-04 80.48955 down 
hsa-miR-652-4395463 7.05E-06 8.060042 down 
hsa-miR-654-5p-4381014 6.82E-05 71.09107 down 
hsa-miR-660-4380925 3.40E-05 305.576 up 
hsa-miR-671-3p-4395433 2.38E-06 81.73437 down 
hsa-miR-672-4395438 5.28E-04 38.153137 down 
hsa-miR-674-4395193 6.82E-05 72.1159 down 
hsa-miR-744-4395435 2.63E-07 46.19919 down 
hsa-miR-758-4395180 6.82E-05 71.416595 down 
hsa-miR-871-4395465 6.82E-05 71.09107 down 
hsa-miR-872-4395375 6.82E-05 71.09107 down 
hsa-miR-874-4395379 1.11E-04 82.106316 down 
hsa-miR-875-3p-4395315 6.82E-05 71.45992 down 
hsa-miR-876-3p-4395336 6.82E-05 71.09103 down 
hsa-miR-876-5p-4395316 6.82E-05 71.09107 down 
hsa-miR-885-3p-4395483 0.003815113 86.37674 down 
hsa-miR-887-4395485 1.51E-04 54.713673 down 
hsa-miR-889-4395313 0.00100865 23.954018 down 
hsa-miR-890-4395320 6.82E-05 71.09107 down 
hsa-miR-891a-4395302 7.96E-04 37.14928 down 
hsa-miR-891b-4395321 6.82E-05 71.09107 down 
hsa-miR-892a-4395306 6.82E-05 71.09107 down 
hsa-miR-92a-4395169 1.26E-06 121.121605 down 
hsa-miR-93-4373302 7.96E-04 14.133492 down 
hsa-miR-95-4373011 0.001244283 17.408205 down 
hsa-miR-96-4373372 6.82E-05 71.09105 down 
hsa-miR-98-4373009 6.82E-05 66.1558 down 




Supplementary Table 21. Genes differentially expressed between Lennert Lymphoma and 
normal T-lymphocytes. 
Gene ID Corrected p-value Absolute fold change Regulation in Lennert lymphoma 
CCDC107 0.004824301 47.71441 down 
EAF1 0.002051818 16.950863 down 
EFHA1 0.004074807 12.785063 down 
MAGOH 0.001658394 56.60359 down 
MAPBPIP 0.002178571 18.467093 down 
MRPL1 4.12E-04 20.259808 down 
PPIH 6.16E-06 9.901969 down 
RPP38 5.91E-04 23.624487 down 
SIGIRR 5.75E-04 11.742586 down 
TAPT1 0.004604011 14.049687 down 
TERF2IP 1.48E-04 8.229083 down 
TMEM60 0.002367497 13.576537 down 
UQCRQ 0.002908249 21.078123 down 
A1CF 2.48E-04 148.90007 up 
A2M 0.004109861 919.30115 up 
A4GALT 5.30E-05 238.38931 up 
ABCA6 0.002588788 60.411644 up 
ABCA8 7.76E-05 562.2567 up 
ABCC3 0.003477665 192.81596 up 
ABCC8 7.91E-05 94.09664 up 
ABHD12B 0.004047907 70.868416 up 
ABI3BP 1.96E-05 494.4472 up 
ABL2 0.00411369 7.981921 up 
ABP1 5.19E-04 56.52589 up 
ACMSD 3.20E-04 103.09564 up 
ACVRL1 0.004335573 1838.7761 up 
ADAMTS14 4.28E-04 71.91135 up 
ADAMTS18 1.03E-04 289.33682 up 
ADAMTS5 5.48E-06 275.51382 up 
ADCY2 1.56E-05 311.60263 up 
ADCY6 0.001586153 70.971016 up 
ADCYAP1 3.70E-04 163.7449 up 
ADRA1B 3.23E-04 261.2697 up 
AIRE 0.001705347 58.04078 up 
AKR1C4 0.004229457 110.69178 up 
ALDH1A1 0.004618076 837.84015 up 
ALDH3A1 2.25E-04 78.19763 up 
ALK 4.61E-04 34.806988 up 
ALPL 0.00263254 2267.68 up 
ANG 0.001113428 11.674992 up 
ANGPT2 2.48E-05 2365.0767 up 
ANKRD29 0.002515058 328.54285 up 
ANKRD45 0.001436541 71.605865 up 
ANKS1B 7.62E-05 150.37242 up 
ANO5 2.00E-04 111.99926 up 
ANTXR1 1.16E-08 63.353504 up 
APBB2 0.003382847 149.02454 up 
APCDD1L 0.003074952 480.98248 up 
APLNR 1.14E-05 3473.3835 up 
APOC1 1.15E-04 344.844 up 
APOE 7.77E-04 2233.9165 up 
ARL15 0.00270423 22.049297 up 
ASB10 0.003141448 52.688026 up 
ASCL2 0.001964778 118.28999 up 
ASGR2 2.21E-04 57.568855 up 
ASPA 1.14E-05 3224.0264 up 
ATOH8 2.92E-05 1082.949 up 
BAZ1B 0.001176386 97.57641 up 
BGN 3.64E-06 1629.443 up 
BHLHB3 2.16E-04 2960.5522 up 
BNC2 0.001104544 150.11607 up 
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C10ORF11 9.26E-04 172.50426 up 
C10ORF65 4.60E-05 212.2882 up 
C11ORF40 0.004347653 132.00244 up 
C11ORF41 6.09E-04 198.70433 up 
C12ORF64 5.15E-06 94.457596 up 
C13ORF30 6.64E-05 1291.303 up 
C14ORF73 2.81E-04 329.22418 up 
C15ORF38 1.09E-05 395.89264 up 
C16ORF3 0.002115656 489.15015 up 
C17ORF77 2.66E-04 648.3065 up 
C17ORF82 0.001596325 281.1157 up 
C18ORF34 1.18E-04 429.263 up 
C1ORF110 0.003764643 3111.9236 up 
C1ORF95 0.003836555 67.09627 up 
C1QA 9.33E-08 625.223 up 
C1QB 1.11E-05 3583.602 up 
C1QL2 7.90E-04 384.19763 up 
C1QTNF5 0.001791736 311.08853 up 
C1QTNF7 8.58E-04 73.58816 up 
C1S 4.80E-04 197.54514 up 
C20ORF186 7.82E-04 147.35855 up 
C2ORF65 0.002478448 328.45575 up 
C3 5.30E-05 412.74664 up 
C3ORF24 0.004375497 150.04103 up 
C4ORF18 5.02E-08 258.1374 up 
C4ORF37 3.93E-05 203.60419 up 
C4ORF45 0.003388995 93.93394 up 
C4ORF7 5.02E-09 108460.086 up 
C5ORF20 2.25E-04 117.61034 up 
C6ORF138 4.44E-04 46.523273 up 
C7 7.39E-04 454.45554 up 
C8ORF4 1.04E-05 7308.287 up 
C8ORF42 2.46E-04 247.81018 up 
C9 0.001948395 356.19333 up 
C9ORF61 0.002686916 106.81605 up 
CA4 8.57E-04 153.8369 up 
CACNA1E 1.57E-05 195.48915 up 
CACNA2D3 2.63E-04 623.852 up 
CALB1 0.002006047 48.680122 up 
CALML3 9.52E-04 143.59138 up 
CART1 0.00131751 303.34482 up 
CARTPT 9.14E-04 34.514526 up 
CAV1 0.001473657 71.21753 up 
CBFA2T3 2.73E-04 67.96304 up 
CCDC80 2.61E-05 332.15182 up 
CCL11 0.002176097 149.17578 up 
CCL21 3.89E-06 17100.742 up 
CD14 0.001810738 51.036827 up 
CD180 0.001892739 144.80896 up 
CD1E 3.11E-09 121.20033 up 
CD209 3.94E-05 175.3683 up 
CD300LG 0.002122958 67.6576 up 
CD36 0.0011447 64.84553 up 
CDC42EP1 8.56E-06 111.05538 up 
CDC42EP5 2.81E-08 2126.6475 up 
CDCA8 3.43E-04 11.861703 up 
CDH10 3.03E-05 8959.266 up 
CDH11 3.49E-06 135.86707 up 
CDH13 0.004550356 124.89088 up 
CDH5 2.75E-07 411.45947 up 
CDX1 5.96E-07 723.2297 up 
CEACAM20 0.002311474 329.75888 up 
CELSR1 0.00406698 144.05043 up 
CGB2 0.001487034 83.452705 up 
CGNL1 1.05E-04 322.99033 up 
CHRD 2.91E-04 129.61572 up 
CHRDL1 0.001507737 457.46326 up 
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CHRDL2 0.004037772 124.771515 up 
CLDN2 0.0017472 141.44775 up 
CLDN3 0.001003348 35.39689 up 
CLEC14A 7.80E-06 420.6127 up 
CLEC4G 4.62E-04 195.2623 up 
CLEC4M 6.81E-05 231.7394 up 
CLU 0.001613511 51.188614 up 
CMKLR1 0.002228843 660.51776 up 
COL16A1 7.20E-05 61.017914 up 
COL1A1 6.42E-04 219.96974 up 
COL1A2 0.003206673 290.22144 up 
COL3A1 8.44E-05 674.1037 up 
COL4A2 5.40E-05 840.0196 up 
COL4A4 2.47E-05 1123.8839 up 
COMP 6.65E-04 693.0022 up 
CP 7.60E-06 1791.0645 up 
CPVL 7.20E-04 671.02625 up 
CRIM1 0.004679355 90.89279 up 
CRYBA1 9.60E-04 127.26573 up 
CRYBB1 3.87E-04 259.5617 up 
CSDC2 1.39E-05 457.7034 up 
CSMD2 0.00103971 44.628788 up 
CSN3 0.003536882 1489.3837 up 
CSPG4 6.52E-05 1001.82794 up 
CST9 2.67E-04 128.37216 up 
CTGF 0.003019353 68.822426 up 
CUEDC1 6.18E-05 118.245 up 
CX3CL1 0.003605685 226.8698 up 
CXCL12 1.43E-07 285.7934 up 
CXCL14 3.89E-09 4735.3433 up 
CYP2C19 0.004225662 970.40063 up 
CYP4F11 0.004890965 64.39434 up 
CYP8B1 0.002256816 120.34287 up 
CYR61 0.001668595 739.83136 up 
DAAM2 0.00149221 41.989517 up 
DACT2 1.89E-05 131.11925 up 
DAPL1 6.93E-04 132.9525 up 
DCLK1 1.65E-06 324.77914 up 
DCN 2.11E-07 1564.5222 up 
DEFB122 2.25E-06 570.08154 up 
DEFB125 0.002905576 304.0734 up 
DEFB129 2.04E-06 376.678 up 
DES 0.003394246 157.65027 up 
DIO2 2.09E-04 79.228035 up 
DLL4 2.87E-04 153.34657 up 
DLX1 2.82E-05 56.58711 up 
DLX5 0.001596655 98.3629 up 
DMRT3 8.56E-05 204.13988 up 
DNALI1 0.001791371 29.736288 up 
DOK3 0.003878779 752.33435 up 
DPPA2 0.001257183 55.031273 up 
DPT 1.53E-05 61.211666 up 
DSC2 4.92E-05 170.65591 up 
DSCR10 6.47E-04 51.88543 up 
DSE 0.001671509 19.59557 up 
DTNA 5.35E-07 630.1794 up 
DUX3 6.47E-05 6843.355 up 
DZIP1 0.004565985 96.16974 up 
EBF3 1.04E-04 54.036602 up 
EDNRA 1.42E-05 11640.301 up 
EFEMP1 1.26E-08 230.84818 up 
EFS 4.39E-05 105.1983 up 
EGFLAM 3.60E-07 282.19333 up 
ELA3A 0.002186013 147.34988 up 
EMILIN1 0.004873649 318.553 up 
EPHA2 9.97E-04 175.6159 up 
EPHA3 6.99E-06 135.0204 up 
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ERC2 6.84E-04 104.00445 up 
ERVWE1 0.001722565 106.04717 up 
ETV1 9.44E-04 82.34332 up 
EVI1 8.89E-04 89.03203 up 
EYA4 0.003720977 65.86412 up 
F10 7.08E-04 637.6613 up 
F8 0.001630355 35.73296 up 
FA2H 0.002530525 181.99431 up 
FAM107A 4.75E-07 159.64517 up 
FAM123A 1.43E-06 376.09506 up 
FAM155A 3.49E-04 133.82468 up 
FAM19A5 0.003436749 236.76608 up 
FAM20A 0.001061105 164.18413 up 
FAM3D 5.84E-05 278.88446 up 
FAM43B 7.48E-04 83.4497 up 
FAM70A 5.16E-06 442.61203 up 
FAM70B 2.84E-04 246.27187 up 
FARP1 1.47E-04 47.40466 up 
FBLN1 4.78E-12 99.17179 up 
FBN1 1.49E-07 794.04956 up 
FBN2 3.95E-05 269.9577 up 
FBXO22OS 0.004076702 72.679924 up 
FCN3 9.55E-05 119.374756 up 
FCRL2 7.45E-04 50.109898 up 
FGFR3 5.38E-04 31.377474 up 
FHL2 3.21E-04 19.971106 up 
FIGN 8.53E-05 1105.1294 up 
FILIP1 6.61E-04 187.55183 up 
FILIP1L 0.003159087 26.868729 up 
FLJ25996 5.43E-04 1166.0594 up 
FLJ35409 0.001648607 103.118675 up 
FLJ44653 0.001286436 298.49823 up 
FLJ45445 3.51E-05 206.28146 up 
FLNC 0.004016951 540.0853 up 
FLRT2 8.55E-04 31.151913 up 
FMO2 8.72E-05 333.3134 up 
FMO3 0.003437823 71.283516 up 
FN1 2.75E-06 332.47342 up 
FOXP2 0.004162769 33.952377 up 
FPR3 0.00462868 504.4062 up 
FREM2 0.001817113 39.243195 up 
FRK 0.003582864 167.15329 up 
FRRS1 0.001788051 23.334436 up 
FXYD2 1.67E-04 25.653507 up 
FXYD6 2.11E-04 489.31894 up 
FZD7 3.17E-04 23.441677 up 
GAB1 2.22E-04 61.992752 up 
GABRB1 1.70E-04 3799.038 up 
GABRR1 0.001085003 193.58792 up 
GAGE12I 1.99E-04 122.79657 up 
GAGE6 4.45E-04 105.42413 up 
GALNTL1 5.48E-06 239.00746 up 
GAS7 5.14E-06 95.60258 up 
GCNT3 5.42E-04 167.22176 up 
GEM 4.40E-04 112.1868 up 
GGTA1 0.001489612 130.66629 up 
GHR 0.003255331 398.58572 up 
GHSR 3.19E-06 163.89807 up 
GKN2 2.58E-04 109.851036 up 
GLI2 0.003188962 204.99214 up 
GLIS1 0.001440324 188.22276 up 
GLT8D2 0.002366317 15.790633 up 
GLUL 1.04E-04 51.363754 up 
GNG12 1.31E-05 1042.1455 up 
GNRHR 0.00456848 69.804306 up 
GOLM1 5.02E-07 38.82523 up 
GPC6 5.86E-04 50.608315 up 
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GPR162 0.003690091 34.816776 up 
GPR176 0.002935388 28.542063 up 
GPR4 1.43E-06 1400.7784 up 
GREM1 2.11E-06 73.58937 up 
GRM3 8.53E-04 5340.1646 up 
GRRP1 1.20E-04 61.554356 up 
GSN 0.002156649 30.12112 up 
GUCY1A2 4.35E-05 1178.7905 up 
H19 0.00429109 1557.6794 up 
HAND1 1.54E-05 1110.7249 up 
HLA-DQA2 5.15E-04 1708.3074 up 
HLA-DQB2 3.53E-04 1482.4127 up 
HOXA13 2.94E-04 504.62964 up 
HOXA6 0.003629437 28.177776 up 
HOXA7 5.58E-05 105.590675 up 
HOXB13 1.33E-05 424.14804 up 
HOXC10 2.32E-04 413.47003 up 
HOXC4 7.05E-04 113.471085 up 
HOXC5 9.01E-04 92.594894 up 
HOXC9 4.41E-04 162.44164 up 
HOXD13 9.98E-05 1413.4087 up 
HS3ST3A1 4.25E-04 37.257675 up 
HTR2A 0.001071974 3164.6924 up 
HTR2B 5.00E-06 70.07199 up 
HTR3D 1.76E-04 74.046936 up 
HTRA1 1.46E-04 137.02522 up 
HTRA4 1.88E-04 200.73428 up 
HYAL1 2.02E-05 50.469807 up 
IGFBP5 1.58E-05 1914.119 up 
IGFBP7 3.93E-05 172.29695 up 
IGFL1 0.001366323 337.98065 up 
IGFL3 2.89E-04 4854.438 up 
IL18 0.001198142 145.2589 up 
IL1RAPL1 0.002290845 2546.491 up 
IL1RAPL2 0.002276349 89.73773 up 
IL31RA 2.06E-04 96.76271 up 
INHBC 2.29E-04 165.13293 up 
IRX3 2.37E-04 435.91623 up 
IRX6 4.75E-06 1632.3883 up 
ISLR 2.39E-04 279.7606 up 
ISLR2 5.65E-04 254.10277 up 
ITGA11 0.002167827 92.08847 up 
ITGA8 5.22E-06 2191.2146 up 
ITIH5 8.33E-08 165.04219 up 
KCNB1 2.05E-05 150.76038 up 
KCNE4 0.001919829 117.4119 up 
KCNF1 1.49E-05 622.38104 up 
KCNJ10 1.22E-05 338.96042 up 
KCNJ5 3.27E-04 155.1142 up 
KCNJ6 8.47E-04 217.86787 up 
KCNJ8 0.001589894 162.59445 up 
KCNMA1 5.94E-07 192.40115 up 
KCNN2 0.001898851 321.46735 up 
KCNN3 0.001136565 42.375698 up 
KCNT1 6.29E-05 366.20413 up 
KIAA0319 1.01E-05 721.6995 up 
KIAA1409 0.001660763 106.65528 up 
KIF17 0.002893751 613.18823 up 
KIRREL 1.15E-05 431.3474 up 
KLK2 2.98E-05 88.02464 up 
KPRP 1.48E-07 482.98526 up 
KRT23 0.00431706 181.0255 up 
KRT6A 0.001132019 144.53497 up 
KRT6B 0.001925398 86.53376 up 
KRTAP10-10 0.002214061 804.22845 up 
KRTAP10-3 0.003796856 124.36412 up 
KRTAP12-4 0.002336789 59.83807 up 
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KRTAP1-3 1.43E-04 198.16115 up 
KRTAP17-1 0.001237259 150.86696 up 
KRTAP19-6 0.003120377 62.078194 up 
KRTAP4-4 4.78E-05 215.9409 up 
KRTDAP 6.79E-04 98.9798 up 
L3MBTL4 0.001976545 20.367863 up 
LAMA4 3.20E-05 2262.7773 up 
LAMB2 4.47E-04 332.431 up 
LDB2 0.001651511 86.49941 up 
LEPREL1 0.004015781 119.51305 up 
LGALS13 0.001188021 123.39415 up 
LGI2 3.95E-05 58.88168 up 
LHFP 5.85E-04 580.59863 up 
LHX1 5.52E-04 144.22237 up 
LHX6 8.63E-04 64.01631 up 
LIFR 6.10E-06 55.019253 up 
LILRB5 1.81E-04 101.5764 up 
LIPG 7.79E-04 59.91872 up 
LMNA 9.00E-04 35.6897 up 
LMOD1 4.68E-05 1776.0135 up 
LOC285016 0.001765019 46.21854 up 
LOC348174 7.42E-06 237.7254 up 
LOC392196 0.00379843 327.80914 up 
LOC440157 6.07E-04 206.01009 up 
LOC731102 8.06E-04 229.54295 up 
LONRF2 0.001787801 43.235313 up 
LOR 0.004821098 1685.4519 up 
LOX 4.08E-05 666.38574 up 
LOXL4 0.003532113 1134.1008 up 
LPAR1 5.02E-07 361.0595 up 
LPAR4 3.52E-04 769.57965 up 
LRFN5 2.04E-05 3432.411 up 
LRIG3 9.56E-04 710.72015 up 
LRRK2 0.001896128 56.143425 up 
LRRTM4 0.001217455 102.53022 up 
LSAMP 1.60E-06 77.765114 up 
LUZP4 0.00219027 140.69855 up 
LY6H 2.67E-06 254.0602 up 
MADCAM1 0.002480526 177.32721 up 
MAGEA10 6.55E-04 550.77234 up 
MAP1LC3A 0.001904424 36.111324 up 
MAP1LC3C 1.67E-05 73.540504 up 
MAPK4 2.21E-04 146.72054 up 
MEFV 0.001605888 72.865616 up 
MEOX2 1.93E-05 275.5825 up 
MFAP4 0.00234179 723.2828 up 
MFAP5 4.81E-05 47.543274 up 
MGC27121 5.14E-05 168.04108 up 
MMP12 5.05E-09 2709.5725 up 
MMP13 5.84E-04 68.96292 up 
MMP2 5.28E-06 61.831566 up 
MMP3 8.51E-04 87.47894 up 
MOSC1 5.81E-06 263.11017 up 
MPDZ 5.09E-04 64.34496 up 
MRAP 5.32E-04 60.589733 up 
MRAS 3.58E-04 272.27283 up 
MSI1 7.03E-04 255.04903 up 
MSRB3 5.52E-05 44.87327 up 
MTNR1B 0.004329397 40.839153 up 
MTTP 5.17E-05 3380.7405 up 
MUSK 1.39E-06 516.88776 up 
MYH11 7.60E-06 750.68353 up 
MYO5B 0.001162439 60.44324 up 
MYOCD 1.72E-05 467.8155 up 
NANOS2 0.003863444 196.19159 up 
NAT8 9.45E-04 214.28177 up 
NAV2 3.68E-06 53.121204 up 
128 
 
NEK5 0.001448384 113.17294 up 
NFATC4 1.21E-06 202.98984 up 
NFIB 3.61E-04 1049.692 up 
NID1 1.57E-05 346.5735 up 
NKX2-1 0.002989617 317.29813 up 
NME5 5.88E-04 644.3234 up 
NOTCH3 8.94E-04 1185.1599 up 
NOX4 0.001169555 227.9215 up 
NPSR1 4.82E-04 154.71399 up 
NPY6R 0.001174096 241.03683 up 
NR2E3 0.001526152 95.86641 up 
NR2F1 1.46E-05 1087.3461 up 
NRP2 0.001072524 42.229126 up 
NRSN1 5.81E-05 793.55634 up 
NRXN2 0.004514083 205.9631 up 
NT5C1B 9.69E-05 273.5819 up 
NUPR1 0.002202877 793.7373 up 
NXPH2 0.003517729 67.41285 up 
ODAM 0.001466551 117.64898 up 
OLFML1 2.34E-05 1543.4946 up 
OR10K2 4.87E-05 129.11392 up 
OR10V1 0.00111295 213.17496 up 
OR14J1 0.001548844 167.61324 up 
OR1C1 9.25E-06 472.94186 up 
OR1K1 1.32E-05 214.81801 up 
OR1L1 0.00128794 99.23074 up 
OR2B11 5.97E-04 3598.4714 up 
OR2B2 0.002063465 43.159 up 
OR2G3 8.86E-04 129.04976 up 
OR2J3 0.001619971 493.38773 up 
OR2T11 7.04E-04 100.30433 up 
OR3A3 0.001021731 197.63304 up 
OR4M1 4.07E-06 231.60004 up 
OR51B5 0.003494288 66.16081 up 
OR51G1 0.002982765 143.17113 up 
OR56B4 1.71E-04 262.6104 up 
OR5F1 6.39E-04 148.26363 up 
OR5H14 5.54E-04 112.95109 up 
OR6B1 8.09E-04 128.85097 up 
OR6C65 1.42E-04 116.61705 up 
OR6T1 3.12E-06 686.43414 up 
OR8D1 8.88E-05 196.64044 up 
OR8G1 2.57E-06 124.24818 up 
OR9I1 0.004601611 835.7051 up 
ORM2 4.73E-05 190.63899 up 
P8 7.14E-04 378.74487 up 
PALM 7.04E-06 56.240726 up 
PANX3 0.004079317 360.93683 up 
PCDH17 2.59E-06 9980.728 up 
PCDHB9 0.003241059 187.77606 up 
PCDHGC4 1.26E-04 72.09526 up 
PDPN 6.57E-08 1008.50433 up 
PDZK3 3.32E-05 99.90719 up 
PEBP4 6.96E-05 112.78131 up 
PEX5L 9.34E-04 174.05534 up 
PGM5 0.001382236 225.2195 up 
PGM5P2 2.60E-04 84.71546 up 
PHACTR3 9.86E-05 192.2646 up 
PIWIL3 0.002950644 140.30675 up 
PKD1L2 0.001477617 57.44774 up 
PKLR 0.003794031 48.050297 up 
PLA2G2D 7.89E-04 230.62663 up 
PLA2G7 2.37E-05 125.715775 up 
PLAC9 8.54E-06 2086.843 up 
PLB1 0.00359402 44.618774 up 
PLCXD3 2.73E-09 160.30923 up 
PLD5 0.001055989 229.84026 up 
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PLOD2 4.95E-04 181.44655 up 
PLTP 0.003465322 51.93781 up 
PNLIPRP3 0.003493602 234.86588 up 
PON3 0.003802454 1631.0358 up 
POU4F2 6.09E-04 359.31378 up 
PPAP2B 9.79E-05 206.34972 up 
PPARGC1A 0.002412457 198.6367 up 
PPFIA2 8.06E-05 3782.9546 up 
PPIC 0.001913146 235.22502 up 
PPP1R1B 7.08E-04 37.030556 up 
PRICKLE1 0.004674999 307.3969 up 
PRKD1 3.67E-04 82.32182 up 
PRM2 0.004219161 156.84526 up 
PRODH2 0.003957356 90.40628 up 
PROL1 0.001222166 888.17 up 
PRRT2 9.77E-04 68.4832 up 
PRRX1 5.55E-07 368.77744 up 
PTGDS 7.10E-04 143.50684 up 
PTPN21 0.00327386 607.1209 up 
RAB39 4.01E-05 171.18495 up 
RAG2 3.17E-05 213.9133 up 
RALGDS 9.19E-05 14.426056 up 
RAMP2 2.54E-04 452.15808 up 
RAMP3 0.00446462 1118.2327 up 
RARRES1 3.23E-04 124.77976 up 
RASL12 3.84E-04 73.79914 up 
RBP5 0.004485567 12.2856455 up 
REG1B 7.30E-07 418.95358 up 
REM1 0.003050858 249.94296 up 
RERG 5.46E-04 327.1301 up 
RET 5.39E-04 82.4246 up 
RGMA 5.91E-04 26.182306 up 
RGS17 0.001259865 199.95795 up 
RHOJ 1.86E-05 134.22394 up 
RNASE4 0.002249527 35.068375 up 
RNF126P1 0.004019871 137.05261 up 
RNF150 1.18E-04 3844.842 up 
ROR2 1.61E-04 65.22503 up 
RORB 0.003360013 136.6301 up 
RPESP 1.75E-05 572.2533 up 
RSPO1 0.001233968 720.04456 up 
RSPO3 1.97E-05 372.38776 up 
RTN1 6.31E-07 214.88795 up 
S100A1 0.002133442 198.5234 up 
S100A3 1.08E-06 696.359 up 
S100A7A 0.001056142 339.94147 up 
SCARA3 9.48E-09 270.27948 up 
SCARA5 1.12E-04 232.99756 up 
SCGB1A1 0.001438105 1483.2852 up 
SCN2A 3.00E-05 155.35559 up 
SCRG1 0.003827123 157.83875 up 
SDC3 8.79E-05 825.1376 up 
SDS 0.004168576 316.6017 up 
SEBOX 9.36E-04 122.36459 up 
SERPINA1 1.07E-04 58.425026 up 
SERPINA3 1.46E-06 173.20938 up 
SHANK1 6.65E-04 127.22191 up 
SHANK3 1.85E-04 102.214836 up 
SHE 7.45E-05 261.58145 up 
SIGLEC15 5.88E-04 465.40466 up 
SIGLEC16 1.62E-04 572.7653 up 
SIGLEC8 6.38E-05 252.1981 up 
SLC13A4 0.002034852 510.63922 up 
SLC13A5 1.76E-05 169.95865 up 
SLC18A1 3.95E-04 126.1464 up 
SLC1A3 0.004293684 145.53325 up 
SLC22A11 0.001525222 237.51735 up 
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SLC22A8 0.00132263 151.87383 up 
SLC26A3 2.55E-04 298.81332 up 
SLC2A10 1.17E-04 380.36444 up 
SLC30A4 8.06E-04 117.31016 up 
SLC35D3 3.74E-06 110.1957 up 
SLC36A2 2.80E-04 406.93173 up 
SLC6A10P 0.001531576 47.97308 up 
SLC6A11 7.50E-04 3513.751 up 
SLC6A17 0.001758472 73.8967 up 
SLC7A10 9.65E-04 151.2397 up 
SLCO2A1 9.91E-07 163.38977 up 
SLCO2B1 1.61E-09 830.4838 up 
SLN 2.67E-04 204.70993 up 
SMAD9 2.63E-06 214.02264 up 
SMOC2 6.00E-07 259.05295 up 
SNAI2 1.59E-05 42.37089 up 
SNAP25 8.95E-04 41.470043 up 
SNAP91 2.56E-07 1499.8495 up 
SOD3 1.73E-05 730.4651 up 
SORBS1 0.002527741 53.59134 up 
SORCS1 6.79E-04 144.44037 up 
SOX11 0.00315207 4497.8096 up 
SPANXB1 0.002434531 134.49309 up 
SPARCL1 7.23E-08 2456.402 up 
SPATA12 4.61E-04 106.80242 up 
SPATA3 0.001180969 125.55184 up 
SPHKAP 0.002730298 89.17387 up 
SPIC 0.001247437 72.561165 up 
SPRR1A 0.001425172 36.418526 up 
SPRR2F 0.002502649 52.818954 up 
ST5 2.06E-05 52.736828 up 
ST6GALNAC5 1.67E-05 146.01675 up 
STARD13 1.71E-06 92.28207 up 
STEAP3 6.83E-04 66.18517 up 
STEAP4 2.51E-07 351.58655 up 
STGC3 9.52E-06 56.281895 up 
STK32B 2.36E-04 280.14255 up 
STOX2 6.47E-05 1338.115 up 
SULT1C3 0.002288653 198.22928 up 
SULT2B1 1.05E-04 50.864433 up 
SVEP1 1.23E-08 229.75906 up 
SYNPO2 6.48E-04 57.020897 up 
SYT15 2.65E-04 23.90129 up 
SYTL4 2.74E-04 473.2943 up 
TAS1R1 3.00E-06 191.2977 up 
TEAD3 8.00E-04 139.49211 up 
TFF3 9.16E-07 2068.8347 up 
TGM2 1.42E-05 164.37233 up 
TGM3 0.002707904 28.728588 up 
THBS2 1.32E-06 4278.7144 up 
THSD4 0.001163739 917.2173 up 
THY1 1.15E-04 733.15814 up 
TIMP3 9.99E-04 299.3404 up 
TINAGL1 1.12E-06 2395.152 up 
TJP1 1.26E-05 46.303905 up 
TLR2 0.003287221 58.478287 up 
TLR8 2.15E-04 41.789314 up 
TM4SF1 0.001288201 274.4715 up 
TMEM171 1.49E-04 594.2408 up 
TMEM195 0.003266833 74.15769 up 
TMEM26 0.001393076 113.79935 up 
TMEM75 8.80E-05 168.10236 up 
TMTC1 2.72E-06 85.9973 up 
TNFAIP8L3 0.004190413 49.924923 up 
TNS1 6.67E-04 15.689797 up 
TRPM3 2.65E-04 142.75385 up 
TUBA3E 7.54E-04 137.89758 up 
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UNC13A 0.003771088 17.918474 up 
UNC13C 4.83E-04 84.42842 up 
UNC5A 7.22E-04 186.22348 up 
VNN1 1.51E-04 289.19934 up 
VWA1 0.001006489 153.42297 up 
VWA3B 0.002667479 116.05175 up 
WFDC10A 2.17E-04 244.91806 up 
WFIKKN2 0.00300101 123.60882 up 
WIPF3 0.004153004 142.43684 up 
WISP2 3.66E-05 249.52612 up 
WNT5A 0.00223808 294.5755 up 
WNT7B 7.20E-05 508.14038 up 
XCR1 2.28E-04 63.998413 up 
XIRP2 0.002705287 2361.8362 up 
XKR4 0.001337646 130.1594 up 
XKR5 0.003984506 142.36823 up 
XLKD1 1.78E-04 602.039 up 
ZCCHC13 1.52E-04 1167.9548 up 
ZDHHC1 0.003813832 384.42322 up 
ZNF205 8.94E-05 155.21086 up 
ZNF280A 0.001214629 95.34848 up 
ZNF385D 1.56E-04 818.25183 up 
ZNF521 0.001165658 590.53326 up 
ZNF793 0.004648638 24.574905 up 
ZSCAN4 1.23E-04 749.0319 up 
 
Supplementary Table 22. GSEA of genes differentially expressed between Lennert 
Lymphoma and normal T-lymphocytes. Malignant phenotype-related processes were 




cell surface receptor linked signal transduction 
protein-membrane targeting 
angiogenesis 
cell adhesion/cell-cell signaling 
Microenvironment 









Supplementary Table 23. ANOVA analysis uncovers genes differentially expressed among F-
PTCL, AITL and Tfh-PTCL/NOS. 





























AADACL1 0.001246996 9.904725 down 2.175747 down 4.5523324 up 
AAMP 0.009295695 3.4186523 down 1.5310509 down 2.2328796 up 
AASDHPPT 1.07E-04 13.124998 down 3.144928 up 41.277176 up 
AASS 4.74E-07 71.739685 down 13.6204605 down 5.267051 up 
ABAT 0.004343298 11.01732 down 1.2647185 down 8.711282 up 
ABCA10 1.15E-06 78.97764 down 14.27884 down 5.5310946 up 
ABCD2 6.53E-05 30.074425 down 5.573287 down 5.3961735 up 
ABCG1 5.14E-04 7.1144695 down 1.8464853 down 3.8529792 up 
ACCN2 0.008303245 12.381062 down 1.832688 down 6.755684 up 
ACN9 1.94E-05 21.397886 down 4.096282 down 5.2237315 up 
ACSL5 6.54E-06 10.398006 down 1.3989923 down 7.4324985 up 
ACSS2 2.66E-06 13.295097 down 2.1199014 down 6.2715645 up 
ACTN1 0.00559174 2.795224 up 3.2780654 down 9.162927 down 
ADD1 2.06E-07 39.967064 down 5.622322 down 7.10864 up 
ADIPOR1 6.74E-04 10.277856 down 2.126429 down 4.8333874 up 
AFAP1 2.46E-04 13.257741 down 1.689685 down 7.8462806 up 
AFAP1L2 0.002347473 7.593563 down 1.7708074 down 4.288193 up 
AFTPH 0.008122655 2.5097299 down 2.8622034 up 7.183357 up 
AGL 6.68E-07 16.168526 down 1.1938038 down 13.543705 up 
AGPAT1 0.002387813 4.1738486 down 1.2225398 up 5.102696 up 
AHNAK 5.17E-07 8.019853 down 2.1932101 down 3.6566732 up 
AIM2 6.94E-07 34.74169 down 23.48162 down 1.4795269 up 
AKAP11 0.003588038 1.7516906 down 3.65986 up 6.4109416 up 
ALAS1 6.07E-06 5.3228407 down 1.8349404 up 9.767095 up 
ALDH1B1 1.25E-05 17.793158 down 2.9807088 down 5.9694376 up 
ALDH6A1 2.14E-13 529.4471 down 48.15558 down 10.994508 up 
ALG13 3.97E-05 24.527004 down 3.3062491 down 7.418378 up 
ANGPTL4 1.79E-04 30.106907 down 10.276458 down 2.9296973 up 
ANKRD32 6.97E-05 10.229765 down 1.6579145 down 6.1702604 up 
ANKRD35 4.70E-10 286.24924 down 155.26956 down 1.8435636 up 
ANKRD9 3.51E-05 3.8828113 up 21.909216 up 5.6426167 up 
ANKS6 0.001738924 62.17433 down 7.7144723 down 8.059438 up 
ANXA7 3.69E-08 37.629814 down 1.0734142 up 40.392372 up 
AP2A1 0.002037566 2.4466686 down 4.1612477 up 10.181193 up 
AP2B1 0.001094781 2.4232616 up 23.275143 up 9.604879 up 
APLP1 7.62E-06 25.448235 down 5.720786 down 4.44838 up 
APLP2 2.96E-07 197.61658 down 45.58968 down 4.334678 up 
APOBEC3F 4.09E-05 4.235448 down 2.61094 down 1.6221929 up 
APOBEC3G 9.90E-07 16.910416 down 22.663546 down 1.3402123 down 
APOLD1 0.001122735 5.015797 up 61.081253 up 12.177776 up 
AQR 3.64E-10 129.09029 down 24.508722 down 5.2671165 up 
ARFGEF1 4.75E-08 63.772713 down 8.537048 down 7.4701123 up 
ARID2 2.03E-05 37.394726 down 3.7664998 down 9.928244 up 
ARL5A 1.48E-06 12.794352 down 1.4137621 down 9.049862 up 
ARL6IP1 5.67E-05 13.101061 down 5.7216125 down 2.2897499 up 
ARMET 0.003449182 3.5742214 up 2.9759593 down 10.636738 down 
ARPC4 0.003511525 2.3130229 down 1.750456 up 4.048845 up 
ARRB2 4.30E-06 5.1609178 down 1.1482829 down 4.4944654 up 
ARSB 4.37E-04 8.794027 down 2.9599025 down 2.971053 up 
ASB5 0.001178149 168.59918 down 45.047447 down 3.7427025 up 
ASCC3 0.003937953 5.68304 down 1.7321751 down 3.280869 up 
ATF5 0.003724473 1.7016205 down 9.788631 down 5.752536 down 
ATM 1.76E-04 5.3131356 down 1.0619304 down 5.0032797 up 
ATP11C 7.67E-08 6.114761 down 1.8620368 down 3.2839098 up 
ATP2B1 4.41E-05 4.168872 down 1.1628553 up 4.847795 up 
ATP5G2 0.005278971 5.0369673 down 1.4072149 down 3.579387 up 
ATP5L 2.21E-08 48.565826 down 11.2997055 down 4.297974 up 
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ATP6V1G2 1.35E-04 5.6181703 down 1.9775796 up 11.110379 up 
ATP8B2 0.009249712 1.3420045 down 4.074953 up 5.468606 up 
ATPBD4 2.38E-05 23.61913 down 5.132805 down 4.601603 up 
ATXN2 0.002202987 1.0571984 down 10.637157 down 10.061647 down 
AUH 0.003189515 5.727949 up 1.3075429 down 7.489539 down 
BAG5 2.63E-04 12.724475 down 1.2921387 down 9.847608 up 
BAZ1B 2.13E-04 4.30323 up 23.257877 up 5.4047494 up 
BBS7 1.64E-04 7.690821 down 1.2984395 down 5.923126 up 
BCAP31 0.00796214 1.5180069 up 4.866111 down 7.386791 down 
BCAS2 2.81E-04 17.096949 down 4.900972 down 3.4884803 up 
BCCIP 3.24E-05 3.0433586 down 1.3689297 up 4.166144 up 
BCL7B 6.95E-04 1.955827 up 1.5303007 down 2.9930036 down 
BFAR 0.001193434 9.199177 down 2.8891294 up 26.577612 up 
BRCA1 2.79E-04 13.979983 down 7.6151934 down 1.8358012 up 
BRE 8.59E-05 3.7354674 down 1.4953438 up 5.585808 up 
BRWD1 2.49E-06 9.2595 down 1.5731457 down 5.8859763 up 
BTBD1 3.97E-04 5.191556 down 1.0548459 up 5.476292 up 
C11ORF2 0.001575938 4.8104544 up 1.3838251 down 6.656827 down 
C11ORF46 0.001723428 2.1481802 up 22.80408 up 10.615533 up 
C11ORF57 0.00441437 10.6306095 down 2.7204897 down 3.9076092 up 
C11ORF58 3.21E-12 203.9501 down 24.138603 down 8.449126 up 
C12ORF10 0.003947689 1.7051575 down 9.361445 down 5.490077 down 
C12ORF30 4.36E-06 22.89879 down 3.389835 down 6.755136 up 
C12ORF35 8.80E-08 26.772688 down 2.7401166 down 9.77064 up 
C14ORF118 2.49E-04 3.0249796 down 4.318876 up 13.064511 up 
C14ORF135 0.00265581 10.2977915 down 2.067354 down 4.9811463 up 
C14ORF138 2.58E-06 5.4421487 down 3.3879352 up 18.437647 up 
C14ORF142 5.23E-04 9.858709 down 1.0932045 down 9.018175 up 
C14ORF43 4.91E-05 2.159268 down 3.4558392 up 7.4620814 up 
C14ORF80 0.007015869 1.0889019 up 7.9593167 down 8.666915 down 
C14ORF85 1.13E-04 42.235912 down 149.10243 down 3.5302281 down 
C15ORF5 9.99E-04 11.17792 down 18.255774 down 1.6331993 down 
C17ORF70 0.004404484 1.1758431 down 13.4976225 down 11.4791 down 
C17ORF81 4.96E-06 5.5671334 down 1.0218657 up 5.688863 up 
C18ORF10 1.03E-04 30.550146 down 12.206318 down 2.5028143 up 
C18ORF22 0.006550901 7.782738 up 1.7032353 down 13.255833 down 
C18ORF54 9.54E-10 125.29043 down 10.372313 down 12.079316 up 
C19ORF12 0.006464407 4.031581 down 2.1703336 down 1.8575857 up 
C1D 1.22E-05 20.613302 down 1.2006072 down 17.16907 up 
C1GALT1C1 6.17E-08 36.576504 down 3.448389 down 10.606838 up 
C1ORF25 1.68E-05 14.3245325 down 4.4451237 down 3.2225273 up 
C1ORF9 3.24E-04 14.680495 down 1.0514292 up 15.435501 up 
C1QBP 6.90E-07 25.762548 up 12.265031 up 2.100488 down 
C20ORF7 0.001573397 4.659437 down 1.5425037 up 7.187198 up 
C20ORF94 4.34E-05 6.4175563 down 4.157234 down 1.543708 up 
C20ORF96 1.08E-04 530.22955 down 128.80238 down 4.116612 up 
C2ORF56 0.001005175 2.7590113 down 2.1958876 down 1.2564447 up 
C2ORF63 1.86E-05 20.037655 down 5.762256 down 3.4773974 up 
C3ORF17 4.37E-05 3.8582609 down 1.4391828 up 5.552743 up 
C3ORF42 1.30E-05 3.4663858 down 5.351521 up 18.550438 up 
C4ORF18 0.007799124 13.150004 down 1.3149791 down 10.000161 up 
C4ORF43 0.004450902 9.963679 down 1.5402771 up 15.346827 up 
C5ORF34 2.73E-05 171.51009 down 44.67423 down 3.8391283 up 
C6ORF204 0.005850927 4.4938726 down 1.3733133 up 6.1714954 up 
C7ORF54 0.004138387 1.2066888 up 8.320272 down 10.039979 down 
C8ORF33 1.70E-09 8.610316 down 5.143032 down 1.6741713 up 
C9ORF10OS 0.001592465 8.3046665 down 3.94565 up 32.76731 up 
C9ORF142 9.11E-04 4.5617256 up 5.017203 down 22.887108 down 
C9ORF41 0.002140351 3.3928452 up 4.449594 up 1.3114638 up 
C9ORF5 0.007543863 2.5723488 down 4.9881954 up 12.83138 up 
C9ORF6 1.07E-04 44.5116 down 6.7946615 down 6.550966 up 
C9ORF72 1.27E-04 13.662694 down 1.5791752 down 8.651792 up 
CA12 0.007189686 7.2197328 down 2.1882696 down 3.299288 up 
CAMK1D 6.40E-04 8.236349 down 1.0860595 up 8.945166 up 
CAMK2D 3.63E-05 5.6928477 down 1.0834448 down 5.254396 up 
CAMK4 2.92E-06 110.37201 down 2.7331512 down 40.382694 up 
CAMKK2 4.07E-06 16.935188 down 4.238069 down 3.9959671 up 
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CAND1 7.61E-06 15.086078 down 1.3366377 down 11.286586 up 
CAPRIN1 7.79E-06 8.620933 down 1.4162129 up 12.209074 up 
CAPZB 4.78E-06 93.08448 down 67.7006 down 1.3749435 up 
CASP4 3.40E-07 15.640286 down 1.06344 down 14.70726 up 
CASP6 0.004623504 2.143239 down 4.361602 up 9.347956 up 
CASP8 0.00325764 1.6286442 up 4.077292 up 2.5034883 up 
CBL 4.02E-06 7.169271 down 1.15638 down 6.199753 up 
CCBL2 1.01E-04 2.6370053 down 2.5427816 up 6.705328 up 
CCDC117 0.00306498 31.154354 down 4.23758 down 7.351923 up 
CCDC132 1.73E-06 12.1627035 down 1.4434386 down 8.426201 up 
CCDC28B 1.07E-04 21.085524 down 13.018768 down 1.6196252 up 
CCDC34 3.87E-05 9.583994 down 1.2927667 down 7.4135528 up 
CCDC75 0.004216792 6.0038686 down 1.8100219 up 10.867133 up 
CCDC84 6.38E-05 52.152954 up 128.052 up 2.4553163 up 
CCDC91 1.29E-05 22.582506 down 2.4538512 down 9.202882 up 
CCNG1 2.55E-04 6.701451 down 4.106789 down 1.6317983 up 
CCNT2 2.13E-08 9.104096 down 1.2217581 up 11.123002 up 
CCNY 7.29E-04 11.202788 down 2.321396 down 4.825884 up 
CD14 1.11E-04 13.002725 down 2.5200295 down 5.159751 up 
CD302 1.25E-04 30.98856 down 2.5040636 down 12.375309 up 
CD46 0.002449624 2.484371 up 11.242708 up 4.5253744 up 
CD86 0.002879767 4.4291444 down 1.3726383 up 6.079613 up 
CDC14A 1.31E-05 6.318688 down 2.1705766 up 13.715196 up 
CDC2L5 2.20E-05 6.060674 down 1.6446925 up 9.967944 up 
CDC42 5.42E-04 1.9608763 down 5.6598606 up 11.098288 up 
CDC7 0.005795735 17.057585 down 1.7067695 down 9.994079 up 
CDH6 4.76E-09 237.00363 down 48.682053 down 4.8683987 up 
CDYL 7.34E-05 9.144621 down 1.5190665 up 13.891286 up 
CENPH 0.002678235 9.034363 up 10.292864 up 1.1393018 up 
CENTA1 0.008997127 1.5869792 up 5.0921755 down 8.081176 down 
CENTB2 1.99E-08 28.440783 down 1.5682466 down 18.135399 up 
CENTD1 9.01E-06 8.903371 down 2.6250186 up 23.371517 up 
CEP170 0.003953619 1.3944284 up 8.709852 up 6.246181 up 
CFD 0.008404002 2.1304965 down 12.296059 down 5.7714524 down 
CGGBP1 0.001935814 2.5231285 down 2.2492425 up 5.675128 up 
CHD6 9.24E-04 6.9827895 down 1.8124697 down 3.8526375 up 
CHL1 1.06E-04 35.08638 down 2.9682133 down 11.820706 up 
CHN1 3.51E-06 27.954819 down 1.0837982 up 30.29738 up 
CHORDC1 4.64E-04 19.114462 down 1.0751766 down 17.777973 up 
CHPT1 1.95E-04 5.700605 down 1.0872836 up 6.1981745 up 
CICK0721Q.1 0.008639534 1.8583665 down 11.315681 up 21.028683 up 
CLASP2 0.002288599 8.182097 up 80.66772 up 9.859052 up 
CLEC2D 0.002764909 1.6594439 down 6.2119575 up 10.308395 up 
CLIP1 0.003852108 1.8752615 down 2.679027 up 5.023876 up 
CLTA 1.74E-05 6.8595667 down 1.7558178 up 12.044148 up 
CMTM3 9.89E-06 4.514377 down 1.8920391 up 8.541378 up 
CNNM2 0.002910974 10.870246 down 3.7469494 down 2.901092 up 
CNOT1 4.99E-08 11.741206 down 1.1164685 up 13.108686 up 
CNOT7 8.15E-07 7.1379547 down 1.029604 down 6.932718 up 
CNPY3 2.73E-05 6.626014 up 38.411995 up 5.79715 up 
COL5A1 5.09E-04 28.602577 down 4.3755636 down 6.5368896 up 
COL6A3 0.008423174 5.66545 down 1.5018104 up 8.508432 up 
COL8A1 8.47E-04 26.323908 down 3.871358 down 6.799658 up 
COMMD10 0.002490725 10.726184 down 1.0212939 up 10.954586 up 
COMMD6 3.72E-06 11.820783 down 1.0880262 up 12.861322 up 
COMMD8 3.42E-07 122.818245 down 9.94667 down 12.347673 up 
COPS2 4.11E-06 69.262344 down 13.851325 down 5.000412 up 
COPS8 0.006057812 3.4114227 down 2.048898 up 6.9896564 up 
COQ2 3.34E-04 320.44833 down 31.02767 down 10.327825 up 
COQ7 6.65E-06 7.584196 up 96.48538 up 12.721901 up 
CPEB3 8.12E-08 80.90322 down 33.154354 down 2.440199 up 
CPNE8 3.67E-04 21.38781 down 3.610503 down 5.923776 up 
CRLF3 0.008547629 7.5367403 down 1.0050765 down 7.498674 up 
CROP 0.003121943 8.063984 down 1.2076457 down 6.6774416 up 
CSF3R 0.006368076 10.450152 down 2.969644 down 3.5189915 up 
CSMD2 6.50E-04 48.579887 down 28.481722 down 1.7056515 up 
CSTF3 0.002729614 1.429186 down 5.0671988 up 7.2419696 up 
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CTAGE5 3.57E-04 14.72133 down 1.5155886 down 9.713276 up 
CTHRC1 6.39E-07 179.28728 down 20.111801 down 8.91453 up 
CTPS2 1.26E-04 2.687841 down 6.2268977 up 16.736912 up 
CUGBP1 2.78E-05 4.234678 down 1.3432223 up 5.6881137 up 
CUL4A 8.63E-04 30.053667 down 4.3952765 down 6.8377194 up 
CXCL11 1.45E-05 136.15999 down 11.336061 down 12.011225 up 
CXORF40A 9.92E-07 4.845087 up 24.014153 up 4.9563923 up 
CYP20A1 5.88E-05 8.071167 down 1.4811857 up 11.954899 up 
CYP2U1 5.27E-04 53.00102 down 13.726109 down 3.8613293 up 
CYP7B1 0.007764282 19.698 down 4.8605137 down 4.0526586 up 
DAAM1 1.68E-04 42.180164 down 25.258785 down 1.6699207 up 
DARS 0.001079141 1.0129716 up 4.2799354 down 4.335453 down 
DBR1 1.59E-05 10.893142 down 4.095151 down 2.6600099 up 
DBT 0.009230945 1.0450393 up 5.736111 down 5.994461 down 
DCK 2.95E-04 7.9042015 down 1.6174058 up 12.784302 up 
DCTN6 6.34E-07 44.22589 down 4.394694 down 10.063475 up 
DDI2 1.73E-04 2.476255 up 9.440678 up 3.812482 up 
DDT 0.007228914 1.0756946 up 5.741438 down 6.1760335 down 
DDX21 0.001387818 1.3415962 down 16.138866 up 21.651844 up 
DDX59 1.00E-04 7.1355295 down 1.0447564 up 7.4548907 up 
DEPDC1B 0.003059834 30.601454 down 3.5997372 down 8.501024 up 
DEPDC6 0.001671258 59.211323 down 9.433188 down 6.276916 up 
DHRS13 0.0012034 3.529708 down 15.06404 down 4.267787 down 
DIAPH3 2.62E-04 7.0934224 down 4.7782164 down 1.4845337 up 
DIP2A 4.29E-04 1.6176693 up 6.7515445 up 4.1736245 up 
DLEU2L 0.004851418 18.862309 down 1.9830962 down 9.511544 up 
DNAJB14 0.003783139 2.6863444 down 1.0365125 up 2.7844293 up 
DNAJB6 0.001588501 1.6615915 up 14.124414 up 8.500533 up 
DNAJC21 5.42E-05 16.3427 down 6.1820235 down 2.643584 up 
DNMT3A 5.09E-05 3.2664802 up 23.469175 up 7.1848526 up 
DOK3 0.004626186 7.406154 up 4.551228 down 33.707104 down 
DPH3 0.006211512 2.4159834 up 6.5938597 up 2.7292652 up 
DPY30 1.63E-07 5.6862535 up 48.782364 up 8.5789995 up 
DSCC1 6.53E-04 8.940125 down 9.444442 down 1.0564104 down 
DSEL 1.57E-07 204.17982 down 20.554495 down 9.933589 up 
DSP 1.86E-04 51.593758 down 8.99091 down 5.7384357 up 
DST 1.51E-05 8.180347 down 1.568211 up 12.828513 up 
DTWD1 2.02E-04 1.930194 down 3.8965423 up 7.521082 up 
DUSP22 9.30E-04 9.075396 down 1.0903138 up 9.89503 up 
DUSP3 0.001856833 5.175609 down 13.1385355 down 2.5385492 down 
DYNC2LI1 0.001033654 8.683132 down 1.1889133 up 10.323492 up 
DYNLT3 2.09E-06 17.349197 down 2.444413 down 7.09749 up 
DYRK1A 7.99E-07 11.732118 down 1.2438458 down 9.43213 up 
DYRK2 0.002471531 5.876634 down 1.0065339 up 5.9150314 up 
EAF1 0.008829953 13.536249 down 1.8206338 down 7.4349113 up 
EDEM3 2.87E-05 23.759974 down 6.2795315 down 3.7837174 up 
EEF1D 0.003241727 1.7025343 up 6.969356 up 4.0935183 up 
EEF1E1 7.69E-04 32.327827 down 6.9569054 down 4.646868 up 
EFNA1 9.55E-07 8.454091 down 1.3131679 up 11.101642 up 
EGFR 2.45E-06 28.686802 down 2.0741303 down 13.83076 up 
EGLN2 6.36E-04 9.404717 down 5.6819205 down 1.6552004 up 
EHD4 0.004176542 22.756878 up 37.869507 up 1.6640906 up 
EID2B 2.95E-04 52.563522 down 69.699135 down 1.3259982 down 
EIF1AX 2.57E-04 4.8611574 down 1.7993506 up 8.746927 up 
EIF3J 0.003042212 5.180734 down 2.5675426 up 13.301756 up 
EIF4A1 0.008876865 2.7072546 up 3.8327951 up 1.4157498 up 
EIF5A2 2.14E-07 714.739 down 96.493546 down 7.4071174 up 
EOMES 0.002033323 1.0102395 down 10.905686 down 10.795148 down 
EPB41 7.74E-04 6.291788 down 1.3555015 up 8.528528 up 
EPB41L2 1.90E-04 37.55555 down 2.9290788 down 12.821627 up 
EPN1 0.00559278 1.2299707 down 9.616178 down 7.8182178 down 
ERAL1 4.00E-04 2.4313023 down 10.915455 down 4.48955 down 
ERC1 0.001633283 5.3521786 down 1.0153263 down 5.271388 up 
ERMN 1.27E-05 18.369017 down 1.1965694 down 15.3513975 up 
ETV6 0.001186558 2.4133296 down 15.039108 down 6.2316847 down 
EVI2B 0.006932993 13.780733 down 1.4690162 down 9.380928 up 
FABP5 0.009540696 4.996763 down 1.2458599 down 4.010694 up 
136 
 
FAHD1 0.004465252 9.26783 down 1.5594801 down 5.942898 up 
FAIM 3.85E-04 7.07123 down 1.2608625 up 8.915849 up 
FAM108B1 1.59E-05 4.585267 down 2.2000718 up 10.087914 up 
FAM116A 5.07E-05 11.725 down 1.153098 down 10.168262 up 
FAM122A 8.54E-07 95.91794 down 11.173426 down 8.584471 up 
FAM126A 5.19E-06 136.32053 down 20.556187 down 6.6316056 up 
FAM126B 1.64E-07 40.280502 down 2.846622 down 14.150282 up 
FAM133B 0.00521203 5.605519 down 2.2008693 down 2.5469568 up 
FAM134B 5.95E-04 1.3238282 up 9.194124 up 6.9451036 up 
FAM135A 1.88E-10 473.1892 down 11.565421 down 40.914135 up 
FAM158A 0.001960101 2.6322176 up 5.78529 down 15.228142 down 
FAM177A1 3.28E-05 5.1595407 down 1.3700769 down 3.7658768 up 
FAM38A 0.003196077 2.0549228 up 5.9086227 down 12.141764 down 
FAM48A 1.25E-04 2.3725362 up 23.848028 up 10.051703 up 
FAM49B 1.77E-06 14.621328 down 1.3007001 down 11.241121 up 
FAM53B 2.25E-07 41.035698 down 23.678072 down 1.7330678 up 
FAM98A 0.00166707 5.7734246 down 13.817567 down 2.393305 down 
FAM98B 0.006262566 6.4610553 down 3.3611047 down 1.9223013 up 
FANCC 0.009213107 10.501526 down 2.3458505 down 4.476639 up 
FAS 0.008276012 9.734545 down 1.2582617 down 7.736503 up 
FBXL10 1.03E-04 16.486692 down 2.3955095 down 6.882332 up 
FBXL5 5.00E-06 6.700698 down 1.3204118 up 8.84768 up 
FBXO11 2.00E-08 7.0109916 down 2.167934 down 3.2339509 up 
FBXO3 2.61E-06 15.472262 down 1.0076846 down 15.354269 up 
FBXO30 6.41E-07 6.3222632 down 1.7054402 up 10.782243 up 
FBXO5 4.83E-09 157.02716 down 22.07946 down 7.111912 up 
FBXW11 0.001750636 9.120728 down 1.0144235 down 8.991045 up 
FBXW7 2.31E-04 4.76063 down 1.1840707 down 4.0205626 up 
FEM1C 7.81E-09 40.470467 down 18.65839 down 2.1690226 up 
FEN1 0.00178487 4.5905895 up 2.0807688 up 2.2061985 down 
FGFR1OP2 0.002117208 8.191137 down 7.035421 down 1.1642711 up 
FGR 4.54E-04 10.95887 down 10.045702 down 1.0909014 up 
FKBP9 1.14E-04 31.178705 down 1.2519028 down 24.905056 up 
FN3KRP 0.001284373 209.12703 down 30.18241 down 6.928772 up 
FNTA 5.20E-05 3.246649 down 1.1845907 up 3.8459501 up 
FOXK1 3.19E-05 6.9784207 down 3.311436 down 2.1073701 up 
FOXN3 0.002008155 50.237125 down 7.7715883 down 6.464203 up 
FOXO4 3.69E-04 13.497975 down 16.194887 down 1.1998012 down 
FOXP1 0.003953058 6.2018867 down 1.4898136 down 4.1628613 up 
FYB 2.03E-06 5.7482224 down 2.287686 up 13.150131 up 
FYTTD1 6.49E-04 5.073023 down 2.5889766 down 1.9594704 up 
GABARAPL2 5.69E-10 14.737273 down 5.8641047 down 2.513133 up 
GABPA 1.55E-09 1117.9828 down 20.69278 down 54.02769 up 
GALNT1 1.23E-07 193.9958 down 13.533997 down 14.333962 up 
GALNT7 5.63E-04 6.7276382 down 3.3531816 up 22.558992 up 
GBP4 0.002967842 7.4265313 down 1.4224347 up 10.563755 up 
GCLM 0.002786256 65.47651 down 38.46505 down 1.7022339 up 
GCN1L1 0.008817226 2.2645416 down 9.124068 down 4.029101 down 
GCNT1 4.69E-05 59.21103 down 44.644897 down 1.3262664 up 
GFPT1 2.76E-10 234.82909 down 32.4352 down 7.2399464 up 
GFRA1 1.69E-05 25.143847 down 2.5656877 down 9.800043 up 
GGNBP2 7.94E-06 26.503847 up 149.64116 up 5.6460156 up 
GIMAP2 0.001107436 13.35949 down 1.0795429 up 14.422142 up 
GIMAP5 3.55E-04 163.69382 down 267.79944 down 1.6359779 down 
GJC1 0.004110443 15.1259 down 7.302077 down 2.071452 up 
GLB1L 0.006900696 29.799995 down 24.494576 down 1.2165959 up 
GLMN 2.75E-04 10.229098 down 1.0611 up 10.854096 up 
GMEB1 0.004739895 9.7296715 up 13.283859 up 1.3652939 up 
GNAI1 2.75E-12 257.3373 down 69.33706 down 3.7113967 up 
GNAQ 7.62E-05 2.193989 down 16.596046 up 36.411545 up 
GNAS 2.94E-07 29.977169 down 1.7149321 down 17.480091 up 
GNPTG 0.00609777 24.386105 up 14.094748 up 1.7301553 down 
GOLT1B 0.006657008 25.09118 down 1.269323 up 31.848818 up 
GOSR2 0.001350936 8.605287 down 1.6781911 up 14.441317 up 
GPBP1L1 0.005646233 18.246496 down 4.8769503 down 3.7413747 up 
GPR177 3.36E-04 11.310786 down 1.3638299 down 8.293401 up 
GPR52 9.81E-05 6.914979 down 1.0448744 up 7.225284 up 
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GPR64 0.001883869 45.255013 down 5.175649 down 8.743833 up 
GPX1 0.005916653 14.681089 down 1.3859973 down 10.592436 up 
GRINL1A 0.001228461 1.0850697 down 11.419933 up 12.391422 up 
GSDMD 0.009581806 1.0123322 down 6.7394004 down 6.657301 down 
GSR 7.31E-04 2.078229 down 5.922943 down 2.849995 down 
GTF2A1 0.006253314 10.044042 down 1.4753186 down 6.808049 up 
GTF2F2 0.001569423 10.505913 down 2.0282261 down 5.1798525 up 
GTF2H2 0.005379363 1.719688 down 10.466433 up 17.998997 up 
GTF2H3 1.38E-04 32.12152 down 13.827334 down 2.3230453 up 
GUCY1A3 6.07E-07 118.35761 down 19.728878 down 5.999207 up 
H2AFY 0.002108078 9.820655 down 2.0233867 down 4.8535733 up 
HBXIP 6.33E-08 4.93098 up 44.76022 up 9.077346 up 
HDAC9 0.001077939 17.959415 down 1.8112288 down 9.915596 up 
HDHD3 0.002759276 1.8215264 down 9.350478 down 5.13332 down 
HEATR3 0.001358968 11.889785 down 1.0882158 down 10.925944 up 
HECA 2.61E-09 10.711477 down 2.2539809 up 24.14347 up 
HERPUD2 3.59E-05 10.391134 down 2.0004613 down 5.1943674 up 
HHEX 1.21E-05 15.716794 down 1.9019333 down 8.263589 up 
HIAT1 4.17E-08 12.991061 down 1.6441956 down 7.9011655 up 
HINT2 0.004989176 4.24004 up 2.6247795 down 11.129169 down 
HIPK1 5.81E-04 7.198212 down 1.0437564 down 6.8964486 up 
HIPK2 0.002110592 1.7727716 down 11.906194 down 6.7161465 down 
HIST1H1E 0.004333782 2.6260324 down 4.1076775 up 10.786895 up 
HK1 1.43E-05 11.173793 down 1.5568973 down 7.176962 up 
HLA-E 3.31E-06 36.091705 down 126.870316 down 3.5152214 down 
HMGA1 3.47E-07 17.937365 down 2.8732607 down 6.2428613 up 
HMGN1 0.009876753 1.0394559 up 18.312157 up 17.61706 up 
HN1 0.00989945 7.129945 down 2.9131281 up 20.770443 up 
HNRNPH2 0.001185441 10.414838 down 1.4630586 down 7.118539 up 
HNRPC 0.002507886 6.3655343 up 12.152678 up 1.9091371 up 
HNRPK 0.004013233 1.7446643 down 16.115274 up 28.115753 up 
HOOK3 2.08E-05 9.218437 down 1.5258414 down 6.041543 up 
HOXA2 3.86E-13 237.02618 down 53.005295 down 4.4717455 up 
HOXC6 8.60E-04 9.550111 down 2.2786646 down 4.1911 up 
HSPD1 2.21E-04 4.726075 down 2.4694428 up 11.670771 up 
ICK 1.67E-06 55.393986 down 5.736879 down 9.65577 up 
ID4 0.007065751 53.52036 down 5.87956 down 9.102783 up 
IDH1 0.006324537 1.9263746 up 8.435468 up 4.378934 up 
IGF1 5.01E-07 185.71706 down 16.044197 down 11.575339 up 
IGF2BP2 0.003339899 1.1057867 down 10.079997 down 9.115681 down 
IIP45 0.006701313 28.405573 up 108.87883 up 3.8330088 up 
IKBKAP 0.003471525 14.781226 down 2.9808226 down 4.958774 up 
IL33 5.95E-06 397.38214 down 12.628908 down 31.466072 up 
IL7 1.11E-05 167.70605 down 17.384308 down 9.646979 up 
IMPDH1 8.74E-06 15.215018 down 3.9641762 down 3.8381288 up 
INCENP 0.002613781 3.1451616 up 14.045565 up 4.465769 up 
INPP5F 0.002803432 6.945363 down 2.8211236 down 2.4619136 up 
IPO8 0.003751391 2.0631042 down 8.538611 up 17.616047 up 
IQCC 7.30E-04 7.0553875 down 11.905117 down 1.6873797 down 
IRAK1 0.004043514 2.61604 up 4.170231 down 10.90949 down 
IRF2 6.91E-06 19.785364 down 4.089206 down 4.8384356 up 
ITFG1 2.09E-04 13.572194 down 1.5725269 down 8.630818 up 
ITGB1 3.97E-13 10.69448 down 1.3682294 down 7.8162904 up 
ITM2B 7.81E-06 134.46323 down 6.3441377 down 21.194881 up 
JARID1A 8.96E-05 1123.0938 down 283.76633 down 3.9578133 up 
JMY 0.001278945 2.9973602 up 17.05962 up 5.691548 up 
KCNJ10 0.001460063 2.7032263 down 11.204566 down 4.144886 down 
KCTD17 6.49E-04 9.5382185 down 5.702253 down 1.6727105 up 
KHDRBS3 1.97E-10 200.35898 down 163.35817 down 1.226501 up 
KIAA1128 5.51E-04 1.677084 up 9.3544445 up 5.577803 up 
KIAA1143 0.005855662 13.462083 down 2.4121325 down 5.580987 up 
KIAA1199 0.009992975 76.85203 down 2.6680794 down 28.80425 up 
KIAA1274 0.005573234 7.813993 down 19.980244 down 2.556982 down 
KIAA1333 3.01E-07 157.43074 down 34.416027 down 4.574344 up 
KIAA1370 2.20E-07 22.017706 down 1.4862624 down 14.814141 up 
KIAA1704 1.97E-05 41.120255 down 4.1744547 down 9.850449 up 
KIR3DL3 0.007881652 27.608913 down 17.119606 down 1.612707 up 
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KITLG 0.004934522 6.2074533 down 1.1776636 up 7.3102922 up 
KLF12 8.00E-04 6.409878 down 1.3745602 up 8.810764 up 
KLF3 0.007196833 1.5176562 down 4.408005 up 6.689837 up 
KLHL14 1.09E-08 159.2065 down 19.63116 down 8.10989 up 
KLHL5 0.003410083 1.9573686 down 3.578653 up 7.0047436 up 
KLHL7 5.12E-05 35.6645 down 4.233876 down 8.423607 up 
KMO 1.71E-13 236.06337 down 54.359653 down 4.342621 up 
KPNA3 6.10E-06 13.830012 down 2.2781088 up 31.506273 up 
KRAS 4.50E-12 14.512139 down 1.3210471 up 19.171223 up 
KRIT1 9.59E-11 121.00392 down 14.98657 down 8.074157 up 
KTELC1 5.24E-06 23.11791 down 15.097835 down 1.5312067 up 
LAMB1 8.71E-06 21.627012 down 7.4199057 down 2.9147289 up 
LAMP2 0.001239809 5.2560015 down 1.0154163 up 5.33703 up 
LARP4 0.009858452 7.2839923 down 4.149282 down 1.7554827 up 
LCORL 2.64E-08 181.3411 down 14.798675 down 12.253874 up 
LEPR 8.25E-05 11.61754 down 1.4851083 down 7.822688 up 
LFNG 0.00154863 4.9705286 down 1.6865714 up 8.383152 up 
LGALS8 3.30E-10 12.158772 down 2.3452728 down 5.184375 up 
LIG4 4.34E-09 47.895954 down 7.127392 down 6.7199836 up 
LIN7C 5.98E-07 74.66467 down 5.855038 down 12.752212 up 
LMBRD2 1.26E-07 42.713417 down 8.882486 down 4.808723 up 
LNX2 0.001184876 11.066767 down 1.2263937 down 9.0238285 up 
LOC389517 6.19E-05 30.220291 down 3.8523164 down 7.8447065 up 
LOC400986 3.25E-06 20.030231 down 4.1007776 down 4.8844953 up 
LOC440295 0.002048643 67.57112 down 14.920686 down 4.528687 up 
LOC649159 0.009859664 21.845201 down 2.065604 down 10.575697 up 
LOXL1 0.001091797 1.7497603 up 18.263783 up 10.437879 up 
LPCAT4 1.71E-04 10.496793 up 46.757126 up 4.4544196 up 
LPP 0.00422731 1.81944 down 11.011743 down 6.0522704 down 
LRBA 2.25E-05 4.965517 up 7.1164956 up 1.4331832 up 
LRRC41 9.49E-05 12.876652 down 5.590602 down 2.303267 up 
LRRCC1 7.49E-06 9.134536 down 1.132945 up 10.3489275 up 
LRRN2 0.005490519 22.002138 down 8.403005 down 2.6183655 up 
LUM 1.02E-08 214.79869 down 10.248967 down 20.958082 up 
LYPLA1 9.42E-08 399.4567 down 23.249031 down 17.181654 up 
M6PRBP1 0.001523081 9.723795 down 5.018289 down 1.9376711 up 
MAK10 0.009923156 2.375538 down 2.0057766 up 4.764799 up 
MAML2 3.54E-05 2.7321782 down 2.583916 up 7.059718 up 
MAN2A1 9.40E-07 69.97159 down 13.377403 down 5.2305813 up 
MAP9 0.003974533 10.266039 down 3.3316138 down 3.081401 up 
MARS2 6.22E-07 12.773468 down 1.3107413 up 16.742716 up 
MATR3 3.02E-04 1.2734149 down 4.327333 up 5.51049 up 
MBD2 0.009495194 9.130391 down 1.1638645 down 7.844892 up 
MBNL3 1.87E-04 10.553734 down 1.2641286 down 8.348622 up 
MCM8 1.93E-04 23.391054 down 2.6916099 down 8.690359 up 
MCTP1 4.38E-06 12.204741 down 1.1294104 down 10.806294 up 
ME2 1.47E-05 17.5825 down 1.8336841 down 9.588622 up 
MED13 3.21E-05 10.258539 down 1.8127862 down 5.658991 up 
MED23 0.005417526 4.8839235 down 1.011102 down 4.830298 up 
MED30 7.23E-06 18.463022 up 111.39466 up 6.0333924 up 
MED31 6.15E-09 403.7064 down 34.833733 down 11.589523 up 
MEF2A 0.004415452 1.1514846 down 10.025066 up 11.543711 up 
MET 2.60E-06 19.414341 down 7.3057513 down 2.6574051 up 
METT10D 0.002912228 9.853692 up 15.992661 up 1.623012 up 
METTL1 0.001330216 29.648531 down 5.47839 down 5.411906 up 
MFF 0.001725928 18.361006 down 1.9070679 down 9.6278715 up 
MFN1 0.003977393 16.017588 down 2.4632297 down 6.502676 up 
MOBKL1A 0.002852561 9.310981 down 4.508898 down 2.065024 up 
MOSPD2 2.20E-09 486.43158 down 67.09868 down 7.249493 up 
MOXD1 0.007334051 21.313742 down 2.5787258 down 8.265222 up 
MPDZ 2.87E-05 8.733337 down 2.4237306 down 3.6032617 up 
MRC1L1 0.004563219 1.7223642 up 22.986298 up 13.345782 up 
MRPL3 1.36E-06 42.637222 down 7.13509 down 5.97571 up 
MRPS12 0.001736133 7.601594 down 1.5771123 down 4.8199444 up 
MRPS16 0.00973183 1.6724702 up 6.701245 down 11.207633 down 
MRPS28 0.005862697 1.4914746 up 17.222477 up 11.547282 up 
MS4A4A 1.77E-09 52.302067 down 1.6558609 down 31.586025 up 
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MS4A7 9.88E-05 2.872869 up 15.16044 up 5.2771077 up 
MSH2 0.003212148 2.483918 up 11.702062 up 4.71113 up 
MST4 4.65E-04 6.4599204 down 1.8683835 up 12.069609 up 
MTM1 1.12E-06 1.391843 up 94.294304 up 67.7478 up 
MTMR9 4.96E-05 9.30774 down 1.9763287 down 4.7096114 up 
MTX2 5.12E-08 26.983728 down 2.4727705 down 10.912346 up 
MUC1 0.007696882 8.181167 down 4.6583314 down 1.7562441 up 
MYADM 2.13E-04 4.1062875 down 2.1739745 up 8.926965 up 
MYLK 1.20E-06 18.286156 down 1.9677991 down 9.292695 up 
MYNN 0.006479343 17.98544 down 3.920522 down 4.587511 up 
MYST4 0.006286535 8.624426 down 3.8666904 up 33.347977 up 
N4BP2L1 0.00767875 7.796064 down 1.1935241 down 6.531971 up 
N6AMT1 6.98E-04 8.429369 down 1.7085234 down 4.9337163 up 
NAB1 0.007626717 7.284132 down 1.1189065 down 6.510046 up 
NAP1L1 0.002751237 5.7457547 down 1.2047071 up 6.9219522 up 
NAPEPLD 1.25E-10 290.15524 down 7.897009 down 36.74243 up 
NAT11 0.003193242 3.1503613 up 50.628826 up 16.070797 up 
NAT13 0.00676134 3.162337 down 1.413904 up 4.471241 up 
NAV2 0.004129249 5.6218333 down 1.2648709 down 4.4445906 up 
NBPF15 4.09E-04 3.1942167 down 3.8553326 up 12.314768 up 
NCAPG2 6.26E-04 5.9330454 up 79.42693 up 13.387211 up 
NCKAP1L 8.58E-04 6.9983354 down 32.479652 down 4.641054 down 
NCOA1 4.95E-04 7.7209563 down 1.0618298 down 7.271369 up 
NDRG1 0.001500237 8.090146 down 13.991383 down 1.7294351 down 
NDRG4 4.96E-04 10.072089 down 1.2360748 up 12.449857 up 
NDUFS7 0.002981367 1.5848469 up 5.2585316 down 8.333967 down 
NEDD9 4.05E-07 12.268205 down 1.9509029 down 6.288476 up 
NFAT5 6.90E-06 9.472188 down 1.2730764 down 7.440392 up 
NFATC2 2.56E-06 13.405881 down 1.2140319 down 11.042445 up 
NFATC3 0.004788925 3.2973022 down 1.6234404 up 5.3529735 up 
NFIA 7.55E-04 18.464762 down 1.0405116 down 17.74585 up 
NFXL1 3.28E-05 20.427988 down 4.7171674 down 4.3305626 up 
NIN 1.38E-06 6.022748 down 1.5192481 down 3.9642954 up 
NKG7 0.001432874 3.022726 up 3.747447 down 11.327506 down 
NLGN4X 1.78E-07 137.42421 down 7.945553 down 17.295738 up 
NNT 8.91E-04 2.727686 down 4.0158143 up 10.95388 up 
NOL8 0.002590406 4.1103773 down 1.870514 down 2.197459 up 
NOTCH2NL 1.75E-04 15.665 down 3.3258367 down 4.7100935 up 
N-PAC 0.00346187 1.0552106 up 14.760106 up 13.987831 up 
NQO1 1.13E-06 13.433853 down 2.288561 down 5.869999 up 
NR1H3 0.007210864 1.7432098 down 11.243439 down 6.449847 down 
NSUN6 0.003503544 11.104871 down 12.944696 down 1.1656773 down 
NT5C 0.004214983 1.4111062 up 5.0594897 down 7.1394763 down 
NTS 3.94E-07 165.26573 down 6.7430167 down 24.509161 up 
NUCKS1 0.002361547 5.7921 down 11.153186 down 1.9255857 down 
NUDT21 2.60E-04 5.727261 down 1.4824113 up 8.490156 up 
NUFIP1 6.35E-04 39.52353 down 15.043396 down 2.627301 up 
NUP43 2.13E-06 41.12042 down 7.0919256 down 5.7982016 up 
NUS1 1.38E-05 8.8615885 down 1.8841668 down 4.703187 up 
NUSAP1 2.68E-04 6.8090754 down 1.0127379 up 6.895809 up 
OAS3 2.51E-07 126.159454 down 8.26494 down 15.264411 up 
OLFM1 2.56E-05 29.158213 down 4.25994 down 6.844748 up 
OPA1 1.72E-06 11.941727 down 1.344821 up 16.059486 up 
ORC5L 8.90E-08 6.983898 down 1.8668504 up 13.037892 up 
OXTR 0.002038054 17.838482 down 46.027496 down 2.5802362 down 
P2RY13 1.15E-06 20.879519 down 2.6181147 down 7.97502 up 
PAG1 1.76E-06 1.1712118 down 5.5300117 up 6.476815 up 
PALM 0.008643085 9.486322 down 1.7710583 down 5.356301 up 
PANK2 5.52E-05 6.172885 down 2.0828664 up 12.857293 up 
PAQR8 6.99E-04 3.517141 down 8.769183 down 2.4932704 down 
PARP12 0.00227428 1.2191415 down 8.662431 down 7.105353 down 
PARP9 2.41E-05 71.75259 down 17.321856 down 4.142315 up 
PARVA 7.69E-08 247.23334 down 9.589851 down 25.780725 up 
PDCD10 0.002378464 6.2965646 down 1.462538 up 9.208966 up 
PDCD5 2.35E-04 1.5486423 down 8.090751 up 12.529679 up 
PDCD6IP 1.73E-04 43.0234 down 3.9710898 down 10.834155 up 
PDE3B 6.49E-04 1.0468297 up 33.25751 up 31.769745 up 
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PDE5A 1.16E-06 11.281831 down 1.6449213 up 18.557722 up 
PEMT 1.57E-05 8.662327 down 1.0171723 up 8.811079 up 
PER2 2.70E-08 15.182093 down 1.5539488 down 9.770009 up 
PES1 7.42E-05 12.714315 down 25.038574 down 1.9693213 down 
PEX11G 1.49E-04 14.48946 down 23.36378 down 1.6124672 down 
PHF14 3.85E-04 9.631312 down 4.026732 down 2.3918436 up 
PHF3 3.00E-04 38.256657 down 4.0348635 down 9.4815235 up 
PHKA2 6.22E-04 1.1365372 up 7.3392177 down 8.341294 down 
PHOSPHO2 1.13E-13 211.928 down 10.28182 down 20.61192 up 
PI15 9.40E-07 7.3512435 down 1.0285556 down 7.147152 up 
PI4K2B 3.21E-09 15.732318 down 3.5230727 down 4.46551 up 
PIAS2 3.65E-06 14.331547 down 1.7571716 down 8.156032 up 
PICALM 3.13E-04 7.18382 down 1.0187378 down 7.051687 up 
PIGQ 0.002960897 1.0294267 up 7.898721 down 8.131154 down 
PIGU 0.007703219 1.3873187 down 7.44217 down 5.3644266 down 
PIK3CA 9.32E-05 3.7560902 down 2.2704422 up 8.527986 up 
PIK3R1 0.008839984 4.0413327 down 1.8703835 up 7.5588417 up 
PKIA 3.38E-05 7.1112723 down 2.315107 up 16.46336 up 
PLCL1 1.91E-06 40.642204 down 7.320416 down 5.5518975 up 
PLD3 0.003207914 10.642531 down 1.2296128 down 8.655189 up 
PLEKHG1 2.20E-06 99.23481 down 15.791914 down 6.2839007 up 
PLEKHH3 0.004072717 22.8319 down 13.146231 down 1.7367642 up 
PLEKHO1 0.003336418 1.3467159 down 8.150619 down 6.0522184 down 
PLSCR4 0.003514292 21.587084 down 5.3686056 down 4.0209846 up 
PNPLA8 0.001587247 18.550701 down 3.0226085 down 6.1373158 up 
POLG 3.94E-04 1.1935964 up 22.537111 up 18.88169 up 
POLK 5.52E-04 14.247483 down 1.5928235 down 8.9447975 up 
POLR2G 0.002288943 1.0156279 up 3.025785 down 3.0730715 down 
POLR2J3 9.03E-05 9.367654 down 1.7078247 up 15.99831 up 
POLR3F 3.77E-05 10.813741 down 6.1143355 down 1.768588 up 
POMP 2.99E-08 271.48096 down 21.331226 down 12.726923 up 
PPA2 0.008432304 5.9932437 down 1.346811 up 8.071766 up 
PPIL4 2.54E-04 13.694382 down 1.0748713 up 14.7197 up 
PPP1CB 0.008382075 1.6539217 down 4.811564 up 7.95795 up 
PPP2R2D 1.69E-04 3.7548544 down 1.7788857 up 6.679457 up 
PPT2 1.12E-05 22.466637 down 3.8161795 down 5.887207 up 
PRDM4 0.005748785 1.4950874 down 10.724314 down 7.173035 down 
PRKACB 1.13E-08 15.971311 down 1.0867783 down 14.696016 up 
PRKAG2 1.13E-06 2.997834 down 1.5132383 up 4.5364375 up 
PRKCB1 0.003439614 3.493342 down 1.3847489 down 2.5227256 up 
PRKX 0.002009163 5.372691 up 8.666451 up 1.6130557 up 
PRMT6 0.003053468 8.841437 down 2.3077857 down 3.8311348 up 
PSAT1 1.95E-05 8.8213215 down 1.1514546 up 10.15735 up 
PSCDBP 5.51E-05 24.940912 down 1.5546597 down 16.042686 up 
PSMB1 0.009982433 1.2877831 up 3.983861 down 5.130349 down 
PSMB10 0.007183051 1.5658293 down 9.616911 down 6.1417365 down 
PSMD1 0.001123151 3.2779691 up 3.9241211 down 12.863148 down 
PSMD10 0.002145903 2.0157065 down 3.1240005 up 6.297069 up 
PSMD6 3.05E-06 6.523827 down 1.973789 down 3.3052301 up 
PSPH 7.04E-04 8.220119 up 21.99862 up 2.676192 up 
PSRC1 6.02E-04 7.541325 down 2.1586294 down 3.493571 up 
PTGFRN 3.24E-07 125.03998 down 14.123866 down 8.853099 up 
PTPLAD1 5.31E-04 7.0569057 up 12.222071 up 1.7319307 up 
PTPN22 1.11E-08 27.66733 down 1.5664712 down 17.662203 up 
PTPRU 1.74E-04 21.717295 down 11.49789 down 1.8888068 up 
PYGL 1.44E-04 6.9343495 down 1.5910488 down 4.358351 up 
R3HDM2 0.003866316 7.4239974 down 1.557549 down 4.766462 up 
RAB11FIP1 4.81E-11 8.213332 down 1.0559459 down 7.778176 up 
RAB14 2.19E-07 31.366182 down 5.5596366 down 5.6417675 up 
RAB30 2.31E-04 5.6773148 down 1.3136588 down 4.3217573 up 
RABGGTB 1.69E-06 24.114546 down 9.35427 down 2.5779183 up 
RAD17 9.80E-10 15.764736 down 1.1974355 down 13.165413 up 
RAD50 2.10E-07 11.307503 down 2.0041196 up 22.66159 up 
RAD54L 1.20E-04 8.542316 down 9.324137 down 1.0915232 down 
RAG1AP1 8.22E-08 110.390396 down 22.24524 down 4.9624276 up 
RAI1 0.001477566 3.294564 down 4.451799 up 14.666737 up 
RALGPS2 0.00420607 12.850125 down 1.0342727 down 12.424311 up 
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RANBP2 2.90E-05 11.956906 down 1.5375684 up 18.38456 up 
RAP1GDS1 0.002324897 5.9801173 down 1.3961884 up 8.349371 up 
RBBP9 0.001302954 7.475199 down 2.0649567 down 3.6200273 up 
RBL1 8.23E-10 5.555052 down 2.27847 up 12.657019 up 
RBM3 0.006988636 10.974837 down 5.1557875 down 2.128644 up 
RBMS1 8.80E-04 3.0370889 down 1.9745857 up 5.9969916 up 
RBPJ 8.92E-04 5.1883717 down 2.4935017 up 12.937213 up 
RCC2 0.008722604 3.2919636 up 3.7634346 down 12.389089 down 
RCN1 4.68E-08 1931.6104 down 187.38063 down 10.308484 up 
RCN2 0.001207017 3.7042944 down 1.8743887 up 6.943288 up 
RDH11 1.63E-06 21.490473 down 10.045404 down 2.1393335 up 
RECQL 3.71E-05 7.0416822 down 1.4022089 down 5.021849 up 
RELN 1.19E-06 95.59824 down 7.5415096 down 12.676274 up 
RFX5 5.33E-07 21.228926 down 5.6485868 down 3.7582722 up 
RFXAP 0.00662855 6.99262 down 1.4685609 up 10.269088 up 
RGPD5 0.001890577 10.783755 down 1.6457385 down 6.552532 up 
RHEBL1 0.007252186 22.5372 down 10.359314 down 2.1755493 up 
RHOJ 0.00369335 41.075268 down 5.6820483 down 7.228953 up 
RIOK3 5.72E-05 7.644051 down 1.6435905 up 12.56369 up 
RNASEH2B 0.002552729 1.58258 down 9.527301 down 6.0201073 down 
RNASEN 1.89E-04 16.952 down 5.8214335 down 2.911998 up 
RNF11 3.52E-09 106.87527 down 28.746521 down 3.717851 up 
RNF138 0.005600598 15.289233 down 1.2903286 up 19.728134 up 
RNF146 9.18E-04 4.1823926 up 21.163317 up 5.0600986 up 
RNF38 0.002195766 4.3251867 down 1.204116 down 3.592002 up 
RNF7 5.72E-06 16.398153 down 7.353568 down 2.229959 up 
ROBO1 4.88E-04 16.772564 down 4.042655 down 4.148898 up 
RPAP3 1.12E-08 26.437904 down 3.0988815 down 8.531435 up 
RPL22 9.72E-04 4.9986415 up 41.404293 up 8.283109 up 
RPL7 6.55E-05 1.7430243 down 8.760912 up 15.270482 up 
RPS26 0.001252586 22.104454 up 11.528796 up 1.9173257 down 
RPS6KC1 1.45E-12 29.431967 down 14.251197 down 2.0652277 up 
RRP1B 1.52E-05 4.026398 down 5.681751 up 22.87699 up 
RRP7A 0.001282253 2.8175774 down 17.236958 down 6.117653 down 
RRS1 2.93E-04 4.6843753 down 5.9345093 up 27.799473 up 
RSBN1L 4.18E-06 15.025451 down 1.0967731 up 16.479511 up 
RUNDC3B 0.002557344 1.6432617 down 17.837715 down 10.855064 down 
RYK 1.67E-04 2.2418928 down 3.5815806 up 8.029521 up 
SAMSN1 2.80E-05 8.686577 down 1.6891397 down 5.142604 up 
SC5DL 7.01E-04 6.537944 down 1.0484343 up 6.854605 up 
SCAMP1 2.84E-04 1.9808297 down 4.6856003 up 9.281375 up 
SCMH1 0.001827465 5.87433 down 1.0055887 down 5.841682 up 
SCML1 0.001537268 7.0845537 down 1.6290653 up 11.541202 up 
SCNN1D 3.71E-04 1.289663 down 12.220806 down 9.47597 down 
SCRIB 5.92E-05 8.95509 down 1.0431473 down 8.584683 up 
SCYL1BP1 4.65E-06 20.571194 down 5.2053556 down 3.9519277 up 
SDF4 6.89E-07 5.102552 down 2.6296375 up 13.417861 up 
SDHD 0.001093202 7.437263 down 4.1244307 up 30.674475 up 
SEC24C 0.003767617 5.644759 down 1.7614206 down 3.2046626 up 
SEC62 2.73E-07 13.665146 down 2.3873982 down 5.723865 up 
SEH1L 0.004251851 2.6577344 down 2.9345245 up 7.799186 up 
SELM 0.003665327 1.7513821 up 7.8737764 down 13.789991 down 
SENP6 2.80E-08 18.299578 down 5.733956 down 3.1914406 up 
SENP7 0.003431266 4.3176417 down 2.81381 up 12.149023 up 
SERAC1 0.001404165 15.370831 down 6.1535826 down 2.4978669 up 
SERF1B 6.15E-06 114.98696 down 4.245132 down 27.086784 up 
SERPINI1 1.04E-04 68.225105 down 15.913138 down 4.2873445 up 
SETD3 4.03E-06 9.152396 down 1.1309292 up 10.350714 up 
SETD6 5.09E-06 1015.6609 down 623.90845 down 1.6279002 up 
SETDB2 2.95E-05 7.1602154 down 26.06232 down 3.6398795 down 
SF3B3 0.005955674 3.4810174 up 1.448063 down 5.0407324 down 
SF4 1.45E-04 1.4186026 down 7.087206 down 4.9959064 down 
SFRP4 3.71E-09 645.5158 down 70.33453 down 9.177796 up 
SFRS2B 0.001143766 1.5469866 up 6.8364787 up 4.419223 up 
SFRS3 1.93E-07 24.722982 down 1.390048 down 17.78571 up 
SGOL2 0.002171958 55.20704 down 5.8952947 down 9.364594 up 
SH3BGRL 9.33E-06 26.52516 down 1.1126796 down 23.838997 up 
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SKI 0.003753592 3.3107417 down 2.5441647 up 8.423072 up 
SLAMF8 6.26E-05 679.2688 down 1173.5913 down 1.727727 down 
SLC10A7 1.47E-07 8.065574 down 1.503079 up 12.123195 up 
SLC12A6 0.004253994 3.1686015 down 2.3791173 up 7.5384755 up 
SLC15A4 0.002744256 3.8999882 up 20.188938 up 5.176667 up 
SLC22A17 2.15E-04 8.498817 down 1.2768453 down 6.6561065 up 
SLC25A23 0.002307631 2.4396906 up 4.344635 down 10.599566 down 
SLC25A32 0.002937946 17.137173 down 2.985614 down 5.7399144 up 
SLC25A40 0.009588216 2.7571132 up 22.022684 up 7.987586 up 
SLC26A6 2.56E-05 14.273289 down 2.8242145 down 5.0538964 up 
SLC29A1 1.52E-09 10.2297 down 3.786554 down 2.7015855 up 
SLC30A5 0.004439674 14.013604 down 1.7273985 down 8.112549 up 
SLC30A7 8.70E-04 2.2008038 down 11.535338 down 5.2414207 down 
SLC41A3 0.005071448 7.1072893 down 1.3614538 up 9.676246 up 
SLC4A5 0.009846691 16.100517 down 2.2384746 down 7.1926293 up 
SLC6A9 5.55E-07 15.332633 down 3.9689453 down 3.8631504 up 
SLC9A6 1.69E-07 11.971249 down 1.1739352 up 14.053468 up 
SLCO3A1 2.94E-06 9.850855 down 1.0691134 down 9.214042 up 
SLFN11 3.59E-07 71.14539 down 4.1624947 down 17.09201 up 
SLK 0.005554502 8.88517 down 1.4707506 down 6.0412483 up 
SLTM 2.62E-04 3.6996272 down 1.584603 up 5.86244 up 
SMAD2 2.48E-04 16.294104 down 1.2305472 down 13.241345 up 
SMC2 0.009035276 6.258391 down 1.2401171 down 5.046613 up 
SMC6 0.005427342 17.837673 down 1.1931552 up 21.283113 up 
SMG7 4.11E-06 3.6336079 down 1.1574938 up 4.2058787 up 
SMPD1 1.41E-04 11.094001 down 2.1838887 down 5.07993 up 
SMPDL3A 2.01E-06 90.51843 down 7.201459 down 12.569457 up 
SNAPC4 9.07E-04 1.2094554 up 9.083944 down 10.986626 down 
SNORD107 1.39E-04 20.249323 down 2.0026956 up 40.553215 up 
SNRPD1 0.009445871 10.277269 down 2.311563 down 4.446026 up 
SNRPN 1.10E-10 6.0401745 down 1.4836541 up 8.961529 up 
SNX1 1.48E-05 2.4319503 up 13.213169 up 5.4331574 up 
SP3 9.67E-05 4.6089344 down 2.701559 up 12.451309 up 
SPAST 8.94E-06 8.06534 down 1.1734318 up 9.464127 up 
SPC24 1.93E-04 1.0042573 down 15.117227 down 15.053143 down 
SPCS3 0.001737695 42.13478 down 2.777251 down 15.171398 up 
SPIC 3.23E-08 168.19083 down 11.336265 down 14.83653 up 
SPOPL 1.70E-05 22.34085 down 2.1026425 down 10.625132 up 
SPPL2B 0.003603679 6.5860186 down 1.8362278 down 3.586711 up 
SQSTM1 0.002099883 2.2986104 down 14.846299 down 6.4588146 down 
SRP9 0.002226583 4.255992 down 1.4425822 up 6.1396184 up 
SRPRB 2.37E-05 26.215557 up 68.392334 up 2.608846 up 
SSBP3 5.02E-05 5.075352 down 1.4636077 up 7.4283247 up 
ST3GAL5 0.0092713 3.0759916 down 1.9154905 up 5.8920326 up 
ST6GAL1 5.97E-04 4.802251 down 2.5717137 up 12.350014 up 
ST6GALNAC3 5.92E-05 24.702171 down 8.771768 down 2.8160992 up 
ST8SIA4 3.45E-04 7.9146743 down 1.3769864 up 10.898398 up 
STAG2 2.15E-05 4.5220423 down 1.7371116 up 7.8552923 up 
STAMBP 0.003216187 2.6281872 down 3.3215811 up 8.729737 up 
STARD3 1.11E-04 12.877834 down 4.586416 down 2.807821 up 
STAU1 0.004371808 2.3173866 down 2.5892754 up 6.0003524 up 
STK17B 0.007832015 15.121467 down 1.7473718 down 8.653833 up 
STRAP 0.002221307 4.6883545 down 1.0055181 up 4.7142253 up 
STX2 0.003845002 1.6774983 down 6.473789 up 10.859771 up 
STYX 1.58E-07 530.4886 down 75.47328 down 7.0288305 up 
SULT1A1 7.45E-04 7.4111643 down 1.3344394 down 5.5537653 up 
SUMF2 2.04E-04 7.7939963 down 2.0380912 down 3.8241646 up 
SUMO1 2.18E-07 31.399881 down 1.5535663 down 20.211485 up 
SUOX 9.41E-06 6.9373584 down 1.1747155 down 5.9055653 up 
SUV420H1 0.006231028 4.7964387 down 1.0827773 down 4.429755 up 
SYCP1 0.003136971 224.46432 down 51.643967 down 4.3463798 up 
SYNE1 9.13E-08 17.009274 down 1.2625734 down 13.471909 up 
SYNE2 0.002230475 4.3484006 down 2.79895 up 12.170956 up 
SYNJ1 2.78E-04 2.0888796 down 3.063252 up 6.398765 up 
SYNJ2BP 0.002357794 2.4766774 up 1.8647044 down 4.6182714 down 
SYT11 0.00935805 1.2080003 up 4.395808 down 5.3101377 down 
TADA1L 0.001455176 4.6171546 down 2.030439 up 9.374849 up 
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TAF1B 7.46E-04 26.991222 down 2.3801825 down 11.339978 up 
TAF9 0.005208395 3.6693075 down 5.085628 up 18.660734 up 
TANK 0.001362066 2.5658553 down 2.2945998 up 5.887611 up 
TAOK2 2.33E-05 10.931411 down 2.340749 down 4.6700487 up 
TAOK3 1.58E-08 1459.3153 down 103.75347 down 14.065223 up 
TARDBP 1.83E-06 10.549396 down 2.2552018 down 4.677806 up 
TAS2R14 0.007060847 5.658673 down 2.898415 up 16.401182 up 
TBC1D22A 0.005599857 7.914468 down 2.1313534 down 3.7133532 up 
TBL1X 0.009261122 1.0052005 up 7.6511955 down 7.690985 down 
TBRG1 2.79E-04 2.2983956 up 22.137026 up 9.631512 up 
TC2N 1.33E-05 9.135517 down 5.328204 up 48.675907 up 
TCERG1 3.67E-05 4.2357664 down 1.9178729 up 8.123661 up 
TCF12 0.001174474 5.227383 down 1.1713647 up 6.1231723 up 
TCF7 0.00370217 1.2752731 down 5.2985783 up 6.7571344 up 
TCP1 3.79E-12 22.603445 down 2.8443542 down 7.946777 up 
TCTN1 0.006478699 10.08844 up 5.4727 up 1.8434117 down 
TDO2 4.65E-05 76.98565 down 13.874537 down 5.5487013 up 
TERF1 3.50E-04 9.139923 down 2.4233074 down 3.7716734 up 
TFG 9.12E-05 3.4841151 down 2.2629988 up 7.884549 up 
TFPI 4.88E-04 7.2029505 down 1.1407381 up 8.216681 up 
TGFBR2 0.002047329 4.6393933 down 2.3302493 up 10.810942 up 
THAP5 8.20E-09 46.291725 down 3.6403468 down 12.716297 up 
THAP6 5.73E-04 6.109356 down 1.0096927 up 6.168572 up 
TIA1 3.41E-06 188.68805 down 19.628876 down 9.612778 up 
TIAL1 0.001795627 1.6368861 down 7.8093376 up 12.782996 up 
TIMM22 4.58E-04 1.7783535 down 7.7498293 down 4.3578687 down 
TIPRL 9.60E-05 2.0484483 down 4.6902337 up 9.607702 up 
TLR3 0.004642209 56.188572 down 7.6077533 down 7.385699 up 
TM4SF18 4.88E-11 150.3495 down 25.458818 down 5.905597 up 
TMEM104 0.007229614 1.7107627 down 41.460464 up 70.929016 up 
TMEM106B 2.07E-04 13.006642 down 1.5249091 up 19.833946 up 
TMEM137 0.001013426 3.5679326 down 28.535751 down 7.99784 down 
TMEM183A 5.67E-05 11.895105 down 4.381351 down 2.7149398 up 
TMEM189 
-UBE2V1 
4.04E-04 7.9764543 down 24.212372 down 3.0354798 down 
TMEM19 6.05E-16 404.12213 down 53.722717 down 7.5223684 up 
TMEM38B 0.005521221 22.167463 down 4.138439 down 5.3564796 up 
TMEM41B 0.005605353 2.0247781 up 3.606849 down 7.303069 down 
TMEM64 0.001839316 1.006199 up 16.737398 up 16.634285 up 
TMEM69 1.45E-06 6.1254535 up 50.38219 up 8.225055 up 
TMSB4X 3.05E-04 2.4892077 down 16.672798 up 41.50205 up 
TNC 7.66E-05 9.045913 down 3.4609208 down 2.6137302 up 
TNFAIP8 2.92E-05 16.28897 down 2.7411337 down 5.9424224 up 
TNFRSF1B 3.54E-04 5.5427384 down 30.085102 down 5.4278398 down 
TNIP3 0.001850497 1.4608194 up 6.9033813 down 10.084593 down 
TOM1 0.005521505 2.0137942 down 13.295589 down 6.602258 down 
TOP1 2.07E-04 16.0336 down 3.404917 down 4.708955 up 
TOPORS 1.16E-06 77.31025 down 5.54056 down 13.953513 up 
TPCN2 0.00385112 1.0582529 up 5.6552176 down 5.984651 down 
TPI1 0.006767832 6.474049 up 1.0711734 down 6.9348297 down 
TPK1 1.66E-04 10.618938 down 2.6232522 down 4.0480056 up 
TPP2 1.44E-06 3.1247053 down 3.1084154 up 9.712883 up 
TRABD 0.002094139 2.0375283 up 4.1379566 down 8.431203 down 
TRAF5 2.71E-10 4.841076 down 3.352071 up 16.22763 up 
TRAPPC2L 0.001729689 1.9559205 up 6.961032 down 13.615226 down 
TRAPPC6B 4.37E-06 7.0665126 down 1.0150145 down 6.961982 up 
TRAT1 1.09E-04 20.47111 down 2.9575875 down 6.9215574 up 
TRIM3 1.74E-07 17.327156 down 2.509284 down 6.9052196 up 
TRIM33 1.92E-05 8.900957 down 1.3160642 down 6.7633147 up 
TRIM4 6.89E-04 6.8921475 down 1.0647311 down 6.4731345 up 
TRPM2 2.67E-06 25.453693 down 2.9268909 down 8.696496 up 
TRPT1 4.15E-05 16.68914 down 2.7049751 down 6.1697955 up 
TSC1 3.90E-04 6.989248 down 1.7791383 down 3.9284456 up 
TSC22D2 2.78E-07 8.655063 down 2.6950092 down 3.211515 up 
TSC22D3 7.84E-04 2.9845226 down 2.509454 up 7.489523 up 
TSNAX 1.22E-05 15.750429 down 4.2329097 down 3.7209456 up 
TSPAN12 8.27E-11 307.26852 down 30.281181 down 10.147178 up 
TSPAN13 9.42E-04 11.554177 down 1.1338136 up 13.100282 up 
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TSPAN33 0.00613541 2.501188 down 16.489416 down 6.592634 down 
TSPAN4 0.001761541 16.38268 down 1.300723 down 12.595056 up 
TSPAN7 0.001039907 87.62003 down 8.881055 down 9.865947 up 
TSR1 2.45E-05 65.30981 down 3.794855 down 17.210089 up 
TTC23 0.001620816 7.3842096 down 3.6497812 down 2.0231924 up 
TTC39B 1.27E-06 98.98506 down 16.514227 down 5.993926 up 
TTF1 3.36E-10 26.353401 down 3.6051302 down 7.309971 up 
TTRAP 1.25E-04 5.5379086 down 2.2799292 up 12.626039 up 
TUFM 7.82E-04 3.6293569 up 3.824123 down 13.879106 down 
TWF1 0.002106424 4.5469346 down 1.0784723 down 4.216089 up 
TXNRD2 0.004894615 2.0033112 down 12.318226 down 6.148934 down 
TYW3 8.70E-05 8.997397 down 10.222054 down 1.1361122 down 
UBE2D2 1.45E-06 5.7851043 down 2.6052413 down 2.2205637 up 
UBE2D3 2.42E-08 10.865164 down 1.1240911 down 9.665733 up 
UBE2H 1.97E-05 7.4031305 down 1.3136909 up 9.725424 up 
UBE2Z 0.002731817 1.3880645 up 11.654188 up 8.395999 up 
UBE4B 0.005822326 8.4463215 down 3.7183237 down 2.2715402 up 
UBR5 0.00318293 8.255534 down 4.5141 down 1.8288326 up 
UBR7 2.58E-04 4.61853 down 1.7280157 up 7.980891 up 
UNC119 0.006902074 4.587935 down 1.3712082 down 3.3459072 up 
UPF2 1.54E-04 11.068828 down 1.3227906 down 8.367785 up 
UQCC 4.26E-04 5.6558146 down 1.0289153 up 5.819354 up 
USP16 0.001374591 3.630336 down 1.5643557 up 5.679137 up 
USP48 1.19E-04 8.408603 down 1.6513907 down 5.091831 up 
USPL1 0.004945296 4.6374593 down 1.1363279 up 5.269674 up 
UTP3 2.44E-06 247.37401 down 19.278603 down 12.831528 up 
VAMP8 0.00243003 4.3750324 up 1.2482661 down 5.4612045 down 
VARS2 0.001245543 1.625337 up 6.5147533 down 10.58867 down 
VASH2 1.04E-05 114.04187 down 18.063295 down 6.313461 up 
VEZT 4.59E-11 74.00654 down 15.173254 down 4.877434 up 
VPS13A 3.47E-08 9.663795 down 1.178689 down 8.198767 up 
VPS13B 4.38E-06 7.0657854 down 1.4157226 up 10.003193 up 
VPS24 4.21E-05 6.1457205 down 1.899725 up 11.675179 up 
WBP11 0.009260353 4.1503353 down 2.6407003 up 10.959794 up 
WBP5 1.06E-08 68.87768 down 30.051939 down 2.2919543 up 
WDR26 2.68E-05 8.021877 down 1.1101507 up 8.905493 up 
WDR44 0.005568679 39.653145 down 5.6428657 down 7.02713 up 
WDR46 0.00179891 7.6913476 up 2.4126773 down 18.556736 down 
WDSUB1 6.15E-05 180.93266 down 36.461765 down 4.9622574 up 
WHSC1 0.0012189 11.545975 down 2.6363404 down 4.379546 up 
WIPF1 5.14E-04 2.9015427 down 6.0911565 up 17.673754 up 
WWP1 5.87E-09 86.644775 down 23.274904 down 3.72267 up 
WWP2 0.00105414 2.9178462 down 3.6091866 up 10.531052 up 
XPO6 6.19E-09 18.474125 up 20.896225 up 1.1311076 up 
XRCC5 0.001141931 1.1199814 up 14.1366415 up 12.6222105 up 
YAF2 2.84E-05 8.718427 down 2.6534238 down 3.285727 up 
YES1 0.004749542 4.0908623 down 5.3011575 down 1.2958535 down 
YIPF4 4.85E-06 27.776245 down 4.6407657 down 5.985272 up 
YME1L1 1.30E-04 4.047181 up 6.569345 up 1.6231902 up 
YOD1 0.00716745 14.993594 down 3.292332 down 4.5540953 up 
YPEL3 0.003913292 14.365424 up 98.21181 up 6.83668 up 
YTHDF3 4.42E-07 6.116748 down 1.3097258 down 4.670251 up 
YWHAE 0.006567453 4.0390725 down 1.2054291 up 4.8688154 up 
ZAP70 0.00941424 3.9931872 up 5.7434764 up 1.438319 up 
ZBTB11 0.005830909 9.577617 down 1.0353694 up 9.916371 up 
ZBTB3 3.47E-05 3.579126 down 14.509221 down 4.053845 down 
ZC3H7A 7.92E-10 463.68134 down 129.67134 down 3.5758195 up 
ZCCHC6 8.55E-06 30.641006 down 33.206764 down 1.0837358 down 
ZDHHC16 0.008849635 1.9925271 down 4.7530785 up 9.470638 up 
ZDHHC4 0.009627339 30.245811 down 3.8074656 down 7.943817 up 
ZFAND1 0.00343089 8.096212 down 1.8804401 down 4.305488 up 
ZFAND2A 6.99E-04 1.0062547 down 8.323114 down 8.271379 down 
ZFAND6 4.08E-08 105.78078 down 3.7741256 down 28.02789 up 
ZFP106 0.004666306 1.3642471 up 6.2868414 up 4.608287 up 
ZFP91 0.006881047 1.2046837 down 3.8671474 up 4.658689 up 
ZFYVE1 0.001720764 8.695094 down 8.093691 down 1.0743052 up 
ZMYND11 0.002739006 6.5577617 down 2.0223913 down 3.2425778 up 
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ZNF124 0.00266481 6.885966 down 1.1876531 up 8.178139 up 
ZNF131 2.98E-04 12.154433 down 2.5474272 down 4.771259 up 
ZNF141 6.21E-08 29.349707 down 1.0155233 up 29.805304 up 
ZNF227 6.70E-07 12.667595 down 3.9416342 down 3.213792 up 
ZNF23 6.45E-07 76.04954 down 17.593714 down 4.3225403 up 
ZNF253 0.002447995 30.671535 down 2.5956028 down 11.816731 up 
ZNF273 0.006807428 16.80808 down 2.403022 down 6.9945583 up 
ZNF318 3.06E-07 21.514616 down 2.4030108 down 8.953189 up 
ZNF322A 2.52E-06 15.518061 down 4.6302257 down 3.3514698 up 
ZNF431 1.68E-06 90.29036 down 6.926899 down 13.034742 up 
ZNF490 8.06E-09 475.23242 down 61.763958 down 7.6943297 up 
ZNF493 1.33E-04 21.440052 down 5.9030714 down 3.6320155 up 
ZNF526 6.59E-04 4.387784 down 10.010195 down 2.281378 down 
ZNF567 3.37E-11 154.9765 down 14.825055 down 10.453688 up 
ZNF593 0.001063756 1.2341977 down 11.589249 down 9.390107 down 
ZNF653 0.00106378 1.8039771 up 5.3189297 down 9.595228 down 
ZNF827 0.001880202 1.4905915 up 5.470114 down 8.153706 down 
ZNF83 1.96E-04 7.862181 down 3.6259406 up 28.507801 up 
ZNF93 0.003682921 1.5066208 up 11.371461 up 7.54766 up 
ZSCAN18 2.06E-07 12.366672 up 15.575254 up 1.2594541 up 
 
Supplementary Table 24. Genes differentially expressed between F-PTCL and AITL. 
Gene ID Corrected p-value Absolute Fold Change Regulation in F-PTCL 
AASS 0.006721099 6.9508505 down 
ABCA1 0.009255056 4.471113 down 
ABCA10 0.001512908 7.4106607 down 
ABCD2 0.002290321 6.078836 down 
ABI3BP 0.002592176 8.837785 down 
ACBD7 0.001505991 4.5303264 down 
ADD1 0.005487896 5.024453 down 
AIM2 8.70E-05 13.001065 down 
ALDH6A1 7.15E-04 30.292324 down 
ALDH7A1 0.003865223 8.697635 down 
AMY2B 0.008165984 3.3694634 down 
ANGPTL4 0.002918107 7.2624784 down 
ANKRD35 9.77E-04 58.401836 down 
ANKRD40 0.007821908 5.8272347 down 
ANKS6 6.32E-05 18.939423 down 
APLP2 0.006265898 15.759454 down 
APOBEC3D 0.001018839 9.934807 down 
APOBEC3F 0.005923716 3.2091925 down 
AQR 0.001163615 12.736328 down 
ARHGAP21 0.003212553 4.7678223 down 
ARHGAP22 9.53E-04 11.024778 down 
ARL16 0.007043136 9.75806 down 
ARL6IP1 0.001867556 4.391882 down 
ARMC1 7.15E-04 6.287192 down 
ASB5 4.22E-04 42.96255 down 
ATG12 0.008160952 4.8810673 down 
ATP5L 0.006257816 6.8606515 down 
ATPBD4 0.008797346 5.274579 down 
BACE2 0.005768979 5.311481 down 
BAG4 0.007221074 3.8730369 down 
BCL6B 0.003099599 6.637295 down 
BRCA1 4.10E-04 8.163639 down 
BRD7 0.008129506 6.194398 down 
C11ORF58 7.62E-04 18.32515 down 
C12ORF10 0.001795393 7.28373 down 
C13ORF3 0.001512908 8.070674 down 
C14ORF85 1.15E-04 67.8108 down 
C15ORF29 0.005521033 4.8747907 down 
C15ORF5 4.16E-05 21.765945 down 
C17ORF55 2.64E-04 42.862545 down 
C18ORF10 0.003550393 7.838923 down 
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C18ORF45 0.001344154 9.288338 down 
C19ORF66 0.007456531 5.3172026 down 
C1GALT1C1 7.72E-04 5.7198977 down 
C1ORF110 0.006410764 9.589877 down 
C1ORF218 0.006410764 4.3450704 down 
C1QL2 0.003498111 24.732056 down 
C20ORF94 4.79E-04 5.1433 down 
C4ORF34 0.004506461 4.3440757 down 
C5ORF34 0.004023642 12.555799 down 
C7ORF27 0.008129506 6.0288734 down 
C8ORF33 2.58E-04 6.623366 down 
C9ORF169 1.39E-04 7.276296 down 
CADM4 0.009034846 6.162319 down 
CAPZB 0.002327481 23.211348 down 
CCDC28B 9.53E-04 8.554726 down 
CCNB1 0.009892512 5.5475936 down 
CDH6 3.48E-04 17.941332 down 
CDO1 0.006525365 10.504012 down 
CDS1 0.007607385 6.003536 down 
CELSR3 0.002564631 7.402844 down 
CFI 5.33E-04 9.398326 down 
CFLAR 0.005530739 4.9480195 down 
CHCHD4 0.006285127 4.7701654 down 
CHD9 0.001795393 7.444789 down 
CHMP4A 0.009205915 6.538052 down 
CIITA 0.004383729 5.2421994 down 
CIT 0.001427465 8.584574 down 
CLEC3B 0.006644404 11.210837 down 
COL5A1 0.004023642 6.3481 down 
COMMD8 0.003550393 7.491454 down 
COPS2 0.001512908 11.230478 down 
COQ2 0.009979644 25.968605 down 
COTL1 0.006525171 8.595992 down 
CPEB3 3.76E-06 19.95955 down 
CPXM1 0.003740608 7.076955 down 
CROT 0.001427465 5.676471 down 
CSMD2 4.27E-04 20.137575 down 
CSNK1G2 0.008560014 5.9608827 down 
CTHRC1 4.40E-05 22.15206 down 
CYP7B1 0.005837788 4.8154507 down 
DAAM1 0.007880417 9.520425 down 
DAB2 0.001018839 7.429707 down 
DARS 0.007237782 4.112825 down 
DBR1 0.001529687 4.1384196 down 
DBT 0.009205915 4.8676763 down 
DEPDC6 0.009607758 6.4172177 down 
DHRS13 0.00505884 7.252834 down 
DNAJC21 0.001163615 4.9249387 down 
DSCC1 0.006440314 7.667918 down 
DSEL 4.16E-05 25.306608 down 
DTWD2 0.007821908 6.510927 down 
DUSP3 4.89E-04 9.609001 down 
EDEM3 7.15E-04 5.8986506 down 
EEF1E1 0.009016617 6.6618366 down 
EFCAB2 0.001795393 6.935688 down 
EGLN2 0.008817447 4.5341926 down 
EID2B 9.74E-06 48.621124 down 
EIF2AK2 6.75E-04 9.760415 down 
EIF3A 0.003177458 7.017942 down 
EIF3C 0.003718566 7.323435 down 
EIF5A2 0.00211369 38.130432 down 
ELOVL2 0.005530739 11.639583 down 
ENSA 0.003498111 5.633998 down 
EOMES 0.008357832 6.321761 down 
ERAL1 0.003498111 7.447069 down 
ESPNL 0.003621221 12.869572 down 
ETV6 0.003298047 8.728775 down 
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FAM103A1 5.69E-04 8.809606 down 
FAM126A 3.00E-04 15.642905 down 
FAM135A 0.00620863 9.553618 down 
FAM164C 0.005553972 4.321063 down 
FAM179B 0.003620393 5.40688 down 
FAM46A 0.006273667 6.2907057 down 
FAM53B 0.002277786 13.31916 down 
FAM70A 0.006703681 5.5815744 down 
FAM98A 9.77E-04 10.764453 down 
FANCL 0.005130978 9.115642 down 
FASN 0.005487896 5.3522096 down 
FBXO5 0.006686966 11.124021 down 
FEM1C 2.85E-05 14.872466 down 
FH 0.00947703 4.131756 down 
FLJ44124 0.0051334 8.588121 down 
FN3KRP 0.009516406 18.471292 down 
FOXN3 0.003498111 7.037565 down 
GABPA 0.00469059 21.935917 down 
GAGE5 2.64E-04 28.434034 down 
GALNT1 0.001882699 7.9953594 down 
GAS1 0.006665306 4.0365477 down 
GCLM 4.62E-05 28.042463 down 
GCN1L1 0.001970455 6.336624 down 
GCNT1 1.44E-05 31.295786 down 
GFPT1 4.89E-04 19.926119 down 
GJC1 0.002311068 6.4021297 down 
GNAI1 3.94E-04 24.286806 down 
GNPNAT1 0.004264913 4.364096 down 
GPR65 0.00673436 3.5078955 down 
GSR 0.002166688 4.0615 down 
GUCY1A3 3.34E-04 10.131008 down 
HDHD2 0.002174057 7.8749986 down 
HIPK2 0.004845828 7.231289 down 
HLA-E 0.007825849 28.690632 down 
HMHA1 0.009255056 4.7872653 down 
HOXA2 4.08E-05 35.479454 down 
HSPA2 0.006273667 5.2813625 down 
HSPC268 0.002652978 17.389692 down 
IGF1 1.88E-04 14.1034155 down 
IL7 0.004156461 12.013782 down 
IQCC 7.72E-04 12.422295 down 
JARID1A 0.007078458 66.2011 down 
KCNJ10 4.89E-04 7.7967143 down 
KCNMB4 8.43E-04 8.641509 down 
KCNT2 0.003826808 7.430913 down 
KCTD17 4.79E-04 5.182059 down 
KHDRBS3 4.62E-05 46.74356 down 
KHSRP 0.004264913 4.8797398 down 
KIAA1274 0.00211369 8.346205 down 
KIAA1333 4.10E-04 24.689985 down 
KIAA1524 0.002956321 6.7158546 down 
KIAA1704 0.002918107 6.009364 down 
KIAA1751 0.008400832 6.6624775 down 
KIR2DL1 0.006760668 10.854722 down 
KLHL14 0.003502828 11.503036 down 
KMO 4.40E-05 26.816216 down 
KRIT1 2.57E-07 19.790577 down 
KTELC1 0.006337825 10.397751 down 
L3MBTL2 0.009769705 3.2338376 down 
LAMB1 0.004506461 5.543745 down 
LARP4 0.004578318 4.2966576 down 
LCORL 0.007638917 9.755965 down 
LEPREL1 0.00201523 7.68939 down 
LIG4 3.95E-04 5.532438 down 
LOC389286 0.006273667 6.810984 down 
LOC401252 0.007237782 6.5351396 down 
LOC402110 0.002397922 17.058413 down 
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LOC440157 0.003212553 6.071294 down 
LOC440295 0.001980803 14.393967 down 
LOC441426 0.009255056 17.249702 down 
LOC442582 0.001020258 18.748045 down 
LOC54103 0.009518844 7.3338943 down 
LONP2 0.004023642 5.3189163 down 
LPP 0.008719726 6.191133 down 
LSM2 0.00848006 4.0089626 down 
LUM 0.003849729 6.7481155 down 
LYPLA1 0.009046126 12.175904 down 
M6PRBP1 0.009600718 4.109254 down 
MAML3 0.00193337 8.5067215 down 
MAN2A1 0.002915615 8.016293 down 
MAN2B2 0.004844761 7.2362046 down 
MBTD1 0.004260836 8.057388 down 
MED31 0.0068116 14.412442 down 
MET 0.00620863 5.7911243 down 
MKRN1 0.007156577 3.5647945 down 
MND1 0.001750089 7.2679687 down 
MOBKL1A 0.002621011 6.0218325 down 
MOSPD2 3.63E-04 25.38684 down 
MTTP 0.004189321 13.093079 down 
MYO10 5.66E-04 13.408863 down 
NCBP1 0.00585091 6.858417 down 
NEK2 0.008164501 9.597701 down 
NEO1 4.40E-05 6.5865216 down 
NLGN4X 0.002918107 6.784498 down 
NOTCH2NL 9.76E-04 5.0161486 down 
NSUN6 3.48E-04 13.238877 down 
NUAK1 0.003177458 5.219131 down 
NUCKS1 0.005620657 6.508262 down 
NUP43 1.92E-06 12.984548 down 
OXTR 7.09E-04 20.961843 down 
PAQR8 0.00153319 7.150044 down 
PBX2 0.005806869 4.2305865 down 
PEAR1 0.004023642 7.604949 down 
PES1 9.53E-04 14.513564 down 
PEX11G 0.004399243 11.267722 down 
PGAP1 3.94E-04 6.9355206 down 
PHF13 0.005530739 4.8793325 down 
PHF14 0.009516406 3.3742986 down 
PHOSPHO2 0.002166688 10.834834 down 
PIGM 0.007344679 8.893942 down 
PIGX 0.005487896 7.0959525 down 
PLEKHG1 0.002499568 11.7679205 down 
PLEKHH3 3.25E-04 17.142418 down 
POLR3F 0.001638724 5.163976 down 
POMP 0.003669476 11.951405 down 
PPIG 7.72E-04 6.7955914 down 
PPP2R2A 0.007344679 3.120133 down 
PRICKLE1 0.006482872 5.796452 down 
PRR13 0.009313687 4.466944 down 
PRSS23 0.003177458 8.944198 down 
PSMC1 0.009255056 5.1416206 down 
PTGFRN 0.0068116 5.914789 down 
PTP4A2 0.004103434 6.8342104 down 
PTPRU 0.006891795 7.0524616 down 
QSER1 0.005620657 3.8569806 down 
RAD54L 0.002397922 6.635993 down 
RAG1AP1 0.003177458 11.003358 down 
RBM41 0.009255056 5.004678 down 
RCN1 0.001773111 58.72695 down 
RELN 0.004264913 7.3180633 down 
RHOJ 0.004524995 5.980872 down 
RIC8B 0.003208943 14.38852 down 
RNASEH2B 0.002499568 7.20803 down 
RNASEL 0.004676314 3.5855713 down 
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RNASEN 0.003498111 6.4007926 down 
RNF11 3.34E-04 16.78699 down 
RNF150 0.002823318 8.134149 down 
RORB 0.009255056 10.622409 down 
RPS10 0.008797346 7.045753 down 
RPS27L 0.001512908 6.9092183 down 
RPS6KC1 8.81E-05 18.745535 down 
RUNDC3B 0.004578318 9.420786 down 
S100A3 0.007711134 8.942829 down 
SCYL1BP1 0.00577239 5.506925 down 
SDAD1 0.001971543 5.329716 down 
SEC63 0.007086346 3.972795 down 
SELT 4.27E-04 13.3971195 down 
SENP6 0.007427083 4.9874196 down 
SERF1B 0.006750406 8.329057 down 
SETBP1 0.005083294 5.3412967 down 
SETD6 0.00162084 223.82956 down 
SETDB2 3.27E-04 16.13242 down 
SF4 0.004453694 6.1089373 down 
SFRP4 2.58E-04 34.795265 down 
SH3BGRL2 0.002166688 14.539969 down 
SH3BP4 0.009313687 6.506572 down 
SKP1A 0.006871954 3.6610322 down 
SLAMF8 0.008128945 137.59619 down 
SLC19A3 0.008174583 7.510807 down 
SLC25A13 0.009255056 5.241347 down 
SLC30A7 0.001344154 8.956547 down 
SLC35B4 0.009854952 5.390821 down 
SLC36A4 0.003671266 4.410861 down 
SLC38A5 0.009255056 3.9003642 down 
SLITRK2 2.09E-04 14.258287 down 
SNF8 0.00947956 5.330567 down 
SNRPC 0.009607758 4.6638975 down 
SNRPG 0.008504801 4.996765 down 
SNW1 0.001283768 5.942991 down 
SPC24 0.007546236 6.9834805 down 
SPIC 3.94E-04 17.151617 down 
SSPN 0.007156577 12.765097 down 
STYX 0.002823318 27.293037 down 
SUZ12 0.002983367 5.6309605 down 
SYTL4 3.94E-04 12.557737 down 
TAOK3 0.002371385 33.00952 down 
TBL1X 0.004910842 5.5992155 down 
TBX2 0.007078458 7.796086 down 
TDO2 0.00440716 11.081358 down 
TEX11 0.007711134 6.1001973 down 
THAP5 0.005802979 5.0500827 down 
TIA1 0.003225538 16.310478 down 
TIMM22 0.006686966 5.5662274 down 
TMEM137 0.001256493 15.128526 down 
TMEM183A 0.005487896 4.363731 down 
TMEM189-UBE2V1 0.002116912 13.029873 down 
TMEM19 2.57E-07 32.272377 down 
TMEM47 3.25E-04 14.154172 down 
TNFRSF1B 0.006299525 12.061986 down 
TNIP3 0.009569214 4.6899633 down 
TPM3 0.005924117 5.4504294 down 
TSPAN12 7.62E-04 21.84079 down 
TSPAN33 0.009205915 6.4077077 down 
TTF1 0.003453439 4.6966577 down 
TYW3 0.002717147 7.1920743 down 
UBE2M 0.004399243 4.692899 down 
UBE2V2 0.003208943 9.669832 down 
USP28 0.002915615 5.578052 down 
UTP23 0.002376513 4.746803 down 
VASH2 0.001901616 16.094357 down 
VEZT 0.00193337 10.906304 down 
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WBP5 0.003099599 11.244993 down 
WDR44 0.00846132 5.658135 down 
WDR79 0.009358969 3.5898888 down 
WWP1 0.002529311 14.063203 down 
YIPF1 0.002956321 5.4660435 down 
ZBTB1 0.005206829 5.1862197 down 
ZC3H7A 0.002956321 29.289198 down 
ZCCHC6 4.10E-04 18.155394 down 
ZDHHC8 0.008452262 4.9656215 down 
ZNF131 0.0015127 6.5522757 down 
ZNF142 0.003745072 9.126152 down 
ZNF167 0.009407196 4.751402 down 
ZNF227 0.00211369 4.772507 down 
ZNF23 4.40E-05 16.816093 down 
ZNF490 8.43E-04 33.283813 down 
ZNF493 0.002166688 6.2911015 down 
ZNF526 0.002013522 8.138484 down 
ZNF543 0.009034846 5.857266 down 
ZNF557 0.001750089 8.613409 down 
ZNF561 0.008716764 5.943809 down 
ZNF567 0.001114671 15.420288 down 
ZNF652 0.007696924 6.8548446 down 
ZNF771 0.002918107 8.33634 down 
ZYG11B 0.001931335 5.2407746 down 
ADIPOR2 0.009516406 21.0461 up 
AKR1B1 0.008719726 3.7689223 up 
AKR1C2 0.006721099 10.1691 up 
AMD1 0.006721099 4.9025664 up 
ANKHD1 0.001971543 5.0964346 up 
ANKRD9 0.002956321 7.7113457 up 
ANXA5 0.006955957 16.032515 up 
AP2B1 5.15E-04 15.976804 up 
AP2M1 0.008716638 3.9503698 up 
APBA2 0.004578318 20.990068 up 
APBB1IP 0.007221074 5.711016 up 
APOLD1 0.004012966 21.522852 up 
AQP9 0.00425734 8.914484 up 
ARMCX6 0.006410764 5.209512 up 
ARRDC3 0.006122726 16.778696 up 
ATP5F1 0.006721099 3.6082923 up 
AXIN2 0.003177458 31.432663 up 
BACH2 0.009616257 4.667967 up 
BAZ1B 0.001283768 15.451679 up 
BCL7C 0.007806727 4.8054714 up 
BEX2 0.004954486 21.839859 up 
BRF2 0.001283768 9.959711 up 
C10ORF32 0.002416148 10.409831 up 
C14ORF32 0.001998007 24.909534 up 
C1ORF55 0.003498111 9.650796 up 
C1QBP 4.89E-04 8.5476 up 
C20ORF4 0.009548151 20.760876 up 
C2ORF47 0.005911394 9.798617 up 
C3ORF14 0.002290321 24.06436 up 
C5AR1 0.00673436 15.858517 up 
C5ORF25 0.008164501 11.418156 up 
CASP6 0.003963402 4.028067 up 
CCDC107 7.72E-04 30.068472 up 
CCDC59 0.008921199 13.2924385 up 
CCDC84 8.81E-05 79.893875 up 
CCL22 0.008996708 19.531124 up 
CCL23 0.009642038 5.329297 up 
CCL3 0.001379336 15.196657 up 
CCNL1 0.009484064 5.0891705 up 
CD274 0.006703681 12.952867 up 
CD58 0.009979644 10.508957 up 
CDC2 0.006721099 5.3351145 up 
CDK5RAP2 0.007156577 5.535153 up 
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CDKN2D 0.002277786 5.6594872 up 
CENPH 0.003995729 5.340693 up 
CHMP2A 0.008129506 5.7402115 up 
CHMP6 0.006299525 9.703966 up 
CIC 0.008752616 9.791438 up 
CLASP1 0.005197869 28.49741 up 
CLASP2 0.002522355 29.62007 up 
CLIP4 0.002823318 22.020697 up 
CLPTM1L 0.003498111 20.156614 up 
CNOT8 0.007711134 3.6582751 up 
CNPY3 0.00268214 18.267405 up 
COG7 0.005245604 7.591311 up 
COMMD9 0.008268533 10.968375 up 
COPS4 0.006583526 15.082299 up 
COPZ1 0.002661705 28.207102 up 
COQ7 0.007347688 18.814882 up 
CORO7 0.001867556 11.804779 up 
COX7B 0.006721099 3.8473878 up 
CXORF40A 0.001264581 14.514919 up 
CYCS 0.005768979 15.653567 up 
CYFIP2 0.009979644 3.3791854 up 
D4S234E 0.00585091 6.9799743 up 
DDX19B 0.001720097 9.951975 up 
DDX21 0.003745072 12.597267 up 
DNAJB6 7.15E-04 7.0230947 up 
DNMT3A 0.006273667 6.737732 up 
DPH3 0.004148494 7.020444 up 
DPY30 2.58E-04 17.745598 up 
DYM 0.004026739 22.51991 up 
ECD 0.0040299 8.933097 up 
EEF1B2 7.72E-04 4.398258 up 
EEF1D 0.009516406 5.238196 up 
EEPD1 0.009516406 15.211833 up 
EHD4 0.003911523 28.772253 up 
EIF2S2 0.003272869 30.734167 up 
EIF3F 0.006721099 4.0344014 up 
ELF2 0.009467525 8.686361 up 
ELK3 0.008797346 12.927707 up 
ENTPD4 0.006273667 16.312376 up 
ERN1 0.001867556 10.027168 up 
FAM127B 0.009255056 9.094625 up 
FAM162A 0.004190592 11.025533 up 
FAM48A 6.92E-04 15.167932 up 
FAM89A 3.34E-04 11.611632 up 
FASTKD3 0.009255056 10.059738 up 
FASTKD5 0.008797346 6.7576447 up 
FOXO1 0.006873354 13.846647 up 
GBE1 0.005172796 12.341494 up 
GGNBP2 5.65E-05 62.049496 up 
GMEB1 0.001919427 10.927252 up 
GNPTG 0.002956321 10.117929 up 
GPATCH4 0.006525365 7.5065994 up 
GRINL1A 4.27E-04 9.736215 up 
GTF2H4 0.00164392 24.32491 up 
GUSBL2 0.004722433 6.0526247 up 
HBXIP 4.40E-05 33.065296 up 
HDGF 0.008125961 18.977495 up 
HECTD1 0.009407196 8.080266 up 
HK3 0.003849729 28.641922 up 
HMGN1 0.006533589 11.042228 up 
HNRPC 9.53E-04 9.067948 up 
HNRPK 0.008797346 6.2411375 up 
IARS 0.002361708 8.855911 up 
ID2 0.00620863 4.763095 up 
IIP45 0.008868565 27.962267 up 
IL6R 0.006273667 10.037763 up 
IMPACT 0.007156577 24.983097 up 
152 
 
ITGAM 0.001512908 10.035202 up 
ITGB3BP 0.002719009 15.961721 up 
JMY 0.007473841 7.351855 up 
KIAA0141 0.007711134 9.479928 up 
KIAA0247 0.008282234 8.521089 up 
KIAA1128 0.001795393 11.447064 up 
KIF2A 0.002956321 17.09515 up 
KLF9 0.008995289 9.488094 up 
KTN1 0.006490443 7.946556 up 
KYNU 0.005018999 7.129059 up 
LETMD1 6.83E-04 9.640929 up 
LNPEP 0.005768979 3.9658847 up 
LOXL1 0.005553972 13.190039 up 
LRBA 0.003050032 7.4771338 up 
LYRM2 0.001563511 18.623604 up 
MAGOH 0.006337825 15.454308 up 
MED30 8.81E-05 59.22387 up 
MEF2A 0.00440716 7.503465 up 
MFSD8 0.002267259 10.014574 up 
MOAP1 0.008957885 8.551846 up 
MOCS2 0.007640815 6.458394 up 
MORC3 0.006525365 12.431017 up 
MPP7 0.002166688 21.049816 up 
MRC1L1 0.004026739 12.85205 up 
MRPL20 8.21E-04 48.818142 up 
MRPL23 7.72E-04 29.162357 up 
MRPL55 0.005083294 4.2663107 up 
MRPS28 0.006873354 7.4213943 up 
MS4A7 0.005620657 9.893232 up 
MT1H 0.002311068 34.350796 up 
MTHFD1L 0.00469059 9.433249 up 
MTM1 0.003876145 16.335094 up 
MYC 0.008383978 5.139362 up 
MYD88 0.003498111 12.019675 up 
NAAA 0.006347336 5.303448 up 
NBR1 3.94E-04 18.236416 up 
NCAPG2 0.003656701 29.210253 up 
NCKAP1 0.006273667 7.9983687 up 
NDUFA11 0.007546236 5.8516707 up 
NELL2 0.001283768 23.405716 up 
NIP30 0.008365646 15.253654 up 
NLRC4 0.006273667 9.628864 up 
NME6 0.009156768 6.706148 up 
NPDC1 0.002918107 27.822905 up 
NRD1 0.002213799 14.612283 up 
NTN4 0.009255056 6.367585 up 
NUMA1 0.009607758 5.407944 up 
OAT 0.002661705 7.4686866 up 
OSCAR 1.97E-04 20.551737 up 
P4HA2 7.15E-04 8.820416 up 
PABPN1 0.002376513 19.613274 up 
PCBP1 0.004084435 7.754172 up 
PCGF5 0.005173261 8.492847 up 
PDE3B 0.004333112 13.668155 up 
PGGT1B 0.005216889 4.8632555 up 
PHLDA1 0.002311068 6.877027 up 
PKD1 0.002652978 17.080986 up 
PLEKHF2 0.003429672 5.0414157 up 
PMS2 0.00268214 12.781322 up 
PNMA1 0.007711134 7.775702 up 
PPARA 0.004077315 9.680098 up 
PPM1G 4.10E-04 10.687489 up 
PRKX 0.001626937 10.287645 up 
PSMA1 0.006525365 3.6164691 up 
PSMD12 0.009255056 7.700241 up 
PSPH 2.63E-04 17.412756 up 
PXMP3 0.007711134 15.16036 up 
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RABEP1 0.008344029 15.109382 up 
RBBP5 2.93E-04 43.420193 up 
REEP3 0.007156577 11.642192 up 
RNF146 0.004190592 9.127692 up 
RNF4 0.009481185 6.6139364 up 
RPL22 1.82E-04 19.032623 up 
RPL34 0.009255056 5.6620927 up 
RPL8 0.008627201 7.6106944 up 
RPP38 0.007465011 6.4794436 up 
RPS21 0.001283768 39.411095 up 
RPS26 9.92E-05 32.98892 up 
RPS7 0.003774964 12.732931 up 
RUFY1 0.004026739 10.345824 up 
SAMD3 0.007237782 5.1257014 up 
SEC61G 0.001181684 11.130157 up 
SEH1L 0.009034846 4.47619 up 
SFRS2 0.006347336 3.177868 up 
SFRS2B 0.005254331 5.4524736 up 
SFT2D1 9.53E-04 30.565155 up 
SH2D3A 0.002499568 14.893252 up 
SLC15A4 0.001314587 16.96581 up 
SLC25A40 0.00182446 14.469786 up 
SNRPF 0.006265898 9.677233 up 
SNX1 0.00240005 5.9364448 up 
SNX25 0.009516615 7.481325 up 
SNX5 4.27E-04 7.7886863 up 
SORT1 0.005737121 7.419503 up 
SPP1 0.008255319 12.164943 up 
SRP14 0.00636012 5.6107802 up 
SRPRB 0.001505991 25.656576 up 
STARD7 0.002918107 4.8734803 up 
SYPL1 0.009255056 3.9627783 up 
TALDO1 0.006525365 23.500217 up 
TBRG1 0.001505991 12.758599 up 
TBRG4 0.009255056 7.1004543 up 
TCTN1 0.006686966 5.1527348 up 
THNSL1 0.00324789 18.00465 up 
THOC7 0.006703681 7.836243 up 
TM6SF1 8.10E-05 37.92788 up 
TMEM14C 0.009979644 7.9732084 up 
TMEM48 0.006347336 10.984599 up 
TMEM64 6.55E-04 19.834202 up 
TMEM69 0.001314587 24.32409 up 
TMSB4X 0.007221074 5.69777 up 
TNFRSF25 0.009376789 7.9491463 up 
TNPO1 0.001283768 6.945177 up 
TRAF3IP1 0.003498111 13.895607 up 
TTC17 0.005553972 9.3417845 up 
TULP3 0.007711134 17.077192 up 
TXNDC14 0.006686966 13.20815 up 
UBE2E3 0.004260836 5.4336123 up 
UBE2Z 0.005487896 5.845522 up 
UCHL5IP 0.003205248 6.614343 up 
USP3 0.008357832 12.197942 up 
WDR61 0.009358969 14.388639 up 
WIPF1 0.006802904 4.9816713 up 
XPO1 0.006373111 7.0369406 up 
XPO6 0.002218735 7.7901487 up 
YEATS2 0.006703681 12.133443 up 
YME1L1 0.008917047 5.2307835 up 
YTHDC1 0.006257816 3.8322124 up 
ZBED2 0.001998007 37.774826 up 
ZC3H15 0.009255056 5.9778433 up 
ZCCHC14 0.009983876 10.501363 up 
ZCCHC3 0.001899286 25.352436 up 
ZNF295 0.008797346 23.723484 up 
ZNF350 0.002921432 18.235462 up 
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ZNF512 0.009516406 22.665276 up 
ZNF550 0.003778286 11.720262 up 
ZSCAN18 0.001705727 8.766659 up 
ZUFSP 0.001919427 12.769999 up 
 
Supplementary Table 25. Genes differentially expressed between F-PTCL and Tfh-
PTCL/NOS. 
Gene ID Corrected p-value Absolute Fold Change Regulation in F-PTCL 
ACTN1 0.032651957 9.162927 down 
ARMET 0.030497883 10.636738 down 
C9ORF142 0.008475903 22.887108 down 
DOK3 0.015336229 33.707104 down 
FAM158A 0.017402537 15.228142 down 
FAM38A 0.044065177 12.141764 down 
FLJ33590 0.03327304 14.82872 down 
IRAK1 0.03983541 10.90949 down 
NDUFS7 0.03936868 8.333967 down 
NKG7 0.009984055 11.327506 down 
PSMD1 0.015925864 12.863148 down 
RCC2 0.049700513 12.389089 down 
SDSL 0.026798014 21.156904 down 
SELM 0.029673908 13.789991 down 
SLC25A23 0.0198869 10.599566 down 
SNAPC4 0.042885497 10.986626 down 
SPC24 0.021338666 15.053143 down 
TRAPPC2L 0.01688599 13.615226 down 
TUFM 0.007843819 13.879106 down 
VARS2 0.041499335 10.58867 down 
WDR46 0.019348864 18.556736 down 
ZNF653 0.028000334 9.595228 down 
AASDHPPT 8.07E-04 41.277176 up 
ACSL5 0.021961661 7.4324985 up 
AGL 0.001870222 13.543705 up 
ALAS1 0.001051498 9.767095 up 
ALDH6A1 0.02039886 10.994508 up 
ANXA7 3.64E-05 40.392372 up 
AP2A1 0.03167923 10.181193 up 
ARFGEF1 0.048668984 7.4701123 up 
ARID2 0.004780149 9.928244 up 
ARL5A 0.014549244 9.049862 up 
ATP6V1G2 0.007860205 11.110379 up 
BFAR 3.05E-04 26.577612 up 
BRWD1 0.046356093 5.8859763 up 
C11ORF58 0.021391474 8.449126 up 
C12ORF35 0.007745674 9.77064 up 
C14ORF118 0.005698534 13.064511 up 
C14ORF138 4.38E-04 18.437647 up 
C14ORF43 0.012537808 7.4620814 up 
C18ORF54 0.009466338 12.079316 up 
C1D 5.02E-04 17.16907 up 
C1GALT1C1 0.008882707 10.606838 up 
C1ORF9 0.00838236 15.435501 up 
C3ORF42 4.87E-04 18.550438 up 
C6ORF204 0.019206485 6.1714954 up 
C9ORF10OS 8.47E-05 32.76731 up 
C9ORF5 0.033942744 12.83138 up 
CAMK1D 0.049306374 8.945166 up 
CAMK4 3.83E-04 40.382694 up 
CAND1 0.01402145 11.286586 up 
CAPRIN1 0.004135245 12.209074 up 
CASP4 5.86E-04 14.70726 up 
CASP7 0.0298692 9.471577 up 
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CBL 0.03706347 6.199753 up 
CCBL2 0.014091983 6.705328 up 
CCDC132 0.009961066 8.426201 up 
CCDC75 0.04964969 10.867133 up 
CCDC91 0.03512753 9.202882 up 
CCNT2 4.45E-04 11.123002 up 
CDC14A 0.002073128 13.715196 up 
CDC2L5 0.00802759 9.967944 up 
CDC42 0.012525885 11.098288 up 
CDYL 0.009635665 13.891286 up 
CENTB2 2.58E-04 18.135399 up 
CENTD1 4.31E-04 23.371517 up 
CHN1 2.27E-05 30.29738 up 
CHORDC1 0.005117486 17.777973 up 
CLEC2D 0.04525629 10.308395 up 
CLTA 0.005595544 12.044148 up 
CMTM3 0.003568086 8.541378 up 
CNOT1 2.54E-04 13.108686 up 
CNOT7 0.024104986 6.932718 up 
COMMD10 0.01824176 10.954586 up 
COMMD6 0.004976979 12.861322 up 
CR2 0.015186134 25.68522 up 
CTPS2 9.24E-04 16.736912 up 
CYFIP1 0.03136223 7.499896 up 
CYP20A1 0.010266114 11.954899 up 
DCK 0.016406136 12.784302 up 
DDHD1 0.024219202 17.90043 up 
DDX21 0.020346805 21.651844 up 
DST 0.001549506 12.828513 up 
DTWD1 0.048062485 7.521082 up 
DYNC2LI1 0.002310262 10.323492 up 
DYRK1A 0.002618847 9.43213 up 
EFNA1 7.42E-04 11.101642 up 
EGFR 9.86E-04 13.83076 up 
EIF1AX 0.030510424 8.746927 up 
EIF3J 0.039439548 13.301756 up 
EPB41 0.008182965 8.528528 up 
EPB41L2 0.006198023 12.821627 up 
ERMN 0.001211577 15.3513975 up 
FAIM 0.014789138 8.915849 up 
FAM108B1 0.003533945 10.087914 up 
FAM116A 0.040596273 10.168262 up 
FAM126B 0.002526283 14.150282 up 
FAM134B 0.039423604 6.9451036 up 
FAM135A 2.86E-04 40.914135 up 
FAM49B 0.006612108 11.241121 up 
FBXL5 0.010573233 8.84768 up 
FBXO3 0.001707437 15.354269 up 
FBXO30 6.85E-04 10.782243 up 
FKBP9 5.38E-04 24.905056 up 
FYB 9.89E-04 13.150131 up 
GABPA 0.001725848 54.02769 up 
GALNT7 0.004616549 22.558992 up 
GFRA1 0.019593254 9.800043 up 
GIMAP2 0.006579093 14.422142 up 
GLMN 0.04389258 10.854096 up 
GNAQ 0.00182405 36.411545 up 
GNAS 3.99E-05 17.480091 up 
GOLT1B 0.014576786 31.848818 up 
GOSR2 0.005987098 14.441317 up 
GPR162 0.04854598 6.4869947 up 
GPR171 0.019456547 11.700031 up 
HBXIP 0.040494666 9.077346 up 
HECA 4.07E-07 24.14347 up 
HIAT1 0.007237727 7.9011655 up 
HK1 0.009167008 7.176962 up 
HN1 0.046074625 20.770443 up 
156 
 
HSPD1 0.006317423 11.670771 up 
IPO8 0.02395025 17.616047 up 
ITGB1 5.53E-04 7.8162904 up 
ITM2B 4.31E-05 21.194881 up 
KIAA1199 0.042779103 28.80425 up 
KIAA1370 0.001384766 14.814141 up 
KIT 0.03743375 12.335301 up 
KLF12 0.039620526 8.810764 up 
KPNA3 2.26E-04 31.506273 up 
KRAS 3.15E-06 19.171223 up 
KRIT1 0.01222548 8.074157 up 
LAMA3 0.008003891 12.8271055 up 
LEPR 0.020601597 7.822688 up 
LFNG 0.032402307 8.383152 up 
LGALS8 0.041722108 5.184375 up 
LIN7C 0.018642986 12.752212 up 
LRP8 0.04905565 12.190844 up 
LRRCC1 0.010665879 10.3489275 up 
LUM 3.22E-04 20.958082 up 
MAML2 0.0098189 7.059718 up 
MARS2 4.70E-04 16.742716 up 
MCTP1 0.00814017 10.806294 up 
ME2 0.033398382 9.588622 up 
MFF 0.027835509 9.6278715 up 
MS4A1 0.044877257 10.118098 up 
MS4A4A 2.51E-06 31.586025 up 
MST4 0.017647892 12.069609 up 
MTM1 1.83E-04 67.7478 up 
MTX2 0.009700547 10.912346 up 
MYADM 0.00174102 8.926965 up 
MYC 0.010495709 9.041944 up 
MYLK 3.34E-04 9.292695 up 
MYST4 0.005459053 33.347977 up 
NAPEPLD 1.29E-04 36.74243 up 
NBPF15 0.004330082 12.314768 up 
NDRG4 1.99E-04 12.449857 up 
NEDD9 0.038272757 6.288476 up 
NFATC2 0.006347351 11.042445 up 
NFIA 0.005338766 17.74585 up 
NLGN4X 0.008505589 17.295738 up 
NNT 0.028443443 10.95388 up 
NTS 0.02140472 24.509161 up 
NUDT21 0.019612119 8.490156 up 
OAS3 0.002295236 15.264411 up 
OLFM1 0.044097383 6.844748 up 
OPA1 8.55E-04 16.059486 up 
ORC5L 3.69E-04 13.037892 up 
P2RY13 0.047715716 7.97502 up 
PAG1 0.015161951 6.476815 up 
PANK2 5.36E-04 12.857293 up 
PARVA 0.005152434 25.780725 up 
PDCD5 0.013747104 12.529679 up 
PDE3B 0.013638238 31.769745 up 
PDE5A 1.17E-04 18.557722 up 
PEMT 0.009494056 8.811079 up 
PER2 0.002117825 9.770009 up 
PHOSPHO2 4.18E-05 20.61192 up 
PI15 0.009325375 7.147152 up 
PIK3CA 0.01747068 8.527986 up 
PKIA 0.001123408 16.46336 up 
PMS1 0.046308294 19.087858 up 
POLG 0.041365776 18.88169 up 
POLR2J3 9.28E-04 15.99831 up 
PPIL4 0.005258972 14.7197 up 
PPP2R2D 0.042560164 6.679457 up 
PRKACB 1.43E-04 14.696016 up 
PSAT1 0.014526144 10.15735 up 
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PSCDBP 7.47E-05 16.042686 up 
PTPN22 3.05E-04 17.662203 up 
RAB11FIP1 6.21E-04 7.778176 up 
RAD17 1.61E-04 13.165413 up 
RAD50 1.29E-04 22.66159 up 
RAI1 0.010688429 14.666737 up 
RALGPS2 0.044435494 12.424311 up 
RANBP2 8.99E-04 18.38456 up 
RAPH1 0.014703849 8.4397745 up 
RBL1 8.44E-05 12.657019 up 
RBPJ 0.002408673 12.937213 up 
RCOR1 0.007719148 32.216034 up 
RELN 0.004066379 12.676274 up 
RIOK3 0.00952796 12.56369 up 
RNF138 0.03886679 19.728134 up 
RNF4 0.014938999 16.981974 up 
RPAP3 0.011414674 8.531435 up 
RPL7 0.00503679 15.270482 up 
RRP1B 2.62E-04 22.87699 up 
RRS1 0.002793369 27.799473 up 
RSBN1L 0.002684305 16.479511 up 
RYK 0.027394367 8.029521 up 
SCAMP1 0.026224686 9.281375 up 
SCGN 0.002081553 36.131283 up 
SCML1 0.041291155 11.541202 up 
SCRIB 0.03331376 8.584683 up 
SDF4 2.60E-04 13.417861 up 
SDHD 0.007074507 30.674475 up 
SEH1L 0.03716784 7.799186 up 
SENP7 0.033220008 12.149023 up 
SERF1B 0.003061452 27.086784 up 
SETD3 0.001779174 10.350714 up 
SFRP2 0.006193906 42.93927 up 
SFRS3 2.86E-05 17.78571 up 
SH3BGRL 7.49E-04 23.838997 up 
SLA 0.024993343 10.9353 up 
SLC10A7 6.40E-04 12.123195 up 
SLC41A3 0.010409465 9.676246 up 
SLC9A6 6.44E-04 14.053468 up 
SLCO3A1 0.012006078 9.214042 up 
SLFN11 0.009661906 17.09201 up 
SMC6 0.032854587 21.283113 up 
SMPDL3A 0.010840488 12.569457 up 
SNORD107 4.90E-04 40.553215 up 
SNRPN 3.18E-04 8.961529 up 
SOCS2 0.006703933 7.8000255 up 
SP3 0.005744148 12.451309 up 
SPAST 0.006361755 9.464127 up 
SPIC 0.009852324 14.83653 up 
SPOPL 0.003843804 10.625132 up 
SSBP3 0.022611488 7.4283247 up 
ST6GAL1 0.008441367 12.350014 up 
ST8SIA4 0.029863885 10.898398 up 
STAG2 0.017095156 7.8552923 up 
STAMBP 0.036144394 8.729737 up 
SUMO1 9.62E-04 20.211485 up 
SUOX 0.02441466 5.9055653 up 
SYNE1 3.04E-04 13.471909 up 
SYNE2 0.040446144 12.170956 up 
SYPL1 0.037388183 18.29962 up 
TADA1L 0.027129823 9.374849 up 
TAF9 0.0374676 18.660734 up 
TAS2R14 0.029178554 16.401182 up 
TC2N 6.89E-05 48.675907 up 
TCERG1 0.006760553 8.123661 up 
TCP1 0.002559799 7.946777 up 
TFG 0.023799472 7.884549 up 
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TGFBR2 0.010612262 10.810942 up 
THAP5 0.001529566 12.716297 up 
TIPRL 0.01842422 9.607702 up 
TMEM104 6.49E-04 70.929016 up 
TMEM106B 8.78E-05 19.833946 up 
TMEM128 0.03516394 16.539415 up 
TMEM19 0.002633689 7.5223684 up 
TMSB4X 0.004418903 41.50205 up 
TOPORS 0.02619806 13.953513 up 
TPP2 0.002498981 9.712883 up 
TRAF5 9.02E-06 16.22763 up 
TRAPPC6B 0.025020275 6.961982 up 
TRIM3 0.005567181 6.9052196 up 
TSC22D3 0.017641831 7.489523 up 
TSPAN13 0.026092144 13.100282 up 
TSPAN4 0.02809923 12.595056 up 
TSR1 0.005438575 17.210089 up 
TTC33 0.015244305 18.70002 up 
TTF1 0.020189717 7.309971 up 
TTRAP 0.008262022 12.626039 up 
TUSC3 0.036112882 8.189791 up 
TXK 0.006980763 24.003275 up 
TXNL4A 0.008832347 24.957693 up 
UBE2D3 0.001188838 9.665733 up 
UBE2H 0.010766036 9.725424 up 
VPS13A 0.00419009 8.198767 up 
VPS13B 0.00383473 10.003193 up 
VPS24 0.00646249 11.675179 up 
WDR26 0.013391696 8.905493 up 
WIPF1 0.00946921 17.673754 up 
WWP2 0.014749949 10.531052 up 
XRN2 0.03012715 23.389383 up 
ZBTB11 0.036008757 9.916371 up 
ZFAND6 7.41E-05 28.02789 up 
ZFY 0.030169657 31.325817 up 
ZNF141 9.51E-05 29.805304 up 
ZNF318 0.001075414 8.953189 up 
ZNF567 0.020276193 10.453688 up 
ZNF83 0.002010679 28.507801 up 
 
Supplementary Table 26. Genes differentially expressed between AITL and Tfh-PTCL/NOS. 
Gene ID Corrected p-value Absolute Fold Change Regulation in AITL 
AIM2 0.002566941 23.48162 down 
ALDH6A1 1.55E-05 48.15558 down 
ANKRD35 2.97E-06 155.26956 down 
APLP2 0.003657815 45.58968 down 
APOBEC3G 8.40E-04 22.663546 down 
AQR 8.54E-04 24.508722 down 
ATP5L 0.03967707 11.2997055 down 
C11ORF58 2.86E-04 24.138603 down 
C14ORF85 0.001103142 149.10243 down 
C15ORF5 0.03700855 18.255774 down 
C20ORF96 0.045317184 128.80238 down 
C5ORF34 0.04028918 44.67423 down 
CAPZB 0.001680586 67.7006 down 
CDH6 3.31E-04 48.682053 down 
CPEB3 9.87E-04 33.154354 down 
DHRS13 0.032171253 15.06404 down 
EID2B 0.009678989 69.699135 down 
EIF5A2 0.003201631 96.493546 down 
ERAL1 0.042740557 10.915455 down 
ETV6 0.044373468 15.039108 down 
FAM53B 0.002020156 23.678072 down 
FAM98A 0.04986558 13.817567 down 
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FBXO5 0.005901064 22.07946 down 
FEM1C 7.73E-04 18.65839 down 
FOXO4 0.045249026 16.194887 down 
GCNT1 0.009365761 44.644897 down 
GFPT1 5.15E-04 32.4352 down 
GIMAP5 0.005055221 267.79944 down 
GNAI1 3.00E-06 69.33706 down 
HLA-E 1.20E-04 126.870316 down 
HOXA2 1.52E-06 53.005295 down 
JARID1A 0.024651164 283.76633 down 
KCNJ10 0.049150266 11.204566 down 
KHDRBS3 4.91E-07 163.35817 down 
KIAA1333 0.007214521 34.416027 down 
KLHL14 0.012276984 19.63116 down 
KMO 1.30E-06 54.359653 down 
KRIT1 0.005959029 14.98657 down 
KTELC1 0.018496703 15.097835 down 
MED31 0.004702204 34.833733 down 
MOSPD2 3.83E-04 67.09868 down 
NCKAP1L 0.01019731 32.479652 down 
OXTR 0.01693197 46.027496 down 
PES1 0.005020364 25.038574 down 
PEX11G 0.01086219 23.36378 down 
PHOSPHO2 0.015676547 10.28182 down 
POMP 0.048381988 21.331226 down 
RAG1AP1 0.011287431 22.24524 down 
RCN1 0.00103686 187.38063 down 
RNF11 7.99E-04 28.746521 down 
RPS6KC1 1.44E-04 14.251197 down 
RRP7A 0.033799168 17.236958 down 
SETD6 7.10E-04 623.90845 down 
SETDB2 0.001869267 26.06232 down 
SFRP4 4.06E-04 70.33453 down 
SLAMF8 0.001013491 1173.5913 down 
SPC24 0.041140508 15.117227 down 
STYX 0.003580729 75.47328 down 
TAOK3 0.001891624 103.75347 down 
TM4SF18 1.96E-04 25.458818 down 
TMEM137 0.014504074 28.535751 down 
TMEM189-UBE2V1 0.01013291 24.212372 down 
TMEM19 2.45E-07 53.722717 down 
TNFRSF1B 0.005939021 30.085102 down 
TSPAN12 7.36E-04 30.281181 down 
VEZT 0.001580042 15.173254 down 
WBP5 4.84E-04 30.051939 down 
WWP1 0.001683327 23.274904 down 
ZBTB3 0.005124753 14.509221 down 
ZC3H7A 2.15E-05 129.67134 down 
ZCCHC6 0.002566889 33.206764 down 
ZNF23 0.044095717 17.593714 down 
ZNF490 0.001055645 61.763958 down 
ZNF526 0.04116124 10.010195 down 
ZNF567 0.003522322 14.825055 down 
ANKRD9 0.002761816 21.909216 up 
AP2B1 0.02397262 23.275143 up 
APOLD1 0.005926091 61.081253 up 
BAZ1B 0.005163072 23.257877 up 
C11ORF46 0.035647195 22.80408 up 
C1QBP 0.024113987 12.265031 up 
CCDC84 0.00129678 128.052 up 
CLASP2 0.010201118 80.66772 up 
CNPY3 9.32E-04 38.411995 up 
COQ7 1.62E-04 96.48538 up 
CXORF40A 1.60E-04 24.014153 up 
DDI2 0.028972138 9.440678 up 
DNMT3A 0.002798959 23.469175 up 
DPY30 3.72E-05 48.782364 up 
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FAM48A 0.006025021 23.848028 up 
GGNBP2 1.39E-04 149.64116 up 
HBXIP 2.75E-05 44.76022 up 
HNRPC 0.048685484 12.152678 up 
IIP45 0.02503481 108.87883 up 
INCENP 0.027921667 14.045565 up 
JMY 0.029629907 17.05962 up 
LOXL1 0.04009175 18.263783 up 
LPCAT4 0.002374276 46.757126 up 
MED30 1.60E-04 111.39466 up 
MS4A7 0.006395315 15.16044 up 
MTM1 2.61E-04 94.294304 up 
NAT11 0.023560397 50.628826 up 
NCAPG2 0.004161646 79.42693 up 
PDE3B 0.041418705 33.25751 up 
POLG 0.036636703 22.537111 up 
PSPH 0.015550672 21.99862 up 
PTPLAD1 0.04920792 12.222071 up 
RNF146 0.016585218 21.163317 up 
RPL22 0.008697484 41.404293 up 
SLC15A4 0.035324644 20.188938 up 
SNX1 0.005495214 13.213169 up 
SRPRB 7.43E-04 68.392334 up 
TBRG1 0.013072972 22.137026 up 
TM6SF1 0.04395993 41.096355 up 
TMEM69 1.25E-04 50.38219 up 
XPO6 1.73E-04 20.896225 up 
YPEL3 0.010119362 98.21181 up 
ZSCAN18 9.93E-04 15.575254 up 
 
 
 
 
 
 
 
 
 
 
 
